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Abstract 
The urinary tract (UT) is a sterile environment despite being constantly challenged by pathogens 
from its surrounding environment. Protection of the uroepithelium from microbial assault involves 
the innate immune system, but still, to date, little is known of the actual mechanisms that function in 
such defences. The focus of the research presented in this thesis, which used RT4 and VK-2 E6/E7 
in vitro cell systems to model the bladder and vaginal epithelia respectively, was to interrogate the 
mechanisms by which these epithelia recognise and respond to microbial assault.  
The RNA of bladder RT4 cells challenged with motile and non-motile Escherichia coli strains was 
analysed via a TLR related gene array. The data supported upregulation of the NF-κB dependent 
cytokine IL-8 and thus NF-κB signalling was used to measure the uroepithelial response to microbial 
infection. Flagellin, recognised by TLR-5, and responsible for bacterial motility, induced a 
significant (p<0.001), 44.9±1.7 fold increase, in RT4 NF-κB signalling within 4h of challenge and 
with use of TLR-5 blocking antibody was identified as the key activating PAMP in the UT. Other 
bacterial cell wall components, namely LPS and peptidoglycan, failed to induce comparable NF-κB 
activation (maximum 10.7± 0.8 and 6.3±0.6 fold increase at 16 hours post challenge).  
These data led to the hypothesis that strains associated with urinary tract infection (UTI) have 
reduced or no motility. However, 12/24 clinical strains associated with UTI were motile and induced 
a NF-κB signalling response. Variability in the responses (3.4±0.3 to 40.3±1.8 fold at 8 hours post 
challenge), could not be explained by flagellin, suggesting that other factors, host and bacterial, may 
also contribute to the intensity of the response. Analysing UPEC strains isolated from the urine of 
patients carrying a C1174T SNP encoding a truncated TLR-5 revealed such strains to induce normal 
NF-κB signalling (39.5±0.3 fold) in RT4 cells. These data emphasised the importance of TLR-5 and 
bacterial motility in the innate response of the host to a UTI.  
Human (h) βD-2, a member of the Defensin family with microbial killing properties, is important in 
the innate defences of the uroepithelium. To identify agents that could be used therapeutically to 
enhance the innate defences of the UT, a reporter construct (phβD-2-Luc), containing 2 kbp of hβD-
2 5’UTR sequence, was transfected into RT4 and VK-2 E6/E7 vaginal cells. Reporter activity (fold 
increase) was significantly increased with calcitriol (VitD, 10 nM), or 17β-oestradiol (17β-oes, 4 
nM), treatments when challenging VK-2 E6/E7 with either flagellin (68.1±8.5 vs. 196.3±28.3 for 
VitD, p<0.001, or vs. 199.5±37.7 for 17β-oes, p<0.01) or E. coli NCTC 10418(19.9±3.8 vs. 
40.1±4.3 for VitD, p<0.01) or vs. 40.2±6.6 for 17β-oes, p<0.05). The hβD-2 reporter data also 
revealed Zymosan (50 μg/ml) enhancing reporter activity in both cell lines (RT4 34.8±5.0 and VK-2 
E6/E7 27.2±2.9, both p<0.001) and had a synergistic effect to flagellin increasing reporter activity 
by more than 60 % (p<0.05). These data suggested that Zymosan, vitamin D as well as oestrogen 
regulate the hβD-2 gene.  
The expression of hβD-3, another member of the Defensin family with microbial killing properties, 
was identified in human bladder biopsies so its expression was further investigated in vitro. While no 
hβD-3 expression was measured in the RT4 cells, constitutive and inducible expression was 
identified in VK-2 E6/E7 cells. Human βD-3 expression was enhanced at 8 hours following 
challenge of the cells (PBS 70.5±13.4) with E. coli NCTC 10418 (1094.5±293.8, p<0.001), flagellin 
(518±139.2, p<0.01) and Zymosan (280.8±65.7, p<0.01). Induction was also observed with LPS but 
at 16 hours (27.0±8.1 (PBS), 612.2±260.8, p<0.001) but not with peptidoglycan (32.2±12.3, p>0.05). 
These data suggested that hβD-3 functions in the defence of urogenital tract and as its expression 
was inducible, a potential target for therapeutic strategies.  
The fungal cell wall β1,3-glucan, Zymosan, induced NF-κB signalling as well as hβD-2 in the RT4 
and VK-2 E6/E7 cells, and hβD-3 expression and secretion in VK-2 E6/E7 cells. Molecular analysis 
of the cell RNA identified the expression of three isoforms (417, 330, 211 bp) of the Dectin-1 
(CLEC7A) receptor and immunocytochemistry identified the receptor protein localised to the cell 
membrane. Following Zymosan challenge of VK-2 E6/E7 cells, receptor clustering and the 
phosphorylation of a Dectin-1 signalling protein, SYK was observed supporting the presence of 
functional receptors. Induction of NF-κB signalling by Zymosan was inhibited by blocking TLR-5 
(4.2±0.4 vs 2.8±0.1, p<0.01) suggesting functional interactions between Dectin-1 and TLR-5. These 
data provide support for the presence of Dectin-1 receptor in the urogenital tract.  
In conclusion, the data presented in this thesis confirms the importance of TLR-5 in the defence of 
the urogenital tissues. Investigations of hβD-2 and hβD-3 expression and their enhancement in the 
UT have led to the discovery of a role for the Dectin-1 receptor. This receptor represents a target for 
future therapeutic strategies to enhance the innate response.  
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1.1. INFECTIONS OF THE UROGENITAL TRACT 
The urinary tract is considered to be normally a sterile environment. However, it is 
frequently the site of clinical infection, urinary tract infection (UTI), resulting in 
symptoms, need for treatment and secondary health problems. In the UK for example, 
urinary tract infections are responsible for 1-3 % of all GP visits
1
, affecting mainly 
sexually active women and are defined by the presence of ≥104 CFU/ml of a single 
organisms or ≥105 CFU/ml in mixed cultures obtained from a midstream urine sample. 
In fact, between a half and three-quarters of all women will develop a urinary tract 
infection at least once in their lifetime
2
. Of these, 20 % to 50 % will experience 
recurrent UTI, defined as having two or more incidents of UTI in six months or three or 
more in 12 months
3,4
. Analysis of UTIs among female university students revealed an 
incident rate of 0.7 UTIs per person per year
5
. In a more general cohort the incident rate 
was 0.5 UTIs per person per year
5
. This high prevalence and the fact that it affects a 
productive age group mean that UTI has a significant socio-economic impact as well as 
causing personal distress to sufferers. In the United States for example it is estimated 
that US$1.6 billion are spent directly and indirectly for the treatment of UTIs
6
. 
1. TYPES OF URINARY TRACT INFECTIONS 
Urinary tract infections are classified according to the area of occurrence, urgency of 
treatment and the need of post-treatment evaluation, as well as by the presence or 
absence of symptoms. The most common variant is named uncomplicated lower UTI or 
acute cystitis and occurs in the bladder. The symptoms of cystitis vary from dysuria 
(painful micturition), haematuria (visible blood in the urine), suprapubic pain, frequency 
and urgency to urinate, causing great distress for the patients, and which last for an 
average of 6 days if left untreated
7
. Pyelonephritis is the infection of a kidney and 
relatively rare when compared to cystitis with around 12-13 cases of pyelonephritis per 
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10,000 population
8
. It causes symptoms of nausea, vomiting, fever and a typical flank 
pain sometimes preceded by symptoms of lower UTI
9
.  
Complicated cystitis and pyelonephritis are defined by the European Association of 
Urology (EAU) as UTI events combined with factors that raise the need for different 
treatment and an evaluation of patients before and after the treatment
10
. Such factors 
are: the environment where the infection was acquired, e.g. hospital-acquired UTI, the 
cause of infection, e.g. catheterisation, anatomical (vesicoureteric reflux) and functional 
(urine flow obstruction by renal stones) abnormalities, as well as the presence of 
pathological conditions predisposing to UTI, such as diabetes mellitus and the 
immunocompromised patient
11
. Occurrence of UTI in the elderly population often 
fulfils the criteria of complicated UTI and the mortality among elderly UTI patients can 
be up to 33 %
12
. 
Infections of urinary tract can also occur in the absence of symptoms. These infections 
are named asymptomatic bacteriuria (ABU). Hooton et al. (2000) showed that the risk 
factors associated with ABU are the same associated with symptomatic UTI, that ABUs 
are present in 5 % of women and that they increase the risk of developing a 
symptomatic bacteriuria
13
. In the UK, 17 % of elderly women were detected with an 
ABU
14,15
. 
2. RISKS ASSOCIATED WITH UTI 
The main population group affected by UTI is sexually active women, with an increased 
risk for diaphragm and spermicide users or women after the menopause
4
. Although 
sexually active women are the cohort with the highest risk, UTIs occur at all life stages 
and in both genders. In children, genetic factors and anatomical abnormalities are the 
major cause for infections
16
. In the elderly, the main risk for infection is incomplete 
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bladder emptying and greater use of urinary catheterisation
17
. Established risk factors 
for simple cystitis are listed in Table 1.1: 
Table 1.1 Risk factors for uncomplicated cystitis 
Risk Factor Cause 
Sexual activity  
Increased inoculation Urinary incontinence 
Faecal incontinence or constipation 
Spermicide 
Increased binding 
Oestrogen depletion  
Antimicrobial agents  
Decreased commensal ‘healthy’ flora of 
the vagina 
Inadequate fluid uptake (dehydration) Decreased urinary flow 
Diabetes mellitus  Enhanced medium for bacterial growth 
3. ROUTES OF INFECTION 
Infections of the urinary tract originate from a variety of routes (Figure 1.1). In the 
bladder, the most common infection route is through the urethra by bowel commensals 
which develop pathogenicity when they colonise the urinary tract. The inoculation is 
often strengthened during sexual intercourse. Interestingly, the uropathogenic strain is 
commonly found in the bowel reservoir of the sexual partner as well, indicating a 
possible source for re-infection
18
. 
Pathogens can also be introduced into the sterile urinary environment through urinary 
catheterisation, a particular risk for patients requiring long term indwelling or 
intermittent catheterisation and those requiring catheter urinary drainage as part of 
intensive care
17
. 
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 The most common route of infection of the kidney is believed to originate from 
bacteria ascending from the bladder up along the ureters
19
. Recently, the role of 
bacterial ascension of uropathogenic bacteria to the kidneys has been questioned. While 
some investigators conclude that the ascending migration of uropathogens from the 
bladder is possible, the same authors view that this event is uncommon
20,21
. An 
alternative route of kidney infection is from the blood stream to the kidney through the 
glomerulus. This route of infection can occur during surgical procedures although it is 
quite rare due to the sterile operating environments.  
 
 
Figure 1.1 Routes of infection in the Urinary Tract. (1) Uropathogenic Escherichia 
coli entering the urinary tract by ascending the urethra. (2) Cystitis (infection of the 
bladder). (3) UPEC ascending the ureter to infect the kidneys causing (4) 
pyelonephritis. (5) Descending pyelonephritis caused by Sepsis. Diagram extracted 
from Kaper et al.(2004)
19
. 
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1.2. UTI ASSOCIATED PATHOGENS 
Many pathogenic microorganisms are able to infect the urinary tract, e.g. viruses, 
bacteria and fungi, although viral and fungal infections are very rare and mainly found 
in immunocompromised or kidney transplant patients
8
.  
Bacterial infection can be caused either by Gram-positive species, e.g. Enterococcus 
faecalis and Staphylococcus saprophyticus (responsible for 5-15 % of all UTI infections 
and mainly found events of cystitis)
6,22
, or more commonly Gram-negatives, e.g. 
Pseudomonas aeruginosa and Enterobacter species, such as Klebsiella spp., Proteus 
mirabilis, Serratia marcescens and Escherichia coli (E. coli). The bowel commensal E. 
coli is responsible for the vast majority of occurrences of UTI accounting for between 
70 % in dependent care environments such as hospitals and nursing homes and 95 % in 
the case of community-acquired infections in young women. Because of this 
preponderance, the investigation carried out and described in this thesis will focus on 
the main pathogen E. coli. 
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1.3. UROPATHOGENIC ESCHERICHIA COLI  (UPEC) 
 
Figure 1.2 Uropathogenic Escherichia coli with its virulence factor. E. coli shown in 
the centre of the image. Host tissue represents the uroepithelium. The four groups of 
virulence factors are shown: 1) Adherence proteins attach to molecules present in the 
plasma membrane of the uroepithelium. 2) Toxins (α-haemolysin, cytotoxic necrotising 
factor). 3) Siderophore (aerobactin, enterobactin). 4) Membrane changing complexes 
(capsule and LPS manipulating proteins, control of flagellin production). Diagram 
extracted from Johnson (1991)
23
. 
The main source of E. coli infection of the urinary tract is the host’s own bowel flora or 
infection from the bowel flora of a sexual partner
24
. Nonetheless, certain virulence 
factors are necessary for a bowel derived commensal E. coli to become an 
uropathogenic E. coli (UPEC, Fig. 1.2). Investigations comparing the genome of faecal 
originated E. coli and UPECs show several differences, including absence of a type 3 
secretion system and the presence of genes encoding urinary tract virulence factors
25
.  
1. VIRULENCE FACTORS ASSOCIATED WITH UROPATHOGENIC 
ESCHERICHIA COLI  
Four classes of virulence factors are found to be necessary for a wild type and bowel 
derived E. coli to become a UPEC, able to colonise the urinary tract and cause 
symptomatic infection.  
Uroepithelium 
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The first one is the acquisition of iron by the uptake of siderophores, which extract free 
or protein-bound iron from the urine and the uroepithelium, or through the uptake of 
haem moieties. Both iron acquisition mechanisms enhance absorption of iron by the 
bacteria through outer membrane transporters
26
. Examples of functional siderophores 
are aerobactin, enterobactin and its glucosylated form salmochelin, and yersiniabactin
26
. 
The latter two are more common among UPECs when compared to commensal E. coli 
strains isolated from faeces
27
.  
The second type of virulence factor postulated as essential for UPEC colonisation of the 
urinary tract is the presence of adherence proteins named pili or fimbriae
23
. They are 
involved in the attachment of the bacteria to the uroepithelium
23
. The two major pili 
investigated in UTI are P-fimbriae and Type 1 fimbriae
23,28,29
. It has been noticed that 
Type P fimbriae mainly contribute to UPEC attachment to the renal rather than bladder 
epithelium
30
. In clinical isolates from cystitis patients, the genes involved in the P-
fimbriae production were only present in 33 % of the isolates
31
. In the lower urinary 
tract, Type 1 fimbriae are necessary for attachment
32
. Type 1 fimbriae are helical rods of 
repeating FimA subunits with a FimH subunit at the distal tip which when they adhere 
to recognition molecules on the uroepithelial cell surface cause exfoliation of the 
umbrella cells which form the luminal uroepithelial surface
33
. An explanation for this 
differential attachment according to anatomical location could be the localisation of 
ligands of the adherence proteins on the host cell surface. While type 1 fimbriae mainly 
bind to the uroplakins Ia and Ib found in umbrella cells of the uroepithelium in the 
bladder, the PapG adherence molecule of P-fimbriae recognises α-D-galactopyranosyl-
(1-4)-β-D-galactopyranoside, a major glycolipid found in renal epithelium34.  
The third class of virulence factor for the infection of the urinary tract is secretion of 
toxins by the bacteria, e.g. α-hemolysin, cytotoxic necrotising factor 1 and 2, and 
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secreted autotransporter toxin (sat). Alpha-hemolysin is responsible for Ca
+ 
oscillation 
across the renal epithelial cells resulting in cell lysis in a concentration dependent 
manner
35
.  
The fourth class of virulence factors consists of methods of circumventing and 
inhibiting immune protective responses activated by the host. At present, two 
mechanisms are known: First, it has been demonstrated that the laboratory standard 
UPEC strain NU14 can modify the composition of its cell surface. Using the genes 
ampG and waaL, it can change the structure of the peptidoglycan and 
lipopolysaccharide (LPS) membrane, avoiding recognition by the host receptors on 
luminal uroepithelial cells
36
. Secondly, another laboratory UPEC strain, CFT 073 has 
been shown to produce a protein that mimics the activation domain of a host adaptor 
protein involved in the recognition of the pathogen (see section 1.4), thereby inhibiting 
initiation of a host immune response
37
. 
Additionally, intracellular bacterial colonies (IBC) have been reported in mice. UPEC 
binds to umbrella cells of the bladder and is engulfed by the uroepithelial cell. In 
humans, preliminary findings suggest that such IBC cultures can be detected in 
exfoliated epithelia cells
3
.  
Controversy remains about the actual and relative importance of the described virulence 
factors: There is evidence that the adherence through P-fimbriae or type 1 fimbriae is 
not necessary for a UPEC infection of the bladder or the kidney
38
. It was shown that the 
gene for α-hemolysin was present in only 25-35 % of isolates from urinary tract 
infections
31,39
. Of these, some strains did not express functional haemolytic activity 
even if the gene was present
39
. 
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More intriguingly, in a study detecting main virulence present on 550 E. coli clinical 
isolates from people suffering infections of the urinary tract, and 318 strains isolated 
from the surroundings of the urethra and from faeces of the same patients, found that 
around 50 % of the UPEC strains had none or only one of the virulence genes
40
. The 
majority of the E. coli isolated from the bowel and from cystitis had one of the Fim 
genes, which form the fimbriae. Hence, the presence and particular combination of 
virulence factors alone does not explain a successful infection of the bladder
40
. 
Other research has shown that untreated UTIs have a spontaneous cure rate of 37 % 
after 5-7 weeks
41
, suggesting that bacteria can be eradicated by the host defence 
mechanisms. The ways in which the host may eliminate urinary pathogens and hence 
avert or resolve symptomatic infection will be discussed next. 
1.4. IMMUNE MECHANISMS ACTIVE IN THE 
UROGENITAL TRACT DURING INFECTION 
The immune system has been classically divided into two types: the evolutionary older 
one being named the innate immune system, which is non-specific. In contrast, the 
evolutionary later adaptive immune system present in vertebrates is specific due to the 
recognition of a single processed antigen.  
1. ADAPTIVE IMMUNE SYSTEM IN UTI 
The adaptive immune system is composed of two different types of lymphocytes. Both 
cell types have their progenitor in the bone marrow and depending on the location of 
maturation they are classified as bone marrow cells (B-cells) or thymus cells (T-cells). 
T-cells are characterised by the presence of the T- cell receptor (TCR). Additionally, the 
function of the T-cell is determined by the presence of the receptors CD-8 or CD-4. The 
sub-type CD-8+ T-cells are called killer T-cells and are responsible for the cell 
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mediated immune response. The sub-type CD-4+ cells can be differentiated into helper 
T-cell variants; Th1, Th2, and Th17. T-helper cells are involved in the maturation of 
killer T-cells and of B-cells.  
The activation of B-cells is dependent on the recognition of an antigen by the B-cell 
receptor (BCR) and the co-stimulation of a helper T-cell. Upon activation, the B-cells 
are induced to proliferate and differentiate into plasma cells, which secrete specific 
antibodies into the local tissue or blood stream, or into long-lived memory B-cells. B-
cells are therefore responsible for the humoral immune response. 
The presence of activated lymphocytes and antibodies has been detected during urinary 
tract infection
42,43
. However, our knowledge about the role of lymphocytes during 
urinary tract infections is limited and mainly obtained using mice models. Hence, their 
role can only be estimated. A strong indicator of a required role is the finding that nude 
mice are unable to clear a urinary tract infection
44
.  
2. THE INNATE IMMUNE SYSTEM 
For maturation of lymphocytes it is essential that an antigen is processed and presented. 
The presentation of the antigen is conducted by several different types of cells, named 
accordingly as antigen presenting cells (APC). These cells link the adaptive and the 
innate immune systems. They present the antigen using the major histocompatability 
complex (MHC)-type 1 and 2
a
. MHC-1 is expressed by all nucleated cells while MHC-2 
is only expressed by certain cells. Examples of APCs are dendritic cells, mast cells, 
macrophages and B-cells. The infiltration of dendritic cells and macrophages into 
urinary tissues during UTI has been shown previously
42
 and investigations showed that 
dendritic cells not only uptake UPEC, but also release nitric oxide
45
. The same group 
                                                 
a
 The MHC molecules are named Human Leukocyte Antigen (HLA) in humans 
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later showed that monocytes migrated to the bladder, through a CCR2 mediated 
mechanism during UTI
46
. Nonetheless, these investigators concluded that neither 
dendritic cells nor monocytes are necessary for clearance of bacteria causing UTI
45,46
. 
Macrophages, together with other phagocytes such as neutrophils, can in addition to 
their antigen presenting function engulf bacteria via phagocytosis. 
Some lymphoid cells are considered part of the innate immunity and are termed natural 
killer cells (NK-cells). Although NK-cells have the same progenitor as the other 
lymphocytes (B- and T-cells), they lack their characteristic BCR and TCR. Nonetheless, 
they have the ability to kill many different types of cells. It has been shown that they 
can be activated by bacteria FimH through the cell surface pattern-recognition molecule, 
Toll-like receptor-4 (TLR-4)
47
.  
Neutrophils
b
 are granulocytes or polymorphonuclear leukocytes (PMN) and the first 
dedicated innate immune cell type to infiltrate the bladder wall and the urine upon 
bacterial infection. They are attracted by cytokines such as interleukin-8 (IL-8) secreted 
by the uroepithelium following contact adherence by colonising bacteria
48-50
. In contrast 
to the APCs, the PMN cell types are deemed to be essential for effective clearance of 
bacteria causing UTI
51
.  
Upon activation, PMN granulocytes degranulate to release a mixture of different 
antimicrobial peptides and reactive oxygen species
52
. The relative density of neutrophil 
migration during UTI is much higher in the human than in mice. This may be linked to 
the finding that 70 % of leukocytes in human blood are PMNs compared to 30 % in 
mice
53
.   
                                                 
b
 Neutrophils are defined as neutral because of their staining properties, using hematoxylin and eosin 
(H&E) staining, where the granules are stained by both stains resulting in a purple colour.  
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As mentioned before, migration and activation of neutrophils require the presence of 
chemo-attractants secreted by the urothelium. It therefore follows that the uroepithelium 
plays a pivotal crucial role in the early host immune response to UPEC infections. 
1.5. THE ROLE OF THE UROGENITAL EPITHELIA DURING 
UTIS 
The epithelium forms a cell layer covering organs and tissues. It is the first line of 
contact with the external environment (although often internal to the body), and hence it 
is constantly under challenge from external attack. Epithelia have diverse functions, 
depending on location, i.e. barrier, secretion, absorption and sensing functions
54
. In 
recent years, the epithelium has been recognised as a highly effective part of the 
immune system, not only by providing passive barrier function, but also by the active 
recognition and direct killing of pathogens, as well as inducing innate and adaptive 
immune responses
55,56
.  
The uroepithelium that lines the inner luminal surface of the urinary bladder originates 
from the endoderm
57
 and includes three different layers (Fig. 1.3):  
 A  B 
Figure 1.3 Uroepithelium and asymmetric unit membrane. (A) The three layers of 
Uroepithelium. 1. Umbrella cells with multiple nuclei. 2. Intermediate uroepithelium and 3. 
Basal cell layer. Image adapted from 
http://www.dartmouth.edu/~anatomy/Histo/lab_5/renal/DMS154/50.gif. (B) Asymmetric unit 
membrane formed by uroplakins. Image extracted from Lewis (2000)
58
. 
 
1. Umbrella Cells 
2 
3 
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An apical layer of cells directed to the lumen of the bladder named umbrella cells due to 
their shape, a pear-shaped intermediate layer composed of one to several layers of 
transitional epithelial cells and a basal layer with a monolayer of small (10 μm) 
progenitor cells (Fig. 1.3)
54,59
. The outermost epithelial umbrella cells are large (25-250 
μm) in comparison to the intermediate and basal cells and multinucleated59. Depending 
on the filling state of the bladder, the shape of the apical and intermediate cells varies 
from cuboidal shape (empty bladder) to squamous cells (filled bladder), hence the name 
transitional
54
.  
The barrier function of the umbrella cells is provided by inter-cellular tight junctions 
formed by occludins and claudins
60
. Claudins-3, -4, -5, -7, -8 and -12 are expressed in 
human uroepithelium
60
. They inhibit the influx of urine and its constituents into the 
bladder epithelium and the invasion of pathogens
58,61,62
. A unique set of proteins are 
located on the luminal surface of the umbrella cell surface, termed uroplakins. These 
structural proteins form hexagonal plaques named the asymmetric unit membrane, and 
composed of uroplakin (UP) dimers; UP Ia-UP III dimers and UP Ib-UP II dimers
60
. 
Another particular aspect of the umbrella cells is their high lipid composition with high 
concentrations of phosphotidyl choline, cholesterol and cerebroside
59
.  
1.6. PATTERN RECOGNITION RECEPTORS IN THE 
UROEPITHELIUM 
The sentinel function of the uroepithelium is provided by a group of intracellular and 
cell-surface receptors with the common function of recognising pathogen associated 
molecular patterns (PAMPs) which are present on the cell surface and within the cell. 
Accordingly, they are named pattern recognition receptors (PRRs). Recent research has 
mainly focussed on four families of PRRs, i.e. the intracellular retinoic acid inducible 
(RIG)-I gene like receptor (RLR) and nucleotide-binding oligomerisation domain 
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(NOD) like receptor (NLR), the cell-surface C-type lectin receptors (CLR), and the 
intra- and cell-surface receptor family of TOLL-like receptors (TLR)
63
.  
RIG-I is expressed in the uroepithelium when induced by inflammatory cells or 
interferon gamma (IFN-γ)64. The RLR recognise viral double stranded DNA and they 
induce the release of type 1 interferon (IFN-I) when activated
65
. They do not participate 
in an immune response during a bacterial urinary tract infection. 
The second group of PRR are the intracellular NOD-like receptor (NLR). Although 
some NLR recognise viral PAMPs, the majority of them recognise microbial motifs. 
The best characterised NLRs are NOD-1 and NOD-2. They recognise part of 
peptidoglycans, g-D-glutamyl-meso-diaminopimelic acid (iE-DAP) and muramyl 
dipeptide (MDP), respectively. iE-DAP is present on Gram negative bacilli and some 
Gram positive species such as Bacillus subtilis, while MDP is present on all cell  
walls 
63,66,67
.  
CLRs are receptors which detect fungal infections or endogenous ligands
68
. The best 
characterised is the Dectin-1 receptor (CLEC7A), a Ca
+
-independent CLR that 
recognises β-1,3-glucans, e.g. Zymosan, found on the membrane surface of fungi, e.g. 
saccharomyces, candida and aspergillus
69,70
. Dectin-1 was first discovered in dendritic 
cells and shown to be the principle receptor for fungal recognition by macrophages
71-73
.  
Recent investigations have demonstrated the expression of Dectin-1 in pulmonary 
epithelial cells and keratinocytes
74,75
. Dectin-1 recognises β-1,3-glucans through its N-
terminal expressed carbohydrate recognition domain (CRD). Upon binding to β-1,3-
glucans, Dectin-1 starts a signalling cascade through spleen tyrosine kinase (SYK), 
resulting in the translocation of the proinflammatory transcription factor NF-κB to the 
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nucleus, hence promoting an immunological response
76
. Interestingly, interactions with 
TLR-2 have been reported
77
.  
1. TOLL-LIKE RECEPTORS IN THE UROEPITHELIUM  
TLR-2 is part of the TLR-family composed of 11 receptors (TLR-1 to -12; murine TLR-
7 is homologous to human TLR-8) in mammals
65
. TLRs were among the first 
discovered and best characterised PRRs and are present in the epithelia of many 
different tissues
78
. TLRs may be located intracellularly (TLR-3, -8, -9, -10), or in the 
plasma membrane (TLR-1, -2, -4, -5, -6) or in both locations (TLR-4) and are able to 
recognise PAMPs from a variety of microorganisms, such as bacteria, parasites, fungi, 
protozoa as well as viruses and endogenous ligands
79
. Table 1.2 summarises the known 
TLRs and their ligands:  
Table 1.2 Toll like receptors and their ligands. Receptors in brackets are only 
found in mice. 
Cell-surface Ligand 
TLR-2/TLR-1 
Peptidoglycans  
TLR-2/TLR-6 
TLR-4 LPS, among others 
TLR-5 Flagellin 
(TLR-11) unknown UPEC ligand and 
Profilin 
Intracellular Ligand 
TLR-3 dsRNA 
TLR-8 (TLR-7) ssRNA 
TLR-9 CpG-DNA 
(TLR10*) unknown 
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They are homologues of the original Toll-receptor found in 1985 in Drosophila 
melanogaster, where a mutation in the gene changed embryogenesis
80
. Eleven years 
later, protection of fungal infection was associated with the Toll-gene and since then the 
role of TLRs as the principal family of pattern recognition receptors in mammals has 
been established
65
. The investigation described in this thesis will focus on the role of 
extracellular TLRs in the human uroepithelium. Hence, the next part will describe the 
cell-surface TLR’s structure and signalling (Figure 1.4): 
 
Figure 1.4 Extracellular TLRs and their ligands. The cell-surface homodimers TLR-
4 and TLR-5 are shown together with the heterodimer TLR-2/TLR-1 and TLR-2/TLR-
6. Diagram adapted from Kawai et Akira (2010)
65
. 
Structurally, TLRs have a characteristic extracellular leucine-rich repeat at the N-
terminal and an intracellular TOLL/IL-1R homology domain (TIR) responsible for 
ligand induced signalling. Upon recognition of their respective ligands some TLRs form 
homodimers (TLR-4 and -5) or heterodimers (TLR-2/-1, TLR-2/-6) with each other.  
Leucine-rich repeats 
TIR-domain 
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TLRs have been described as having a role in the detection of bacterial UTI. Previous 
research has mainly focussed on mice as an animal model and in particular the role of 
TLR-4. TLR-4
-/-
 mice and C3H/HeJ mice with a mutated TLR-4 gene fail to resolve 
UPEC infections
81,82
. A human correlate of these experimental studies is that a genetic 
mutation in the TLR-4 gene (substitution AC at position 896) found in humans 
increases the risk of recurrent UTIs in childhood
83
. Additionally, children with 
syndromes associated with reduced TLR-4 expression tend to have persistent 
asymptomatic bacteriurea
84
. However, the importance of TLR-4 in human UTI remains 
controversial. TLR-4 is exclusively expressed on superficial umbrella cells which 
exfoliate upon recognition of UPECs
85-87
 and its cofactor CD14 is only found in the 
bladder submucosa
88
. In the human, Hawn et al. (2009) showed that a TLR-4 
polymorphism, which results in a LPS-hyporesponsive TLR-4, protects adult women 
from recurrent UTI
89
 and other studies have established that TLR-4 independent 
mechanisms can result in UPEC clearing
90
.  
In mice, TLR-2 does not appear to play a role in UPEC clearance
91
. In humans, 
however, a SNP in the TLR-2 gene (2251 GA mutation resulting in a Arg753Gln) is 
associated with a higher risk for recurrent UTI and asymptomatic UTI in children
92
. In 
contrast, the investigation of Hawn et al. (2009) showed no significant effect of the 
polymorphism in adult women
89
, although a significantly higher number of ABU was 
noticed
93
. Interestingly, a polymorphism in the TLR-2 associated TLR-1 gene was 
shown to have a protective effect for pyelonephritis
89
. 
The final cell surface TLR characterised in humans is TLR-5. It recognises flagellin 
(FliC), a subunit of the flagellum apparatus responsible for bacterial motility
94
. The role 
of TLR-5 in UTI is not clearly defined. UPEC seems to be able not only to sense the 
presence of TLR-5 but also to switch off its flagella and turn on the FimH production, 
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suggesting no role for TLR-5 in UTI in mice
20,21
. However, TLR-5
-/-
 mice were highly 
prone to UTIs
95
 and in adult humans, the only gene polymorphism associated with a 
higher incidence of recurrent UTI involved the TLR-5 gene
89
. Hence the role of TLR-5 
in the human urinary tract is a legitimate target for further investigation.  
It is important to note that murine TLR-11, a cell surface TLR closely related to TLR-5, 
seems to be important for clearing UPEC infections in mice
90
. In humans however, the 
gene for TLR-11 is truncated and hence not expressed
90
, indicating again problems with 
using mice as a model organism for human UTI. 
In conclusion, the role of cell surface TLRs remains controversial and needs to be better 
defined in the human uroepithelium, as the relevance of findings in the mice model to 
the human situation is compromised by the many structural, molecular and genetic 
differences between murine and human uroepithelium. Hence, the definition of the role 
of each cell-surface TLR in a human model system will be one of the major aims of this 
investigation.  
2. SIGNALLING CASCADE OF CELL SURFACE TLRS 
Activation of TLRs starts a signalling cascade, which leads to the upregulation of many 
genes. Different signalling pathways have been described for specific TLRs and broadly 
defined as MyD88 dependent or independent. All TLRs, except TLR-3, start a 
signalling cascade using the MyD88 pathway, although TLR-4 was shown to use at 
least two MyD88 independent signalling pathways
56,65,96
. The research described in this 
thesis will focus on MyD88 dependent TLRs as shown in Figure 1.5: 
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Figure 1.5. MyD88- dependent TLR-signalling. TLR-5 binds directly to its signalling adaptor 
protein MyD88, while TLR-4 and the TLR-2 heterodimers need TIRAP Diagram extracted from 
Takeuchi et Akira (2010)
79
. 
Upon ligand-binding, TLR-5 directly, and TLR-2/TLR-1, TLR-2/TLR6 heterodimers 
and TLR-4 through TIRAP, activate MyD88 which subsequently binds to IRAK-4 
through its death domain. The complex binds then to IRAK-1 and IRAK-2 releasing the 
IRAK complex from the MyD88. The IRAK-complex then unites with TRAF-6, ubc13 
and Uev1A, resulting in an unconjugated free lysine 63 polyubiquitin chain which 
forms a complex with TAK1, TAB1, TAB2 and TAB3. This complex then 
phosphorylates the inhibitor of NF-kB (IkB), causing its degradation. NF-kB 
translocates to the nucleus where it acts as a transcription factor for a series of immune-
active genes, such as those encoding antimicrobial peptides and cytokines. 
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3. PROTEINS ASSOCIATED WITH TLR INDUCED IMMUNE 
RESPONSES 
Studies suggest that cationic anti-microbial peptides (CAMP) such as human -
Defensin 1 (hBD-1), human -Defensin 5 (HD-5) and the cathelicidin, LL-37, are 
important for urogenital epithelial defence
97
.  
I. CATHELICIDINS 
The cathelicidin family is a group of peptides synthesised in mammals and with 
antimicrobial as well as chemo-attractive properties
98
. Although other mammals e.g. 
sheep and mice, have more than one cathelicidin gene
12,99
 only one has been found to be 
expressed in humans; that encoding LL-37
100
, being synthesised as a propeptide and 
cleaved extra-cellularly into cathelin and the C-terminal peptide also known as LL-37
98
. 
Interestingly, both peptides have antimicrobial activity and interact with FimH 
suggesting that cathelicidin plays a key role in the protection of the UT against bacterial 
(E. coli) infection, although whether the peptide originates from the kidney or the lower 
urinary tract urothelium is undetermined
100,101
.  
II. DEFENSINS 
Another family of CAMPs are the Defensins. They were first characterised in humans 
in skin tissue where these cationic peptides show a broad spectrum of activity
102
. They 
are active against gram-negative as wells as gram-positive bacteria, fungi, some 
parasites and enveloped viruses.  
All Defensins are cationic, due to their high number of lysine and arginine residues 
103,104
. In humans, six highly conserved cysteines form three disulfide bridges. Based on 
the order of this disulfide bridges, the Defensins are subdivided into α or β-Defensins105. 
The order of cysteine forming disulfide bridges is 1–6, 2–4 and 3–5 for α-Defensins and 
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1–5, 2–4 and 3–6 for β-Defensins105. Human α-Defensins and β-Defensin (hβD) 
originate from a common β-Defensin ancestor, hence show a similar secondary 
structure of three β-sheets and one α-helix, have hydrophobic and hydrophilic parts and 
are therefore amphipathic
103,106
. 
The mechanisms by which the Defensins kill microbes are not yet completely 
understood. There are three widely described models: the carpet model, the pore model 
and the inhibition of DNA, RNA and protein synthesis
105
. The carpet model compares 
the β-Defensins to classic detergents, where they bind at high concentration to the 
phospholipid head forming a “carpet” layer, neutralising the negatively charged 
membrane and thereby destroying the transmembrane action potential
103
. The second 
model makes use of hβD amphiphilic properties. First, the positively charged β-
Defensin attaches to the negatively charged bacterial membrane due to the lipid 
composition, then it fuses with the membrane because of hydrophobic interactions 
between the lipid core and β-Defensin molecules and finally, oligomerizes with other β-
Defensins forming a multimeric channel
105
. The third model was based on observations 
that Defensins inhibit the synthesis of DNA, RNA and proteins
107
. To date, none of the 
models have been conclusively proven experimentally but it is probable that the killing 
mechanism in vivo is a combination of all three. 
III. HUMAN BETA DEFENSINS (hβD)  
Human β-Defensin 1 (hβD-1) is ubiquitously expressed by human epithelia, but when 
its killing activities are compared to other Defensins, i.e. hβD-2 & 3, it has only weak 
killing capacity. Mice, which lack defb1 (the gene encoding hβD-1) have a higher risk 
of developing bacteriuria
108
. Recent work by Schroeder et al. (2011) has shown that in 
reducing environments such as those found in the gastro-intestinal tract, the disulphide-
bridges of hβD-1 are broken109. Following reduction the peptide has increased killing 
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properties against the fungus Candida albicans (an opportunistic pathogen in the uro-
genital tract) and anaerobic, Gram-positive commensals including Bifidobacterium and 
Lactobacillus species. The results of this study are novel and exciting as they suggest 
that reduced hβD-1 exists in vivo and helps to protect the healthy epithelium against 
colonisation by commensal bacteria and opportunistic fungi. This in turn indicates an 
important interaction between redox-regulation and the epithelial innate immune 
defences.  
The human β-Defensin 2 (hβD-2, DEFB 4) gene (238 base pairs; bp) is located in the 
Defensin gene cluster on chromosome 8p23.1-p22. The gene contains two exons: the 
first exon (81 bp) encodes the signal peptide and the proform; the second exon encodes 
the mature peptide. The expression of the hβD-2 peptide is induced by many different 
signals, including, for example, presence of cytokines such as interleukin-1α; -1β; 
tumour necrosis factor alpha (TNF-α); IFN-γ. PAMPs, including flagellin and 
lipopolysaccharide (LPS) can induce hβD-2 via Toll-like-receptors, as well110.  
The gene for hBD-3 (DEFB103) is located 13 kbp upstream of hβD-2105. It is composed 
of two exons and encodes a 67 amino acid propeptide that is cleaved into a 45 amino 
acid active peptide
102
. It has a primary amino acid sequence that is dissimilar to the 
other hβDs and its charged amino acids are asymmetrically distributed with most 
clustered towards the C-terminus
102. HβD-3 molecules are amphipathic and can form 
symmetrical dimers although dimerisation does not seem to be involved in its 
antimicrobial activity
102
. 
Regarding the β-Defensins, the main research focus has been related to investigations of 
their antimicrobial activity
111,112
. Beta-Defensins are able to inhibit growth or kill 
bacteria, fungi and even viruses
109,110
. Human βD-2 was reported to have a strong 
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killing activity against Gram-negative bacteria primarily and some fungi, while hBD-3 
is a strong inhibitor of both Gram-negative and Gram-positive bacteria, as well as 
yeast
110
. Both Defensins are more effective against aerobic than anaerobic bacteria. 
Interestingly, the activity of hβD-2 is strongly inhibited by sodium chloride at 
physiological concentrations
113
, whilst the antimicrobial activity of hβD-3 is not103. 
Previous research has also shown that β-Defensins have other functions; hβD-2 has 
chemotactic properties for different cell types, including T-cells and immature dendritic 
cells, as well as keratinocytes
110,114
. Human βD-2 also has the ability to activate 
macrophages, which provides a link to the adaptive immune system through the 
activities of TH-cells. In turn, TH-cells can signal the production of hβD-2 through 
releasing different cytokines
115
, supporting a self-perpetuating innate defence system. 
This loop can be turned off by the immunosuppressive activity of hβD-3116 highlighting 
potential interactions between the different antimicrobial peptides. 
IV. INTERLEUKIN 8 (IL-8) 
As mentioned earlier, NF-κB translocation to the nucleus results in expression and 
secretion of cytokines. The most important cytokine involved in UTI is interleukin-8 
(IL-8). It is part of the interleukin family and responsible for the chemo-attraction of 
neutrophils. It is well known that the urogenital tract epithelia secrete IL-8 in response 
to pathogens such as UPEC
117,118
. The secretion of IL-8 induces a strong infiltration of 
neutrophils into the urinary bladder
48
. Other cytokines and chemokines induced in the 
bladder by UPEC are CCL2, CCL4, CCL5, CXCL, βIL12P40 and IL17, although only 
analysed in bladder rather than elsewhere in the urogenital tract
119
. In humans, IL-6 has 
also been found to be secreted in response to bacterial infection although these data 
come from analysis of the whole bladder
120
 or from cell lines derived from a bladder 
carcinoma
121
 with no specific localisation to the uroepithelium. A further study showed 
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that IL-6 was only found in carcinomatous or inflamed (interstitial cystitis) 
uroepithelium
117
. Other cytokines, such as transforming growth factor beta (TGF-β) and 
IL-4 were present in normal tissue or only in carcinomatous uroepithelial cells, 
respectively
117
.  
V. OTHER INNATE FACTORS   
Other important urinary innate defence factors are Tamm-Horsfall protein (THP), a 
glycoprotein synthesised by the kidney and which functions to prevent bacterial 
attachment and colonisation of the uroepithelium, together with lactoferrin and 
lysozyme
55
. 
In addition, the complement system is also thought to play a key role during UTI
122
. 
This involves pathogens being opsonised by C3b which facilitates their recognition, and 
with other factors such as C3a and C5a facilitating clearance by phagocytes. However, 
the consequences of complement activation may be negative in UTI since complement 
activation can lead to the internalisation of bacteria, potentially leading to subsequent 
recurrent infection when the initial inflammatory response subsides
122
. A reduction of 
the complement response also reduces any damage to infected tissue, shown in the 
kidney
122
. Interestingly, the complete absence of complement inhibits UPEC moving 
from the bladder upwards to the kidneys
123
. 
1.7. PATHWAYS FOR THERAPEUTIC INTERVENTION 
The main, and generally very successful, therapy for UTI is the use of antibiotic 
medication. Unfortunately, several unwanted affects may arise from this treatment. 
First, E. coli is possibly able to form intracellular colonies and biofilms circumventing 
urinary antibiotic activity. Second, antibiotic resistance among UPEC strains is 
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increasing and overuse of antibiotics for many mild self-limiting infections such as 
cystitis and upper respiratory tract infection is increasing this problem
8,124,125
. Hence 
alternative routes urgently need to be investigated.  
The finding that adaptive immunity may play a role in defence against UTI encouraged 
many researches to focus on the development of vaccines using a number of different 
approaches. The first approach was the delivery of antigens normally found in UPEC 
strains. Some target proteins were the proteins involved in LPS synthesis, P-fimbriae, 
Type 1 Fimbriae and α-haemolysin126-128. Each vaccine only showed moderate success 
and none have entered routine practice. There are different causes for this failure. As 
mentioned earlier, UPEC are able to change their LPS structure, thereby avoiding 
tagging by specific antibodies. Additionally, although a P-fimbriae vaccine might be 
specific to the rarer pyelonephritis, it will not be of use in the far more common 
condition of simple cystitis where the role of P-fimbriae appears limited. Type 1 
fimbriae expression is phase variant meaning that the gene is turned on or off depending 
on presence of particular transcription factors. It is also, together with α-haemolysin, not 
a suitable antigen as many of the commensal gut E. coli strains express it. Vaccination 
using specific antigens only could therefore be ineffective and potentially dangerous 
due to its specificity for non-UPEC strains such as the one present in the normal gut 
flora. To avoid these problems, Sivick et al. (2009) screened for proteins only expressed 
in UPECs and found that outer membrane proteins involved in iron uptake were 
fulfilling the pathogen-specific, antigenic, surface-exposed, and in vivo expressed 
(PASivE) requirements
129
. IroN has been used before to immunise mice and it reduced 
the risk of pyelonephritis
130
. Nonetheless, the number and bacterial load of the bladder 
remained constant, maybe indicating a more important role for the innate rather than 
adaptive immunity in bladder infection.  
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Vaccination using whole UPEC organisms has also been investigated. However, side 
effects due to the unspecific antigenic response could be dangerous. Indeed, studies 
using a vaccine composed of 18 UPEC strains showed severe side effects
130
.  
Interestingly, one of the most effective approaches is the inoculation of ABU strains. In 
2001, Darouiche et al. inoculated patients with spinal cord injuries with the ABU strain 
83972 and showed a significant reduction of recurrent UTI compared to the control 
group
131
. In 2006, Roos et al., showed that ABU strain 83972 is able to outcompete 
many UPECs, among them the previously discussed CFT 073 and NU14 strains, in 
urine and in a murine UTI model
132
. It was later shown that ABU 83972 was better in 
forming bio-films when growing in urine
133
.  
Another therapy angle is the modulation of the innate immunity. It is believed that the 
consumption of cranberry juice is able to increase the resistance to recurrent UTI 
although this practice is controversial
134-136
. 
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1.8. BACKGROUND TO RESEARCH 
Pilot work towards this thesis carried out and described in an MRes dissertation 
(unpublished data available from the Author) resulted in the production of an uro-
epithelial cell line (RT4) stably transfected with a NF-κB-Luciferase reporter gene 
construct
137
. This allowed the investigation of NF-κB signalling response of 
uroepithelial cells to bacteria and PAMPs. Flagellin, but not LPS, was identified 
through this work as being a NF-κB activator. In addition, TLR-2, 4 and 5 were all 
identified as being expressed by RT4 uroepithelial cells. Analysis of human tissue 
samples from different levels in the urinary tract using quantitative PCR showed TLR-5 
expression was predominant in ureter and bladder biopsies and TLR4 in the kidney. 
Data from in vitro experiments carried out in our laboratory have shown that RT4 cells, 
used as an in vitro model of the urothelium, when challenged with flagellin originating 
from Salmonella typhimurium secrete the Defensin hβD-2 (Mr Ased Ali, PhD Thesis, 
Newcastle University).  
Little is known about the mechanisms by which the urinary tract, despite being 
challenged continuously by potential pathogens, is able to maintain its sterility. Thus 
this PhD project has a broad aim to increase our understanding of the interactions 
between urinary pathogens and the host epithelium, particularly in relation to the cell-
surface TLRs and Defensin family. 
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1.9. HYPOTHESIS 
The hypothesis that I wished to investigate was: 
Innate Immune Response in the Urinary Tract is dependent 
on Host Recognition of bacterial motility and can be enhanced 
by Immunomodulatory Compounds. 
1.10. AIMS AND OBJECTIVES 
Protection of the urogenital tract from infection is mediated primarily through the innate 
immune system, but still, to date, little is known of the host mechanisms that function in 
such defences. The focus of the research presented in this thesis, which used RT4 and 
VK-2 E6/E7 in vitro cell systems to model the bladder and vaginal epithelia 
respectively, was to interrogate the mechanisms by which these epithelia recognise and 
respond to microbial assault.  
The first aim was to explore the NF-κB signalling response of bladder cells challenged 
with E. coli UTI strains, as well as bacterial PAMPs, with the objectives of defining the 
hierarchy of the uroepithelial TLR response and identifying the importance of bacterial 
motility in urinary tract infections.  
The second aim was to explore the mechanisms, in addition to NF-κB, involved in 
regulating the expression and synthesis of host epithelial defence factors with microbial 
killing properties, specifically hβD-2 and hβD-3, with the objective of identifying 
agents that could be used therapeutically to enhance the innate defences of the 
urogenital tract. 
 C H A P T E R  2   
  
Materials and Methods 
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2.1. CHEMICALS AND REAGENTS 
All chemicals and reagents were purchased from Sigma-Aldrich (St Louis, USA) unless 
otherwise stated. Bacteriological media and agar were bought from Oxoid (Basingstoke, 
Hampshire, UK).  
2.2. TISSUE CULTURE  
The cell lines used were RT4 (ATCC-HTB-2, LGC Standards, UK), a bladder uro-
epithelium isolated from a transitional cell papilloma and VK-2 E6/E7 (ATCC-
CRL2616), a vaginal epithelial cell line immortalised using the human papilloma 
virus
138
. Additionally, a protocol for growing primary human vaginal epithelia from 
vaginal biopsy clinical samples was established. All cell lines were cultured in 5 % CO2 
at 37 ºC.  
1. RT4 BLADDER EPITHELIUM 
RT4 cells were cultured in Corning 75 cm culture flasks (Corning, UK) using RPMI 
growth media (modified by addition of 2.5 % of HEPES buffer), supplemented with 2 
mM L-glutamine and 10 % FCS. The medium was changed twice per week and cells 
passaged weekly. For passaging cells were collected following trypsinisation (5 minutes 
at 37 ºC and 5 % CO2) and seeded at a ratio of 1:50.  
For the stably transfected RT4–NF-κB reporter cells the media was supplemented with 
the eukaryotic antibiotic G418 [0.5 mg/ml]. 
2. VK-2 E6/E7 VAGINAL EPITHELIUM 
VK-2 E6/E7 cells were cultured using Keratinocyte Serum free media supplemented 
with 0.05 ng/ml recombinant human epithelial growth factor, 0.05 mg/ml bovine 
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pituitary extract and 0.4 mM CaCl2. Medium was changed twice weekly. Cells were 
passaged weekly; for passaging, cells were collected following trypsinisation (5 minutes 
at 37 ºC and 5 % CO2) and split at a ratio of 1:20.  
3. PRIMARY HUMAN VAGINAL EPITHELIUM 
Vaginal biopsies were collected in PBS from the Royal Victoria Infirmary, Newcastle 
upon Tyne, UK. The tissue was dissected of excess fatty tissue or stroma and washed 
three times using PBS supplemented with Penicillin-Streptomycin-Amphotericin B 
(Lonza, Walkersville, USA) (PBS-PSA). The epithelial cells were detached from the 
connective tissue by incubating the tissue in Dispase [1U/ml], diluted in 10 ml of PBS-
PSA for 24 h at 4 ºC. The epithelial layer was removed from the connective tissue using 
a forceps and incubated in prewarmed trypsin for 10 minutes at 37 ºC with occasional 
shaking. The trypsin was neutralised by the addition of RPMI medium containing 10 % 
FCS and the cells collected by centrifugation at 1500 x G for 5 minutes. The 
supernatant was decanted off and the cell pellet resuspended in two ml Epilife medium 
(Life Technologies, Carlsbad, USA) without supplements; one ml was used to seed each 
well of a six well plate The medium was changed after 24 hours, the cells washed twice 
with PBS-PSA 72 hours after seeding and every other day afterwards. Using this 
protocol cells were maintained for up to 8 weeks (5 passages). Experiments were 
performed between passage 3 and 4. 
4. ETHICAL APPROVAL  
The use of vaginal tissue was approved by the Newcastle and North Tyneside Research 
Ethics Committee (REC reference 2003/11). Surgical specimens of the human vaginal 
tissue were collected after receiving informed consent. Samples were obtained from 
patients undergoing surgical removal of vaginal prolapses. 
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2.3. BACTERIAL CULTURE 
All compounds for bacteriological media and agar were purchased from Oxoid 
(Basingstoke, UK). Bacteria were grown in LB-media composed of 10 % (w/v) Bacto-
tryptone, 10 % (w/v) sodium chloride and 5 % (w/v) Bacto-yeast extract diluted in 
deionised water. The pH of the LB-medium was set to 7.4 by the addition of 5M NaOH 
and sterilised at 121 ºC for 20 minutes at 15 PSI. For LB-Agar, the above described LB-
medium was supplemented by 3 % (w/v) of Agar before being sterilised.  
E. coli DH5α competent cells were mixed with plasmid, incubated 30 minutes at 4 oC, 
40 seconds at 42 
o
C and further 30 minutes at 4 
o
C before plating on LB-Agar-XGal-(5-
bromo-4-chloro-3-indoyl-beta-galactopyranoside dissolved in DMSO) Ampicillin plates 
(X-Gal and ampicillin working concentrations were 50µg/ml and 0.1 mg/plate, 
respectively). Transformed colonies were further multiplied in LB-Amp medium with a 
working concentration of 0.1 mg/ml of ampicillin and the plasmid isolated as described 
in section 2.7. 
2.4. TRIZOL RNA ISOLATION  
The isolation of mRNA was performed using TRIzol (Invitrogen, Carlsbad, USA). 
Briefly, the medium bathing the eukaryote cells was removed and the cells were washed 
twice using PBS. The cells were incubated for 5 minutes at room temperature in one ml 
TRIzol (Invitrogen, Carlsbad, USA) per well of a six well plate and 200 μl per well of a 
96 wells plate. The phase separation was initialised by adding 20 % of chloroform of 
the initial TRIzol volume and gently shaking the tubes for 15 seconds. The mixture was 
incubated for 3 minutes at room temperature and the aqueous phase separated from the 
organic phase by centrifugation at 12000 x G for 15 minutes at 4 ºC. The aqueous phase 
was collected and the RNA precipitated in 500 μl isopropanol for 16 hours at -80 ºC. 
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The RNA was collected by centrifugation at 12000 x g for 10 minutes at 4 ºC and 
washed using one ml of 75 % ethanol. The supernatant was discarded and the RNA 
pellet was resuspended in 20 μl MilliQ H2O. The dissolved RNA was incubated for 10 
minutes at 65 ºC and stored at -80 ºC. 
2.5. POLYMERASE CHAIN REACTION  
1. DNASE TREATMENT 
To reduce genomic DNA contamination, purified RNA was DNase treated (Promega kit 
Southampton, UK), as shown below.  
4.5 μg  RNA 
4.5 μl  DNase [1 U/μl] 
2.0 μl  10 x Reaction Buffer (400mM Tris-HCL, pH 8.0, 100mM MgSO4, 10mM CaCl2) 
20 μl reaction volume (adjusted using MilliQ water depending on the RNA concentration) 
After 30 minutes at 37 ºC the reaction was stopped by adding 4 μl DNase Stop solution 
(Promega, Southampton, UK) and incubating at 65 ºC for 10 minutes. 
 
  
2. REVERSE TRANSCRIPTION 
The DNase treated RNA was transcribed to cDNA by incubation with a reverse 
transcriptase isolated from a murine leukaemia retrovirus (MuLV, Applied Biosystems, 
UK) at 42 ºC for one hour. The reaction contained: 
10 μl  DNased RNA (1.875 μg) 
3.2 μl  MgCl2 [25 mM] (Applied Biosystems, UK) 
4 μl  10 x NH4 Buffer (Applied Biosystems, UK) 
16 μl  dNTPs [10mM] (Bioline, UK) 
2 μl  Oligo dT [15mM] (Promega, Southampton, UK) 
1 μl  MuLV Reverse Transcriptase (Applied Biosystems, UK) 
1 μl  RNase inhibitor (Promega, UK)  
2.8 μl  MilliQ water 
40 μl  reaction volume 
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The reaction was stopped by increasing the temperature to 95 ºC for five minutes. The 
cDNA was used for PCR experiments, including endpoint and qPCR. 
3. POLYMERASE CHAIN REACTION 
DNA amplification was conducted using a modified method of the technique developed 
by Mullis et al.(1986)
139
. The amplification was performed using two different 
polymerases. For general gene expression a type A polymerase isolated from Thermus 
aquaticus (Taq) was used. It exhibits 5’3’ synthesis and 5’3’ exonuclease 
activity
140
. For products used in cloning, a modified type B polymerase was used 
isolated from Thermococcus kodakaraensis (KOD). It exhibits 5’3’ synthesis and a 
3’5’ proofreading exonuclease activity141,142. The quantitation of gene expression was 
performed using a LightCycler SYBR Green I Master (Roche, Mannheim, Germany), 
which uses a modified version of the before mentioned Taq-polymerase. 
4. PRIMERS 
Primers were specifically designed for each gene using the NCBI Primer-Blast design 
tool
143
. A prerequisite for the primers was that they were located in two different exons 
or spanning over an exon-exon junction. The retrieved primers were further analysed for 
hetero- and homodimer formation, as well as hairpin formation using Netprimer 
Software (http://www.premierbiosoft.com/netprimer/). The optimal temperature for 
each set of gene primers was detected using a temperature gradient and analysing the 
product using Gel-electrophoresis for endpoint PCR and/or melting curve analysis when 
using qPCR. The sequences of the primers used are listed in Table 2.1: 
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Table 2.1 List of primers used in endpoint and quantitative PCR. Small letters in bold 
show the restriction sites for HindIII and KpnI normal small letters show additional 
nucleic bases to maintain the reading frame. 
Primers used in qPCR assays: 
Gene Direction Sequence Tm/ºC 
Product 
size 
h-βD-3 qPCR 
Marcelo Lanz 
Forward CTTTGCTCTTCCTGTTTTTGG 
57 134 bp 
Reverse CGATCTGTTCCTCCTTTGG 
h-βD-3 qPCR Kalus 
et al. 
Forward GTGAAGCCTAGCAGCTATGAGGAT 
60 89 bp 
Reverse TGATTCCTCCATGACCTGGAA 
GAPDH  premixed unknown (commercial primer) 60 unknown 
     Primers used in Endpoint-PCR assay: 
Gene Direction Sequence Tm/ºC  
Product 
size 
h-βD-3 
Forward CAGCGTGGGGTGAAGCCTA 
65 224 bp 
Reverse CTTTCTTCGGCAGCATTTTCGG 
TLR-6 
Forward GGGACTTTTCTGGTTGTCTTAG  
55 777 bp 
Reverse CATTATCTGGCTGACCTCTTG 
Dectin-1 
Forward GACAATGCTGGCAACTGGGC 
61 330* bp 
Reverse CTCTCCTTCTCCACCCTTCCTC 
* expected size for isoform 1 
Primers used in cloning assays: 
Gene Direction Sequence Tm/ºC 
Product 
size 
promoter h-βD-2 2000 
bp 
Forward CTGGACACTGGTCTCATCTG 
55  
2000 
bp  
promoter h-βD-2 Reverse CTGGGGAGGACATCAAGC 
promoter h-βD-2 2000 
bp – KPNI 
 Forward tttggtaccCTGGACACTGGTCTCATCTG 
61  
2020 
bp  promoter h-βD-2 - 
HindIII 
 Reverse ttaagctttttCTGGGGAGGACATCAAGC 
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5. TAQ POLYMERASE 
PCR using Taq polymerase was used to amplify plasmid DNA or cDNA. 10 μl of 
cDNA and 1.2 ng/ml of plasmid DNA were used. All reactions used 35 cycles of 
amplification unless stated otherwise. The following volumes of reagents were used: 
0.8 μl  MgCl2 [50 mM] (Bioline, UK) 
4 μl  10 x NH4 Buffer (Bioline, UK) 
0.5 μl  Taq Polymerase (Bioline, UK) 
4 μl  Primer (2 μl of forward and 2 μl reverse primer ( both 10µM); IDT DNA, UK) 
8 μl  dNTPS [10mM](Bioline, UK) 
40 μl  reaction volume adjusted using MilliQ H2O 
 
The PCR conditions were: 
Polymerase activation 95 ºC 2 min  
    
Denaturation 95 ºC  30 sec 
35 cycles Annealing Tm 30 sec 
Extension 72 ºC  30 sec 
    
Final extension  72 ºC  12 min  
 
DNA bands were visualised by agarose-gel electrophoresis. 
6. KOD-POLYMERASE 
A modified Kod-hotstart polymerase (Novagen, Darmstadt, Germany) was utilised 
according to the manufacturer’s recommendation. Each reaction was set up as follows: 
5 μl 10 x Buffer 
3 μl MgSO4 
5 μl dNTP 
31.5 μl PCR grade H2O 
3 μl Primer (2 μl of forward and 2 μl reverse primer ( both 10µM); IDT DNA, UK) 
0.5 μl KOD 
2 μl DNA 
50 μl reaction volume 
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 The PCR conditions were dependent on the product’s size: 
Polymerase activation 95 ºC 2 min  
    
Denaturation 95 ºC  20 sec 
30 cycles Annealing Tm 10 sec 
Extension 68 ºC  25 sec 
 
cDNA bands were either visualised by agarose gel electrophoresis, purified for DNA 
cloning or sequenced. 
7. QUANTITATIVE PCR 
The quantitation of gene expression was performed using a LightCycler 480 (Roche, 
UK). The reaction was conducted using LightCycler 480 SYBR Green I Master mix. 
SYBR green is a chemical compound that intercalates with double stranded DNA and is 
excited at 486 nm and emits light at 521 nm. The amount of fluorescence is directly 
dependable to the amount of double stranded DNA, since there is a surplus of SYBR 
green in the reaction. Therefore the concentration of double stranded DNA can be 
quantitated.  
Each reaction was set up as follows: 
5 μl  qPCR SYBR Green I Mastermix 
2.5 μl cDNA or Plasmid 
1.5 μl MilliQ H2O  
1 μl Primer 
10  μl Reaction volume 
The protocol for the reaction was: 
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Preincubation 95 ºC  10:00  
Amplification 
95 ºC 00:10  
60 ºC 00:30 40 cycles 
72 ºC 00:10  
Melting curve 95 ºC 00:05  
 70 ºC 00:01  
Cooling 4 ºC 00:10  
After each run, the amplification curves were analysed using the LightCycler 480 
software (Roche, UK) to determine a Cq-(quantitation cycle) value and the amplification 
of a single product was verified by analysis of the melting curves
144
.  
8. CLONING OF CALIBRATOR PLASMID 
The MIQE guidelines state that determination of the PCR efficiency is pivotal for 
accurate quantitation of RNA
144
. Hence, the efficiency was determined using a 
calibration curve created from a serially diluted cloned PCR product (see section 5.3.I 
for details). A 224 bp PCR product of the hβD-3 gene was cloned into pGem-T Easy 
(Promega, Southampton, UK) following the manufacturer’s recommendations. Briefly, 
the DNA was isolated using the MinElute Gel Extraction kit (Qiagen, Hilden, Germany) 
and 30ng of the isolated DNA were ligated into 50 ng of pGem-T easy by the addition 
of 3 Weiss units of T4 DNA ligase and 5 μl Rapid ligation buffer (both Promega, 
Southampton, UK). The ligation was performed for 16 hours at 4 ºC, before being 
transformed into competent E. coli DH5α, as described in section 2.3. 
2.6. SABIOSCIENCES TLR-PLATE ASSAY 
1. RT4 CHALLENGE, RNA ISOLATION AND DNASE TREATMENT 
The expression of 84 genes associated with TLRs was determined using a gene array 
plate (SABiosciences, Qiagen, Hilden, Germany). RT4 cells were challenged with 
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5x10
4
 CFU/ml for four hours with the E. coli strains K-12, NU14, NCTC 10418 and 
PBS. The RNA was collected using TRIzol, purified using the method described in 
section 2.4, and further purified using RNeasy columns (QIAGEN, Hilden, Germany), 
to increase the purity and perform an on-the-column DNase treatment, as recommended 
by the TLR-gene array manufacturer. Briefly, the RNA was diluted in 100 μl MilliQ 
H2O, mixed with 350 μl RLT buffer and precipitated by adding 250 μl of ethanol. The 
mixture was added to a RNeasy column and centrifuged at 8000 x g for 15 seconds at 
room temperature. The on column DNase digestion was performed by adding 350 μl of 
RW1 buffer to the column followed by a centrifugation at 8000 x g for 15 seconds at 
room temperature. A mixture of 10 μl of DNase in 70 μl of RDD buffer was added to 
the column and incubated for 15 minutes at room temperature. The DNase was washed 
off the column by adding 350 μl of RW1 buffer and centrifuging at 8000 x g for 15 
seconds at room temperature. The column was washed twice with 500 μl of RPE buffer 
followed by centrifugation at 8000 g for two minutes. The RNA was eluted from the 
column using 30 μl of MilliQ H2O and further analysed using Agilent® Bioanalyzer. 
The concentration was determined by a NanoDrop 2000 (Thermo Scientific, Waltham, 
USA) 
2. AGILENT RNA CONTROL ASSAY 
The integrity of the RNA was assessed using the Agilent RNA 6000 Nano Kit 
according to the manufacturer’s protocol. The RNA chip was prepared by adding 550 μl 
of gel to a spin filter and centrifuging at 1500 x g for 10 minutes. 65 μl of the flow 
through were mixed with one μl of RNA 6000 Nano due and centrifuged at 13000 x g 
for 10 minutes. Gel-dye mix (27µl) was added to the RNA Nano chip followed by the 
RNA 6000 Nano marker which was then followed by the loading marker.  
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The ladder and the RNA samples were denatured at 70 ºC for 2 minutes and one μl of 
each was loaded onto the chip, vortexed at 2400 rpm using the Vortex Mixer MS2-S8 
(IKA Works, Staufen, Germany) for 1 minute and loaded on an Agilent 2100 
Bioanalyzer. The experiment was performed and analysed using the Agilent 2100 
software. A RIN (RNA integrity number) above a threshold of 7 was required for 
downstream applications. 
3. RT-QPCR 
Once RIN values indicated good quality nucleic acid the RNA was reverse transcribed 
and gene expression quantitated using a LightCycler 480, and primers available on the 
pre-coated 96 wells plates. For reverse transcription a RT
2
 first strand kit 
(SABiosciences, QIAGEN, Hilden, Germany) was used and the procedure performed 
according to the manufacturer’s instructions. The RT-sample was diluted in 1350 μl of 
H2O and mixed with 1350 μl of 2x RT
2
 SYBR Green Mastermix. 25 μl of the mix was 
added to each well of the plate and expression was measured with the LightCycler 480 
(Roche diagnostics), using the following setup: 
Polymerase activation 95 ºC 10 min  
    
Denaturation 95 ºC  15 sec 
45 cycles 
Annealing 60 ºC  1 min 
    
The Cqs were calculated using the LightCycler 480 software and analysed using the 
SABioscience predesigned Microsoft Excel spread sheet.  
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2.7. PCR AND PLASMID PURIFICATION 
PCR products used for cloning were purified using MiniElute PCR purification kit 
(Qiagen, Hilden, Germany). DNA bands visualised on agarose gels were purified using 
the QIAquick gel extraction kit (Qiagen, Hilden, Germany). Plasmids of transformed 
DH5α strains were isolated using the Plasmid Mini kit (Qiagen, Hilden, Germany). All 
purifications were performed according to the manufacturer’s recommendations. 
2.8. PROTEIN CONCENTRATION DETERMINATION 
Protein concentrations were determined using a 660 nm Protein Assay or Bradford 
assay (both Pierce Protein, Thermo Fisher Scientific, Waltham, USA). For the 660 nm 
protein assay, a calibration curve was established using BSA concentrations ranging 
from 50 μg/ml to 2000 μg/ml. 10 μl of the standard, sample or blank (H2O or PBS) was 
added in triplicate to a 96 wells plate and 150 μl of 660 nm assay reagent added. The 
plate was covered, shaken gently for one minute and incubated for five minutes at room 
temperature before reading the absorbance at 660 nm using a FluoStar Omega plate 
reader (BMG Labtech, Ortenberg, Germany). The sample concentration was calculated 
using the standards as calibrators. 
The Bradford assay was performed in a 96 wells plate and the same range of standards 
was used as for the 660 nm protein assay. Five μl of standard, sample or blank were 
added to 250 μl of comassie blue reagent (Pierce, Thermo Fisher Scientific, Waltham, 
USA), the plate was shaken for 30 seconds and incubated for 10 minutes at room 
temperature. The absorbance at 595nm was read using a FluoStar Omega plate reader 
(BMG Labtech, Ortenberg, Germany). All measurements were made in triplicate. The 
sample concentration was calculated using the standards as calibrators.  
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2.9. PROTEIN ANALYSIS USING SDS-PAGE 
1. 10 % TRICINE-GELS 
Proteins were separated using electrophoresis according to Schagger and von Jagow
145
. 
Briefly, Tricine separation gel (10 % Total acrylamide concentration, with 3 % 
crosslinking) was prepared by mixing 4.7 ml of 40 % acrylamide/bis-acrylamide  
(mix ratio 19:1), with 9.4 ml of separation gel buffer [0.75 M Tris, 0.2 % SDS, pH 8.8], 
4.6 ml H2O, 90 μl of APS (10 %) and 30 μl of TEMED. The mixture was poured gently 
into a gel tank and the stacking gel was prepared while the separation gel polymerised. 
For a 4 % stacking gel, a volume of 380 μl of acrylamide/bis-acrylamide (40 % total 
acrylamide concentration, 3 % crosslinking) was mixed with 1.5 ml H2O and 1.9 ml of 
stacking gel buffer [0.25M Tris, 0.2 % SDS-buffer, pH 6.8]. The polymerisation of the 
stacking gel was initiated by adding 30 μl of APS (10 %) and 10 μl of TEMED. Protein 
samples (10.4 μl) were denatured in 1.6 μl SDS reducing buffer containing 4 μl of 
loading buffer and following incubation at 37 ºC for 15 minutes. Ten μl of the reduced 
protein sample were loaded onto the stacking gel and electrophoresed for 2 hours at 
200V. 
2. 4 %-12 % NOVEX NUPAGE®  
For western blots, the commercially available NOVEX® NuPAGE® (life technologies 
Carlsbad, USA) precast gels were used according to the manufacturer’s 
recommendation. Briefly, 6.5 μl of protein sample was treated with 2.5 μl of NuPAGE 
LDS sample buffer, 1 μl of NuPAGE reducing agent and incubated at 70 ºC for 10 
minutes. After loading onto the gel the protein samples were electrophoresed for 40 
minutes at 200 V. Gels were either stained using coomassie brilliant blue G250 (Pierce, 
Thermo Scientific, Waltham, USA) or used for western blotting. 
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2.10. FLAGELLIN PURIFICATION  
Flagellin isolation was performed in collaboration with Dr Phillip Aldridge and using  
E. coli NCTC 10418. The method of flagellin was adapted from Smith et al.
146
. Briefly, 
the E. coli strain NCTC 10480 was grown overnight on LB-Agar (3 %), one colony 
selected and grown for 16 h at  
37 °C, with shaking. The overnight culture was diluted 10 fold and the OD600 measured. 
The following equation was used to calculate the volume of bacteria required to 
inoculate 1 L of LB at a starting OD600 of 0.05: 
          
    
                 
                    
               
                                    
The one litre bacterial culture was grown until an OD600nm of 0.6. The cells were 
harvested at 5000 g min at 4 °C, washed twice in 30 ml ice-cold phosphate-buffered 
saline (PBS) and resuspended in 30 ml ice cold PBS. The flagellin was twice separated 
from the cells by shearing using a blending stick at 13500 rpm for 1 min with an ice 
cooling step in between. The cell suspension was re-centrifuged for 15 min at 6000 x g, 
the supernatant decanted into a 50 ml ultraclear ultracentrifugation tube and centrifuged 
at 100000 x g for one hour at 4 ºC. The supernatant was decanted off, the pellet washed 
twice with ice cold PBS, resuspended in 1 ml ice cold PBS, left for 16 h at 4 °C to 
dissolve completely and stored at -20 °C. The flagellin was further purified by 
depolymerisation at 70 °C for 15 min, filtration through a 0.22 µm filter and size 
exclusion. Three batches were prepared. Protein concentration was measured using the 
Bradford Assay. 
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2.11. EUKARYOTE CELL TRANSFECTION 
NF-κB reporter constructs and promoter constructs were transfected transiently into the 
RT4 and VK-2 E6/E7 cell lines. Two different transfection technologies to maximise 
cell survival rate and transfection efficiency were utilised.  
1. ATTRACTENE 
Attractene (QIAGEN, Hilden, Germany) is a lipid based transfection reagent, which 
binds DNA in liposomes and fuses with the cell membrane introducing the DNA into 
the cell. The transfection was optimised using the manufacturer’s recommended 
Attractene-DNA ratio. Attractene was used to transfect the VK-2 E6/E7 cells and was 
the transfection method utilised in the hβD-2 promoter study (Chapter 4). The optimised 
transfection conditions for VK-2 E6/E7 cells were: 
135 ng of plasmid DNA were diluted in 50 μl TE Buffer together with 0.5 μl of 
Attractene reagent. The Attractene-DNA sample was mixed and stored for 15 minutes at 
room temperature. During the incubation period, VK-2 E6/E7 cells were trypsinised, 
resuspended to 5 x 10
4 cells per 150 μl of media and added to each well of a 96 wells 
plate. The Attractene-DNA mix was added to the cells and the well contents gently 
mixed. The cells were incubated for 16 hours before the challenge experiments.  
2. TURBOFECT 
The second transfection reagent used was TurboFect (Thermo Fisher Scientific, 
Waltham, USA), a cationic polymer which binds DNA and is uptaken by cells via 
endocytosis. TurboFect was used to transfect RT4 cells. The transfection was optimised 
using the manufacturer’s recommended TurboFect-DNA ratios. The optimised 
concentration was used to study the hβD-2 promoter activation in RT4 cells.  
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150ng of plasmid DNA was resuspended in 20 μl serum free Opti-MEM (life 
Technologies, Carlsbad, USA) medium together with 0.3 μl of TurboFect and incubated 
for 15 minutes at room temperature. During the incubation period RT4 cells were 
harvested by trypsinisation, resuspended to 5 x 10
4 cells per 180 μl of media and added 
to each well of a 96 wells plate. 20 μl TurboFect-DNA mix was added to each well and 
the well contents gently mixed. The cells were incubated for 16 hours at 37 ºC, 5 % CO2 
before the challenge experiments.  
2.12. PROMOTER REPORTER CONSTRUCT 
1. BIOINFORMATICS 
DNA sequences (2 kbp) of the 5’ non-translated regions of the h-βD-2 (DEFB4) and h-
βD-3 (DEFB103) genes were analysed for transcription factor binding sites using the 
PROMO software (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dir 
DB=TF_8.3). Sites of interest were NF-κB, AP-1, and those responsive to vitamin D, 
vitamin A, and oestrogen. The primers specific to the region were used to amplify the 
region of interest using KOD polymerase. The amplicons were cloned into two reporter 
systems utilising either GFP (pGLOW TOPO vector, Life technologies, Carlsbad, USA) 
or Luciferase (pGL4.10, Promega, Southampton, UK).  
2. CLONING USING PGLOW TOPO VECTOR 
The amplicon was cloned into the pGLOW TOPO vector (Life technologies, Carlsbad, 
USA) according to the manufacturer’s recommendations. Briefly, following synthesis, 
the amplicon was treated with 0.5 units of Taq polymerase for 10 minutes at 72 ºC in 
the presence of 2 mM dATP, 1x PCR buffer and 0.8 μl of 25 mM MgCl2, and the 
product purified (section 2.7). 4 μl of the purified PCR product were mixed with 1 μl of 
pGLOW TOPO vector in the presence of 1 μl of diluted salt solution, and incubated for 
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20 minutes at room temperature. Competent DH5α cells were transformed with the 
cloned product, and transformed bacteria selected by blue/white screening LB-agar 
plates, using IPTG [0.1 mM], XGal [50 μg/ml], ampicillin [100 μg/ml]. The white 
colonies were picked, each grown in 5 ml LB containing 100 μg/ml ampicillin and 
plasmid isolated using a plasmid miniPrep kit (see section 2.7). 
3. CLONING USING PGL4.10 
The DNA amplicon was amplified using primers flanked by restriction sites and 
purified using a PCR purification kit (QIAGEN, Hilden, Germany). It was cleaved with 
appropriate restriction enzymes (HindIII and KpnI) and purified using the PCR 
purification kit. The cleaved amplicon was ligated into pGL4.10. The reaction was set 
up as follows:  
pGL4.10 10 μl 
insert 2 μl 
Ligase 1 μl 
Ligase buffer 1 μl 
Total reaction  14 μl  
The ligation product was transformed into DH5α as described previously. Single white 
colonies were picked and further analysed (section 4.5). 
2.13. REPORTER GENE ASSAY 
The reporter gene assays were used to analyse the NF-κB activity of RT4 and VK-2 
E6/E7 challenged cells. Additionally, the hβD-2 promoter study was conducted using 
reporter vectors. 
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1. LUCIFERASE BASED REPORTER 
RT4 cells stably transfected with RT4-NFκB137 were collected by trypsinisation and the 
cell count per ml determined using a ZM Coulter Counter (Coulter Scientific 
Instruments, Hialeah, USA). 5x10
4
 cells/ml were seeded into each well of a white 96 
wells plate, with clear bottom (#3610, Corning, Corning, USA).  
For the promoter reporter assays: the RT4 or VK-2 E6/E7 cells were transfected as 
described in section 2.11. After 16 hours of incubation at 37 ºC and 5 % CO2, the 
confluent eukaryote cells were challenged with either bacterial cells or PAMPs (further 
details are presented in Chapter 3 and 4). Following challenge, the media bathing the 
cells was collected in microcentrifuge tubes and stored at -20 ºC. The cells were lysed 
using RLB (Promega, Southampton, UK) for 16 hours at -80 ºC. The luciferase 
concentration was measured by adding 100 μl of luciferin (Promega, Southampton, UK) 
and the resulting luminescence was measured using a FluoStar Omega microplate 
reader (BMG Labtech, Ortenberg, Germany). The values of the PBS challenged samples 
were used to normalise the results and results were presented as fold increase compared 
to the negative control. 
2. GREEN FLUORESCENT PROTEIN BASED REPORTER 
The NF-κB reporter kit Cignal NF-κB was used for the NF-κB activity measurements in 
VK-2 E6/E7 cells. Briefly, the cells were transfected with reporter DNA using 
TurboFect (see section 2.11) and after 16 hours at 37 ºC and 5 % CO2, challenged as 
described in section 2.14.  
RT4 cells were transfected with the hβD-2 promoter reporter (see section 2.11). 
Following challenge the media bathing the cells was collected and stored at -20 ºC. 
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Fluorescence was measured using a FluoStar Omega microplate reader (BMG Labtech, 
Ortenberg, Germany) with filters for 480 nm for the excitation and 530 nm for the 
emission filter.  
 
2.14. HUMAN UROGENITAL EPITHELIA CHALLENGE 
EXPERIMENTS 
1. ESCHERICHIA coli STRAINS 
Four laboratory strains of E. coli were used. The strains are summarised in Table 2.2: 
Table 2.2 Escherichia coli strains  
Strain Source 
E. coli K-12 Long established strain isolated from the Gut (1922)
5
 
E. coli NCTC 
10418  
Isolated in 1947. Used for antimicrobial and disinfecting testing 
(personal communication Dr Ased Ali) 
E. coli NU14 Laboratory UPEC strain isolated from a cystitis infection
24
 
E. coli CFT073 Isolated from a pyelonephritis infection in 1990; genome sequenced
147
 
The archetypal strain K-12 and the strain NCTC 10418 were kind gifts of Dr John Perry 
(Freeman Hospital, Newcastle). Two UPEC strains were used, CFT 073, ATCC 
700928, and NU14 (a gift of Professor Neil Sheerin). Additionally, 24 UPEC strains 
collected from patients by Dr Kathy Walton (Freeman Hospital, Newcastle) were 
analysed. For the in vitro challenge experiments dead bacteria were used and prepared 
as follows: E. coli strains were grown in 10 ml of LB overnight, the OD600 of the culture 
was determined and used to inoculate 10 ml LB to achieve an OD600 of 0.1. The 
following equation was used to calculate the volume needed for 0.1 OD600: 
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The bacterial culture was incubated at 37 ºC with shaking until an OD600 of 0.6 was 
attained and then kept on ice. The culture was diluted to 10
-5
 to 10
-8
 of the original 
concentration and 10 μl plated onto LB-Agar plates. The actual CFU/ml was determined 
after incubating the plates for 16 hours at 37 ºC and counting the bacterial colonies. The 
remaining culture was pelleted by centrifugation at 13000 x g for 10 minutes, the cells 
were washed twice with PBS and resuspended in one ml of PBS. The bacteria were 
killed by incubating for 20 minutes at 100 ºC. Killing was verified by plating 10 μl of 
the culture diluted in PBS on a LB-agar plate and incubating overnight at 37 ºC.  
The dead bacterial stock was diluted to a concentration of 10
7
 CFU/ml and challenges 
were performed using 5 x 10
4 
CFU/ml /well. For eukaryote cell challenges the 
appropriate volume of the bacterial stock was diluted in 200 μl of RT4 or VK-2 E6/E7 
medium.  
2. PAMPS 
Different PAMPs were used to activate different receptors present on the uro- and 
vaginal epithelial cells. The PAMPs used are described in Table 2.3: 
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Table 2.3: PAMPs used to challenge RT4 and VK-2 E6/E7 cells 
PAMP Source 
Challenge 
concentration 
Stock 
concentration 
catalogue number (supplier) 
LPS O55:B5 E. coli 10 μg/ml 1 mg/ml 
L6529-1mg (Sigma-Aldrich, St 
Louis, USA) 
LPS O26:B6 E. coli 10 μg/ml 1 mg/ml 
L2654-1mg (Sigma-Aldrich, St 
Louis, USA) 
LPS O111:B4 E. coli 10 μg/ml 1 mg/ml 
L4391-1mg (Sigma-Aldrich, St 
Louis, USA) 
Peptidoglycan E. coli 10 μg/ml 2 mg/ml 
PGN-EB (Invivogen, San Diego, 
USA) 
Flagellin E. coli 250 ng/ml 10 μg/ml Own production 
Zymosan S. cerevisae 50 μg/ml 1 mg/ml 
Z4250-1G (Sigma-Aldrich, St Louis, 
USA) 
3. BLOCKING OF TLR USING MONOCLONAL ANTIBODY 
The activation of TLR-5 and of TLR-2 was inhibited by incubating the RT4 NF-κB 
cells with 5 μg/ml of mouse monoclonal TLR-5 antibody (maba2-htlr5, Invivogen, San 
Diego, USA) and 10 μg/ml of chimeric monoclonal TLR-2 antibody (anti-hTLR2-IgA, 
Invivogen, San Diego, USA), 2 hours prior to the challenge with flagellin, bacteria or 
Zymosan.  
4.  MOTILITY DETERMINATION OF E. COLI STRAINS 
The motility of E. coli strains was determined by Dr Phillip Aldridge (ICaMB, 
Newcastle University) by incubating E. coli strains on a reduced concentration of agar 
growth medium [0.3 % Agar (w/v), 1 % tryptone (w/v), 0.5 % NaCl (w/v)]. The strains 
were incubated at 37 °C for eight hours and the motility was detected by the 
identification of a halo.  
2.15. PROTEIN IDENTIFICATION USING WESTERN 
BLOTTING 
The expression and phosphorylation of SYK was assessed using the Phospho-SYK 
antibody sampler kit (#9905, Cell signalling, Beverly, USA). Eukaryote cells were lysed 
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using RIPA lysis buffer (R0278, Sigma-Aldrich, St Louis, USA). The cell lysates were 
analysed using 4-12 % NuPAGE precast gels (life Technologies, Carlsbad, USA). 
Following electrophoresis proteins were transferred to nitrocellulose using a HEP-1 
semi-dry western blot cassette system (Thermo Scientific, Waltham, USA). The setup 
of the western blot was as follows:  
Anode (+)  3 filter papers nitrocellulose membrane electrophoresed gel 3 filter papers  cathode (-) 
Prior to the blotting, the filter paper and the nitrocellulose membrane were soaked in 
western blot transfer buffer (25 mM Tris, 0.2 M Glycine and 20 % Methanol). The 
protein transfer from the gel to the membrane was performed at 10 V for 60 minutes.  
The nitrocellulose membrane was blocked using 50 % blocking buffer (Li-Cor, Lincoln, 
USA), diluted in PBS, for one hour at room temperature. The membrane was washed, 
incubated with the primary antibody at a concentration of 1:1000 for SYK (#12358 for 
total SYK and #2711 for Phospho-SYK, both Cell Signaling) for 16 hours, at 4 ºC or at 
1:5000 for β-actin (SC-1616, Santa Cruz, Dallas, USA) for one hour at room 
temperature. The membrane was washed six times (10 minutes/wash) using PBS-
Tween20 (0.1 %), incubated for 45 minutes at room temperature with an appropriate 
secondary reporter antibody (PN 926-32213, Li-Cor, Lincoln, USA for total SYK or 
Phospho-Syk and PN 926-32224 for β-actin) diluted at 1:5000, in 0.01 % SDS, 0.1 % 
Tween 20, 50 % blocking buffer, PBS. The membrane was finally washed six times 
with PBS-Tween20 for 10 minutes and then scanned using an Odyssey membrane 
reader (Li-Cor, Lincoln, USA). 
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2.16. ELISA 
The enzyme-linked immunosorbent assay (ELISA) is a powerful technique to measure 
the concentration of an antigen in a solution. Two types of ELISA were used in this 
investigation. Both types are shown in Figure 2.1: 
A  B 
Figure 2.1. Principle of an Enzyme-Linked ImmunoSorbent Assay(ELISA). (A) indirect ELISA. 
where the antigen is immobilised on the solid support. (B) sandwich ELISA. The capture antibody is 
immobilised on the solid support. Image adapted from: 
http://www.virology.ws/wp-content/uploads/2010/07/elisa.jpg 
The measurement of an antigen in an indirect ELISA is done with a single specific 
antibody (Fig. 2.1.A). The antigen is immobilised in a well (MaxiSorp) and detected by 
the antibody. The detection antibody is recognised by a reporter antibody (Fig. 2.1.A) 
which is linked to the enzyme horseradish peroxidise (HRP). The unbound detection 
and reporter antibodies are washed off by a sorbent solution. HRP reacts with its 
substrate (TMB) causing a change of colour to the blue spectrum. The substrate is 
reduced by a strong acid (1M HSO4) changing its colour from blue to yellow. The 
absorbance of the substrate solution is then read at 450 nm.  
The indirect ELISA is less sensitive and should only be used in the absence of two 
specific antibodies. A sandwich ELISA (Fig. 2.1.B) is the method of choice to detect 
the protein concentration. It is a modified indirect ELISA.  
In addition to the detection antibody, a capture antibody is used. It ‘catches’ the antigen 
from the solution therefore filtering the antigen out of the solution. Assay sensitivity is 
therefore increased. Additionally the detection antibody is conjugated with biotin. 
antigen 
antigen 
Detection antibody 
Detection antibody 
Reporter antibody 
Reporter enzyme 
Reporter enzyme 
Capture antibody 
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Biotin binds specifically to avidin or streptavidin. The HRP is linked to the streptavidin, 
making the use of a reporter antibody obsolete. Enzymatic reaction of the HRP-
substrate and reading are the same as in the indirect ELISA. 
1. INDIRECT ELISA 
All ELISAs were performed using 96 wells plates MaxiSorp (Nunc, Roskilde, 
Denmark). A hβD-3 standard was prepared ranging from 0.1 to 1 ng/ml. One hundred μl 
of the standard or media removed from challenged eukaryote cells were immobilised on 
a 96 wells plate (MaxiSorp Nunc, Roskilde, Denmark) for 16 hours at room 
temperature. The plate was washed five times using 300 μl of PBS-Tween 20 (0.1 %), 
blocked using 250 μl of 5 % non-fat dry milk dissolved in PBS containing 0.1 % Tween 
20 (Sigma-Aldrich, St Louis, USA) (MPBST) for two hours at room temperature and 
then washed five times with 300 μl of PBS-Tween 20 (0.1 %). For optimisation, 100 μl 
of the detection antibody at different concentrations were used to detect the synthetic 
hβD-3 protein. After optimisation, 2 μg/ml of detection antibody (ab109572, ABCAM, 
UK) diluted in MPBST were used to detect the synthetic hβD-3 and incubated for 16 
hours at 4 ºC. A reporter antibody (A0545-1ML, Sigma-Aldrich, St Louis, USA) was 
diluted in MPBST (1:2000), 100 μl added to each well and incubated for one hour at 
room temperature, before washing using 300 μl of PBS-Tween20/well. 100 μl aliquots 
of TMB (T0440, Sigma-Aldrich, St Louis, USA) were added to each well and left for 
25 minutes at room temperature, in the absence of light. The reaction was stopped using 
100 μl of 2 M H2SO4. The absorbance was read at 450 nm using a FluoStar Omega plate 
reader (BMG Labtech, Ortenberg, Germany). 
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2. SANDWICH ELISA 
The secretion of hβD-3 was initially analysed via an indirect ELISA but due to its low 
sensitivity a sandwich ELISA was developed (see Chapter 5 for details). All reagents 
used, apart from the antibodies, were from the BD optEIA ELISA kit and all washing 
steps were carried out using 300 μl of washing buffer (BD Biosciences, Franklin Lakes, 
USA).  
The primary or capture hβD-3 antibody (ab109572, ABCAM, Cambridge UK) was 
diluted to a concentration of 0.5 μg/ml in coating buffer (BD Biosciences, Franklin 
Lakes, USA) and 100 μl of the capture hβD-3 antibody were added to each well on a 96 
wells plate. The sealed plate was incubated at 4 ºC for 16 hours, the wells washed three 
times before being blocked with 200 μl blocking buffer (BD Biosciences, Franklin 
Lakes, USA) for two hours at room temperature. The wells were washed three times, 
the standards were prepared in cell growth media using synthetic hβD-3 (Peptide Inc., 
Osaka Japan), ranging from 31.25 pg/ml to 1000 pg/ml. 100 μl of standard or sample 
were added and the plate incubated for two hours at room temperature before being 
washed five times. The secondary or detection antibody (ab84234, ABCAM, 
Cambridge UK), conjugated with biotin and at a concentration of 0.25 μg/ml, was 
mixed with SA-HRP (1:250, BD Biosciences, Franklin Lakes, USA) in blocking buffer. 
100 μl of detection antibody-SA-HRP mixture were added to the wells and incubated 
for one hour at room temperature. The plate was finally washed seven times and 100 μl 
of a HRP substrate solution (TMB based, Reagent A and B at a ratio of 1:1, BD 
Biosciences, Franklin Lakes, USA) was added to the wells. The enzymatic reaction, 
protected from light, occurred for 30 minutes at room temperature, before being stopped 
by the addition of 50 μl of Stop solution (BD Biosciences, Franklin Lakes, USA). The 
final result was measured by reading the absorbance at 450 nm, with a correction using 
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the 570nm absorbance, using a FluoStar Omega plate reader (BMG Labtech, Ortenberg, 
Germany). The samples were diluted if their absorbance was not in the range of the 
standard curve and the ELISA repeated. 
3. INTERLEUKIN-8 
To measure IL8 concentrations the BD optEIA IL-8 kit (BD Bioscience, Franklin 
Lakes, USA) was utilised. During the ELISAs the washing steps were carried out using 
300 μl of washing buffer (BD Biosciences, Franklin Lakes, USA). In each case, the 
primary antibody was diluted 1:250 in coating buffer (BD Biosciences, Franklin Lakes, 
USA) and, using a 96 wells plate, 100 μl were added per well,. The sealed plate was 
incubated at 4 ºC for 16 hours, washed three times, blocked with 200 μl blocking buffer 
(BD Biosciences, Franklin Lakes, USA) for two hours at room temperature and again 
washed three times. Standards were prepared according to the manufacturer’s 
recommendation, ranging from 3.125 to 200 pg/ml and 100 μl of standard or sample 
were added to each well. Samples (dilutions ranging from 1:10 to 1:1000) were added to 
the wells, the plate incubated for two hours at room temperature and washed five times. 
A detection secondary antibody conjugated with biotin mixed with SAHRP was diluted 
in the blocking buffer (both 1:250, BD Biosciences, Franklin Lakes, USA) added to the 
wells and incubated for one hour at room temperature. The plate was finally washed 
seven times and the TMB based substrate solution (Reagent A and B at a ratio of 1:1, 
BD Biosciences, Franklin Lakes, USA), protected from light added to the plate for 30 
minutes. The enzymatic reaction was stopped by the addition of 50 μl of Stop solution 
(BD Biosciences, Franklin Lakes, USA).The absorbance was read at 450 nm, with a 
wavelength correction for polystyrene absorbance or turbidities in the medium, 
measured at the 570 nm. All measurements were done using a FluoStar Omega plate 
reader (BMG Labtech, Ortenberg, Germany). 
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2.17. FLOW CYTOMETRY  
VK-2 E6/E7 cells were trypsinised and maintained in PBS containing 5 mM EDTA 
(PBSE). 10
6
 cells were incubated with 2.5 μg of a primary antibody, specific for Dectin-
1 (MAB1859, R & D Systems, Minneapolis, USA), for 30 minutes on ice, before being 
washed twice using PBSE and collected by centrifugation at 500 g for 5 minutes. Cells 
were then incubated with a mouse IgG specific secondary antibody conjugated with 
Alexa Fluor 488 (A-11059, Life technologies, Carlsbad, USA) at a concentration of 
1:200, washed twice with PBSE and resuspended in 400 μl of PBSE. Cell fluorescence 
was analysed using a FACSCanto II (BD Biosystems, Franklin Lakes, USA) flow 
cytometer (Flow cytometer core facility, Newcastle University). The results of the flow 
cytometry were analysed using Flowing Software (University of Turku, Sweden). 
2.18. IMMUNOCYTOCHEMISTRY AND CONFOCAL 
MICROSCOPY 
Fluorescent images were taken using a Nikon Eclipse Ti, coupled to a Photometrics 
Coolsnap HQ CCD camera and Nikon Plan Fluor 100x/1.30 ph3 DL lens. The system is 
controlled by Metamorph 7.7.8.0 (Molecular Devices, Inc., Sunnycale, USA). Confocal 
images were taken at the Bioimaging unit (Newcastle University) using a Nikon A1R or 
a Leica TCS SP2 microscope. 
RT4 cells, VK-2 E6/E7 cells and primary vaginal cells were grown on cover slips and 
stained using non-specific mouse monoclonal IgG (026300, Invitrogen, Carlsbad, 
USA), C11 mouse monoclonal antibodies (NCL-C11, Leica Biosystems, Newcastle, 
UK), Dectin-1 (MAB1859, R&D Systems, Minneapolis, USA) and a rabbit polyclonal 
TLR-5 antibody (ab37071, ABCAM, Cambridge, UK). The cover slips were sterilised 
by washing with 70 % ethanol, followed by washing with methanol. After drying for 20 
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minutes, the cover slips were placed in a six well plate and seeded with eukaryotic cells. 
To achieve this, 10
5
 cells were diluted in 230 μl of appropriate medium and carefully 
added on the coverslip, forming a meniscus. The cells were allowed to settle on the 
cover slips for four hours at 37 ºC and 5 % CO2, before one ml of medium was added. 
The cells were grown to confluence before being challenged or directly fixed. Two 
methods for fixation were used, methanol and paraformaldehyde (4 % PFA) fixation.  
4 % PFA was prepared by dissolving 0.4 g of PFA (Sigma-Aldrich, St Louis, USA) in 
10 ml PBS at 65 ºC. The cells were incubated for 10 minutes at 4 ºC when fixed with 
100 % methanol, but 15 minutes at room temperature, when fixed with 4 % PFA. PFA-
fixed cells were washed three times with 50 mM NH4Cl for three minutes at room 
temperature to quench the PFA and minimise the autofluorescence. The quenched cells 
were washed three times with PBS and, for detection of cytokeratin using C11 antibody, 
further permebealised using 0.25 % Triton X-100 followed again by three washing steps 
with PBS. Blocking was achieved using one ml of 1 % BSA in PBS containing 0.1 % 
tween (PBST) for two hours at room temperature. Incubation with primary antibody, 
diluted in PBST, was performed for one hour at room temperature. Table 2.4 shows the 
working concentration of each antibody.  
Table 2.4 List of primary antibodies used in immunocytochemistry. 
Target Type 
Concen-
tration 
Permea-
bilisation 
Supplier 
Catalog 
number 
C11 
mouse 
monoclonal IgG 
1:20 yes 
Leica 
Biosystems 
NCL-C11 
Dectin-1 
mouse 
monoclonal IgG  
1:200  
(2.5 μg) 
no 
R&D 
Systems 
MAB1859 
TLR-5  
rabbit polyclonal 
IgG 
20 μg/ml no ABCAM 
AB37071 
IgG 
control 
Mouse 
monoclonal 
2.5 μg  no Invitrogen 
026300 
Following incubation with primary antibody the cells were washed three times with 
PBST. The appropriate secondary antibody diluted 1:500 in 1 % BSA-PBST, was 
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incubated with the cells for 30 minutes at room temperature. Following five x 5 minutes 
washes with PBST the cell nuclei were stained for one minute with Propidium iodide 
(Sigma-Aldrich, St Louis, USA), before washing again with PBST. The cells were 
washed with MilliQ H2O and the coverslips mounted on microscope slides using 20 μl 
of Mowiol mounting medium (Calbiochem, Darmstadt, Germany). Mowiol solidified 
by incubating the slides for 16 hours in the dark and at room temperature. The slides 
were stored at 4 ºC until images were taken. 
1. PREPARATION OF MOWIOL 
Mowiol is a polyvinyl alcohol used to mount the cover slips on microscopic slides. It 
was prepared by dissolving 2.4 g of Mowiol (Calbiochem, Darmstadt, Germany) and 6 
g of glycerol in 6 ml of dH2O for 2 hours at room temperature, followed by the addition 
of 12 ml of 0.2 M Tris (pH 8.5, Sigma-Aldrich, St Louis, USA). The mixture was 
incubated at 65 ºC for 25 minutes and centrifuged at 5000 x g for 15 minutes. It was 
either stored at 4 ºC or -20 ºC depending on usage.  
2. INVESTIGATING SPECIFICITY OF MAB 1859  
The specificity of the antibody mab 1859 was verified by incubating the 2.5 μg of the 
antibody with 25 μg of recombinant Dectin-1 (1859-DC, R&D Systems, Minneapolis, 
USA) for one hour at room temperature. After incubation, the antibody was used to 
stain VK-2 E6/E7 cells as described in section 2.18. 
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2.19. BIOINFORMATICS 
1. PROMO TRANSCRIPTION BINDING FACTOR SEARCH TOOL 
A 2000 bp region preceding the transcription start was obtained from the EMBO data 
base. The sequence was added to the PROMO software website and analysed for 
transcription factor binding sites. The transcription factors binding sites added to the 
search were NF-κB, retinoic acid receptor (RAR), vitamin D receptor (VDR), AP-1 and 
oestrogen receptor alpha (ER-α). 
  
C H A P T E R  T H R E E  
 
  
Uroepithelial Innate Immune 
Responses to Uropathogenic 
Escherichia coli 
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3.1. INTRODUCTION 
In healthy women the urinary tract (UT) is maintained free of pathogens despite its 
anatomic localisation close to the heavily bacterial colonised anal and vaginal regions. 
The innate immune system is key in protecting the UT against potential uropathogens 
and antimicrobial peptides secreted upon activation of cell surface receptors, including 
Toll-like receptors (TLRs), function as part of those innate defences. 
Previous research identified the expression of TLR-2, TLR-4 and TLR-5 in bladder 
biopsies, as well as in the RT4 cell line, an in vitro model of bladder epithelium
137
. The 
research focussed on exploring the function of these TLRs in the defence of the uro-
epithelium via analysis of NF-κB signalling; NF-κB was chosen as it is generally 
accepted as the master regulator of innate immunity
148
. Challenge of RT4 cells 
engineered to express a NF-κB luciferase reporter with ligands for TLR-4, which is 
considered one of the most important TLRs in the recognition of pathogens
81,82
, failed 
to significantly induce a NF-κB response. This suggested TLR4 had a reduced function 
in the defence of the UT. In contrast flagellin, the TLR-5 ligand, induced significant 
NF-κB signalling. Moreover, when motile bacteria strains were utilised a NF-κB 
response was observed, but this was not detected with non-motile bacteria. These data 
suggested a pivotal role for TLR-5 in the innate response of the uroepithelium.  
However, the NF-κB signalling pathway had been chosen for study based on 
information assembled from the innate immune signalling literature rather than actual 
experimental analyses of the uroepithelial gene response to infection, and specifically 
TLR signalling. Thus the aim of the research reported in this Chapter was to further 
explore the innate response of the uroepithelium to bacterial challenge and delineate the 
importance of each TLR during infection.  
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3.2. EARLY INNATE IMMUNE RESPONSE TO E. COLI  
LABORATORY STRAINS 
The utilisation of gene arrays enables the simultaneous analysis of multiple genes and is 
therefore a useful screening tool. In this section, the early gene response in the bladder 
in response to infection was analysed using a commercially available pre-designed 
qPCR gene array with 84 genes related to TLRs.  
1. RNA QUALITY CONTROL  
RT4 cells were challenged for four hours with either PBS or 5x10
4
 CFU/ml of the E. 
coli strains K-12, NCTC 10418 and NU14, the latter being a non-motile UPEC strain
137
. 
Four hours was chosen based on pilot data using NCTC 10418, which indicated this 
time-point to reflect a maximal NF-κB signalling response137.  
For the array experiments, it was crucial to use only high quality RNA and the RNA 
isolated from RT4 cells was analysed using the Agilent RNA 6000 Nano kit, according 
to the manufacturer’s instructions. Results of the RNA quality analyses are presented in 
Figure 3.1: 
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A 
B 
Figure 3.1 Analysis of RNA quality using Agilent RNA 6000 Nano kit. (A) RNA gel 
containing RNA isolated from PBS mock challenged and bacteria challenged RT4 cells. Lane 
L shows the marker. Lanes 1 and 2 are RNA samples of a negative control. Lanes 3 and 4 
show the RNA of RT4 challenged with K-12. Lanes 5 and 6 show the RNA of RT4 
challenged with NU14. Lanes 7 and 8 show the RNA of RT4 challenged with NCTC 10418. 
(B) RNA purity analysis performed by the Agilent program. All RNA samples showed a 
RIN<9.8 and were considered optimal for a TLR-Array analysis. 
 
All lanes showed the expected two bands representing the 28S, 18S rRNA subunits 
(Fig. 3.1.A). Using these three bands, the Agilent software calculates the RNA integrity 
number (RIN). All samples showed a very high integrity by having a RIN of 9.8 or 
1-PBS  
2-PBS  
3-K12 
4-K12 
5-NU14 
6-NU14 
7-NCTC 10418  
8-NCTC 10418 
 
28S 
 
18S 
L        1         2      3         4        5       6        7       8 
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higher (A RIN below 8.0 indicates RNA of low integrity, which cannot be utilised; Fig. 
3.1.B) and were utilised for the TLR-array analysis.  
2. TLR-RELATED GENE ARRAY  
RT4 cells were challenged with different E. coli laboratory strains to analyse the early 
response of the urinary epithelium to E. coli colonisation. The strains were chosen 
according to their pathological background (NU14) or their motility, with NCTC 10418 
being strongly motile and K-12 only having low levels of motility (Figure 3.3). The 
RNA was collected and gene expression analysed using a SABioscience TLR-Gene 
Array, according to the manufacturer’s instructions (the RNA was reverse transcribed 
and gene expression was measured using a TLR related gene array qPCR plate 
(SABiosciences, Crawley, UK)). The qPCR was performed using the Lightcycler 480 
(Roche, Burgess Hill, UK). The Cq-values were analysed using the SABioscience 
software and the fold change in gene expression identified. 
Table 3.1 summarises the results of the TLR gene arrays from two independent 
experiments. The results were clustered into three groups according to their fold 
increase compared to a control PBS challenge. Any change ≤ 1.9 or Cq-value beyond 35 
cycles was not considered significant. The majority of genes contained within the array 
did not show a difference in gene expression in response to the four hour bacterial 
challenges (Table 3.1, first column). However, variations were observed when the data 
from the three different challenge experiments were compared. Significantly, neither the 
E. coli K-12 nor NU14 challenges were associated with NF-κB gene activation although 
upregulation of IL-8 gene expression was detected (2.95 and 2.07 fold change, 
respectively). In contrast, the E. coli NCTC 10418 challenge was linked with NF-κB 
(2.6) and IL-8 gene (25.4) gene activation. Both, K12 and NU14 challenges activated 
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gene expression of the anti-inflammatory cytokine IL-10 (1.98 and 2.00 fold, 
respectively), Lymphotoxin A (LTA) (2.41 and 2.22 fold, respectively), and CD14 (2.70 
and 2.47 fold, respectively). The NU14 challenge, additionally, induced LY86 and 
CCL2 gene expression, by 2.13 and 2.30 fold, respectively. Activation of IL-1B (2.16 
fold), IL-1A (2.83 fold) and CXCL10 (11.40 fold) were unique to E. coli NCTC 10418.  
Although the regulation of genes linked to the TLRs was limited the array data 
confirmed a significant role for NF-κB signalling in the response of the uroepithelium to 
bacterial challenge. This was directly obvious from the array data in response to the E. 
coli NCTC 10418 challenge, but indirectly for E. coli K-12 and NU14, and suggested 
only via enhancement of IL-8 gene (NF-κB responsive) expression. However, overall 
these data suggested a significant role for NF-κB signalling in the defence of the UT 
and justified further focus on this pathway.  
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Table 3.1 Results of TLR-associated genes array. The genes were clustered into 3 
different groups depending on the ΔΔCq difference to the PBS challenged control. After 4 
hours challenge, the order of the genes within the groups is correspondent to its fold 
increase over the control. ()-Brackets demonstrates average fold increase. N=2 independent 
experiments 
K-12 
-1.5<Fold change<1.9 
(not significant) 
1.9< Fold change<10 Fold change>10 
CD80, TOLLIP, IRAK1, ELK1, TIRAP, NFKB2, CSF2, 
HRAS, MAP2K3, ECSIT, MAP4K4, IRAK2, IRF3, FADD, 
RIPK2, CASP8, IKBKB, UBE2V1, MAPK8IP3, TAB1, 
MYD88, TICAM1, SARM1, PRKRA, UBE2N, IRF1, NFRKB, 
EIF2AK2, CHUK, NFKB1, PELI1, CD86, TRAF6, IL1B, 
PPARA, JUN, HSPD1, TNFRSF1A, TLR1, RELA, TLR6, 
TLR4, TICAM2, BTK, NR2C2, NFKBIA, MAP3K1, MAP2K4, 
MAPK8, FOS, MAP3K7, TLR-5, HSPA1A, PTGS2, LY96, 
HMGB1, TLR3, TBK1, TLR2, NFKBIL1, IL1A, IL2, REL, 
TLR7, CCL2, TNF, SIGIRR, CXCL10, CSF3, IFNA1, IFNB1, 
IFNG, TLR10, TLR8, CLEC4E, LY86, TLR9, CD180, IL6 
IL10(1.98),IL12A(2.11), LTA(2.41), 
CD14(2.70), IL8(2.95) 
- 
A 
NU14 
-1.5<Fold change<1.9 
(not significant) 
1.9<Fold change<10 Fold change>10 
TOLLIP, CD80, IRAK1, IRF1, TIRAP, MAP2K3, NFKBIL1, 
SARM1, ELK1, ECSIT, FADD, BTK, JUN, HRAS, IRF3, 
MAPK8IP3, RELA, NFRKB, MAP4K4, TAB1, IRAK2, 
MYD88, UBE2V1, SIGIRR, PPARA, RIPK2, HSPA1A, TLR3, 
TICAM1, TLR-5, PRKRA, UBE2N, CSF2, NFKB2, IKBKB, 
PELI1, TLR1, EIF2AK2, HSPD1, CHUK, NFKB1, NR2C2, 
FOS, TNFRSF1A, TRAF6, LY96, IL1B, TLR7, NFKBIA, 
TICAM2, TLR6, MAP2K4, TLR4, CD86, MAPK8, CD180, 
PTGS2, MAP3K1, CASP8, MAP3K7, IL2, TBK1, HMGB1, 
CSF3, IFNA1, IFNB1, IFNG, CXCL10, TLR2, IL12A, IL6, 
IL1A, TLR10, TLR8, CLEC4E, TNF, REL, TLR9 
IL10(2.00), IL-8(2.07), LY86 
(2.13), LTA (2.22), CCL2 (2.30), 
CD14 (2.47) 
- 
B 
NCTC 10418 
-1.5<Fold change<1.9 
(not significant) 
1.9<Fold change<10 Fold change>10 
CD86, CD80, CCL2, IL2,LY96, TIRAP, TLR-5, BTK, 
SARM1, TICAM2, PRKRA, SIGIRR, NR2C2, UBE2N, 
PPARA, ECSIT, NFKB2, FOS, UBE2V1, MYD88, NFKBIL1, 
MAPK8IP3, TNFRSF1A, HRAS, JUN, TRAF6, MAPK8, 
NFRKB, IRF3, IRAK1, TAB1, TLR1, FADD, HSPD1,IKBKB, 
ELK1, MAP4K4, CHUK, MAP2K4, TLR6, RELA, EIF2AK2, 
CASP8, PELI1, HSPA1A, RIPK2, IL10, MAP3K1, CD180, 
TLR4, MAP3K7, TLR3, TLR9, TICAM1, MAP2K3, NFKB1, 
HMGB1, TOLLIP, TNF, LTA, IL6, IRAK2, TBK1, CLEC4E, 
CSF3, IFNA1, IFNB1, LY86, TLR10, TLR8, TLR2, IFNG, 
IRF1, REL, TLR7, PTGS2, IL12A, CSF2 
IL1B (2.16), NFKBIA (2.59),  
CD14 (2.67), IL1A (2.83) 
CXCL10 (14.40), IL-8 
(25.42) 
C 
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3.3. NF-ΚB ACTIVATION BY LABORATORY E. COLI  
STRAINS 
After analysing the early response to three different E. coli strains, a more in depth 
analysis of the innate response was attempted. Furthermore, in addition to the UPEC 
strain NU14 a second UPEC strain E. coli CFT 073, was added to the investigations. 
Data from previous studies, demonstrated that challenging uroepithelium model with 
live bacteria was only possible up to eight hours, due to cell death
137
. To address this, 
RT4 NF-κB cells were challenged with heat-killed bacteria for up to 24 hours (section 
2.14.I). 
The RT4 NF-kB cells were developed by stably transfecting a reporter plasmid into 
RT4, which contains binding sites for NF-kB and a luciferase reporter gene. Upon 
activation of NF-kB as a transcription factor, luciferase will be produced and quantified 
by adding a luciferase substrate (luciferin) and measuring the luminescence. 
The results of these challenges are shown in Figure 3.2. All vertical-axes show the fold 
increase in luminescence when compared to the negative control (cells challenged with 
PBS). One hour following the NCTC 10418 challenge, there was a significant 9.6±2.6 
fold increase in NF-κB activity over the negative control (Fig. 3.2.A). After two hours 
the NF-κB activity was 22.0±1.6 with the peak 43.3±2.5 fold increase observed four 
hours post challenge. After 16 hours, the NF-κB activity was reduced to 22.0±2.3. The 
final measurement (7.5±1.5 fold) at 24 hours was still significantly above the control 
value (Figure 3.2.A). 
In comparison, when RT4 cells were challenged with K-12, significant NF-κB activity 
was observed only after four hours of challenge (4.4±0.6 fold increase over the negative 
control) and this response peaked at 16 hours, (12.3±1.5 fold increase), although this 
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peak value was four times less than the response observed with NCTC 10418 (Figure 
3.2.B). After 24 hours, the NF-κB response fell to 9.9±1.2, but as for NCTC 10418 was 
still above the control value. 
Comparable responses were observed following the CFT 073 and NU14 challenges, 
although the maximum fold increases in NF-κB activity were greater for CFT 073 
(19.8±3.4), than NU14 (7.3±1.0) (Figure 3.2.Cand D). As for NCTC 10418, the peak 
activities measured for CFT 073 were at 4 and 8 hours respectively, but the values 
determined were mid-way between those of NCTC 10418 and the K-12. Interestingly 
the highest NF-κB response to NU14 was measured at 24 hours. 
The cytotoxicity was analysed microscopically and the cells did not show 
morphological changes or signs of cellular death. 
Although the general patterns were similar the level of NF-κB response differed 
between the four E. coli strains. NU14 showed similar results to previous findings, i.e. 
the strain induced a very low NF-κB response, when compared to the other strains137.  
  
70 
 
 
NCTC 10418
0 1 2 4 8 16 24
0
10
20
30
40
50
**
***
***
***
***
Hours
F
o
ld
 i
n
c
re
a
s
e
***
A 
K12
0 1 2 4 8 16 24
0
10
20
30
40
50
Hours
F
o
ld
 i
n
c
re
a
s
e
*
***
***
***
B 
CFT 073
0 1 2 4 8 16 24
0
10
20
30
40
50
Hours
F
o
ld
 i
n
c
re
a
s
e
*** ***
*** ***
C 
NU14
0 1 2 4 8 16 24
0
10
20
30
40
50
*** *** ***
***
Hours
F
o
ld
 i
n
c
re
a
s
e
D 
Figure 3.2 NF-κB Response of RT4 to different laboratory E. coli strains using the NF-kB-
luciferase reporter. The different strains were grown to an OD600nm of 0.6 and heat killed by 
100 ºC for 20 minutes. The CFU/ml was determined and 5x10
4
 CFU/ml were added to RT4 NF-
κB reporter cells and luminescence was measured. (A) Response to NCTC 10418. (B) Response 
to K-12. (C) Response to motile UPEC CFT 073. (D) Response to non-motile NU14. The bars 
are the mean of the fold increase of luciferase activity of challenged cells, when compared to 
PBS challenged ones. N=9, 3 experiments with 3 replicates. Error bars are ± standard error of 
the mean. Statistical significance determined by ANOVA; *=p<0.05, **=p <0.01, ***=p< 
0.001. 
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3.4. DETERMINATION OF MOTILITY OF THE 
LABORATORY STRAINS 
To help explain the differences in RT4 NF-κB responses, the motility of the four E. coli 
strains was analysed, in collaboration with by Dr Philip Aldridge, Newcastle University, 
as described in section 2.14.IV. The results are presented in Figure 3.3 and show that 
the NCTC 10418, K12 and CFT073 strains are associated with halos indicative of 
bacterial motility. The lack of a halo indicated that the NU14 strain was not motile. 
Although only semi-quantitative these data suggest that the highest NF-κB activating 
strain NCTC 10418 was also the strain with the highest motility. It is well established, 
that the flagella complex is responsible for bacterial motility
146
 and flagellin is the 
extracellular part of the flagella complex
94,146
. So to specifically investigate the role of 
motility in the innate response of the urinary tract, flagellin was isolated from E. coli, 
specifically NCTC 10418, and used to challenge RT4 cells.  
 
Figure 3.3 Assessing E. coli’s motility using a soft agar assay. The four E. coli strains were 
grown on a low percentage agar growth plate (0.3 %) for eight hours. K-12 shows a small halo, 
comparable to the UPEC CFT 073, while NCTC 10418’s halo is larger. These three strains 
show therefore motility, while NU14 is non-motile. Experiment was performed by Dr Phillip 
Aldridge (Newcastle University). 
 
 
(motile) 
(motile) (motile) 
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3.5. FLAGELLIN ISOLATION FROM E. COLI  NCTC 10418  
Flagellin was isolated using a procedure previously described
146
. Briefly, 2 L of an E. 
coli NCTC 10418 culture were grown to an OD600 of 0.6 and collected by 
centrifugation. The flagellin protein was separated by sonication and collected by 
ultracentrifugation. Two independent flagellin preparations were isolated. Figures 3.4.A 
and 3.4.E show the results of two independent flagellin isolations.  
Figure 3.4.A shows the result of the first isolation with purified flagellin in lane 8. The 
protein ladder shows that the isolated protein had a molecular weight of approximately 
55 kDa. The protein was further purified by size exclusion and Figure 3.4.B shows the 
result of measuring the absorption at 280 nm of the eluted samples. As no peaks were 
observed, the elution samples collected were electrophoresed on a 10 % SDS-gel 
(Figure 3.4.C). No samples were visible, suggesting complete loss of sample. The size 
exclusion column was verified using 1 mg/ml BSA (Figure 3.4.D) and the peak shown 
in 3.4.D suggested a fully functional size-exclusion column. However, the lack of pure 
protein suggested that the size exclusion filtration was not optimal for flagellin. The 
flagellin isolation was repeated and protein analysed on a 10 % SDS gel (Figure 3.4.E). 
Again, the main band was 55 kDa (blue arrow, Figure 3.4.E). Different concentrations 
of BSA (2 mg/ml, 1.5 mg/ml, 1 mg/ml, 0.75 mg/ml and 0.5 mg/ml) were used for 
qualitative quantification, suggesting a concentration of approximately 0.6 mg/ml. The 
concentration of the isolated flagellin was determined using a Bradford-Assay and the 
final concentration was 0.67 mg/ml.  
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A 
 
B 
C 
 
D 
  
Figure 3.4 Isolation of flagellin from NCTC 10418 (A) The first isolation was 
separated on a denaturing 10 % Tricine SDS-PAGE. Lane 2-6 BSA standard for 
protein concentration determination. The ladder is SeeBlue® Plus2 Pre-Stained 
Standard (Invitrogen, Carlsbad). Blue arrow marks isolated flagellin (B) Absorbance 
of the eluted samples at 280 nm, after passing a size exclusion column. Green arrow 
shows area of expected peak (C) Denaturing 10 % Tricine SDS-PAGE to visualise 
the aliquots. The ladder is SeeBlue® Plus2 Pre-Stained Standard (Invitrogen, 
Carlsbad). (D) Absorbance of 1 mg/ml BSA (red arrow). Expected area for the 
flagellin peak is marked by the green arrow. (E) Second isolation of flagellin, the 
ladder is SeeBlue®. Lane 3-7 BSA standard for protein concentration determination. 
Blue arrow marks isolated flagellin. 
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3.6. INNATE IMMUNE RESPONSE OF THE URO-
EPITHELIUM TO COMPONENTS OF THE BACTERIAL CELL 
WALL 
The previous results showed that the four E. coli strains induced different degrees of  
NF-κB signalling and motility, thus flagellin, appeared to be a major factor in the 
response. Nevertheless, two motile strains, K-12 and CFT 073, caused less NF-κB 
activation than NCTC 10418, suggesting that other factors may have contributed. To try 
and further understand why the strains of E. coli showed different responses, the 
activation of NF-κB by bacterial membrane molecules was assessed. Flagellin, as well 
as LPS and peptidoglycan, two additional major PAMPs of the E. coli cell wall, were 
investigated.  
1. FLAGELLIN  
Flagellin is a protein expressed by the FliC gene and is part of the flagella motor 
responsible for the bacterial mobility
94
. Pilot data indicated that flagellin was able to 
evoke an NF-κB response in RT4 cells, but the flagellin used was isolated from 
Salmonella typhimurium
137
. In the following experiments the flagellin isolated from E. 
coli NCTC 10418 was utilised. 
First, a timecourse of the NF-κB response to 250 ng/ml of flagellin was investigated. 
The media bathing the challenged cells was collected, and the IL-8 concentration was 
measured. Results are shown in Figure 3.5.A and B, respectively.  
A significant increase in NF-κB activity was observed one hour post challenge (7.4±0.6 
fold; p<0.01), but the peak response was measured at four hours (44.9±1.7 fold increase 
over the negative control). From eight to 16 hours, the NF-κB activity gradually 
decreased and at 24 hours was comparable to that measured at one hour. 
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A significant difference between the IL-8 concentration of the negative control and 
flagellin challenged samples was initially observed at four hours (p<0.001). Moreover, 
when compared to the PBS challenge, flagellin induced a 27 fold increase in the mean 
IL-8 concentration measured at four hours (8263.4 ± 192.3 pg/ml) and a 52 fold 
increase at 24 hours (23879.0±631.1 pg/ml). 
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Figure 3.5 NF-κB and IL-8 Response of RT4 uroepithelium to Flagellin isolated from E. 
coli. The RT4 reporter cells were challenged for up to 24 hours using 250 ng/ml of flagellin. 
The NF-κB activity and IL-8 secretion was measured. (A) The RT4 reporter cells were lysed 
and their luminescence caused by the NF-κB reporter was measured. The fold increase over 
the negative control was calculated for each replicate. The bars represent the mean and the 
error bars stand for the standard error of the mean. N=9, 3 experiments with 3 replicates. (B) 
IL-8 concentration the media from three replicates of the challenge above and was measured 
using a sandwich ELISA (BD OPTEIA). N=2 using pooled medium of 3 replicates. Statistical 
significance determined by ANOVA; *=p<0.05, **=p <0.01,***=p< 0.001 
These data showed that challenging the RT4 cells with 250 ng/ml of E. coli flagellin 
resulted in a significant increase in NF-κB reporter activity and within one hour of the 
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challenge. The next experiment investigated whether the NF-κB response and IL-8 
secretion caused by flagellin was concentration dependent. Therefore, flagellin was 
serially diluted (concentrations from 250 ng/ml to 2.5 fg/ml) and the challenge 
experiments were repeated. Due to the different concentrations of flagellin being tested 
only three time points, 4, 8 and 24 hours were analysed. Since 4 hours was associated 
with increased IL-8 concentrations this time-point was used to avoid natural 
accumulation of IL-8 in the media. The results are shown in Figure 3.6.A and B. 
Flagellin induced a significant NF-κB response at all time-points at concentrations of 
250 pg/ml or higher, although at four hours and a concentration of 25 pg/ml, the NF-κB 
response was doubled (2.1±0.4 fold, Fig. 3.6.A). As previously observed with NCTC 
10418, NF-κB activity peaked at four hours post challenge. 
Significant increases in IL-8 were detected when the RT4 cells were challenged with 2.5 
ng/ml of flagellin or higher (Fig. 3.6.B). Although 250 pg/ml of flagellin caused a 
significant NF-κB response, no significant change in the media concentration of IL-8 
was detected. However, a trend was noticed (590.5±75.0 pg/ml compared to 
317.4±109.6 pg/ml of the cells challenged with PBS).  
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Figure 3.6 NF-κB and IL-8 response of RT4 to different concentrations of flagellin. (A) 
RT4 cells are stably transfected with a NF-κB reporter, were challenged with flagellin 
isolated from E. coli NCTC 10418 at the described concentrations. The NF-κB response was 
measured at three different time points (four, eight and 24 hours). The negative control was a 
PBS challenge. Bars represent the mean with their standard errors. The statistical significance 
was measured using two way ANOVA with the Bonferroni post hoc Test. N=6, 2 
experiments with 3 replicates. (B) IL-8 concentration the media from three replicates of the 
challenge above and was measured using a sandwich ELISA (BD OPTEIA). N=2, using 
medium pooled of three replicates. Statistical significance determined by ANOVA; 
*=p<0.05, **=p <0.01, ***=p< 0.001 
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2. INHIBITION OF NF-ΚB ACTIVATION BY TLR-5 BLOCKING 
A NF-κB response was observed in RT4 cells challenged with flagellin. Flagellin 
functions via TLR-5
146
 and to further explore the importance of TLR-5 in the innate 
defences of the bladder, the RT4 cells were treated for one hour with a monoclonal 
antibody specific for TLR-5 before being challenged with 250 ng/ml of flagellin 
(section 2.14.III). The results of the NF-κB reporter activity data following TLR-5 
blocking are shown in Figure 3.7.A. In these experiments NF-κB reporter activity was 
measured at eight hours rather than four hours to accommodate the IL-8 measurements. 
Blocking TLR-5 resulted in reduced NF-κB activity from 30.9±1.6 to 22.9±1.4 fold 
(eight fold difference, p<0.001). A reduction in NF-κB activity was also measured at 16 
(four fold difference, p<0.001) and 24 hours (6.6 fold difference, p<0.001) respectively. 
The results of IL-8 analyses are shown in Figure 3.7.B. The concentration of IL-8 was 
9522.5±55.9 pg/ml after the eight hour flagellin challenge and blocking of TLR-5 
resulted in a significant reduction (p<0.001) to 6783.1±37.3 pg/ml. Significant 
reductions (p<0.001) in IL-8 were also detected at 16 and 24 hours respectively. 
However, blocking TLR-5 did not reduce either the NF-κB reporter activity or IL-8 
concentrations to background (data not shown) suggesting that other components were 
involved in the NF-κB activation. The flagellin preparation used in the challenge 
experiments was not purified by gel exclusion thus it was feasible that contaminants 
including Endotoxin or Lipopolysaccharide (LPS), were playing a role.   
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Figure 3.7 Inhibition of innate response to flagellin through TLR-5 blocking in RT4 
cells. RT4 cells were challenged with 250 ng/ml of flagellin and preincubated with 5 μg/ml 
monoclonal TLR-5 specific antibody. (A)The NF-κB activity was measured using a reporter 
assay (N=9, 3 experiments with 3 replicates) (B) The IL-8 secretion into the bathing media 
was measured using a sandwich ELISA (N=3, using medium pooled of three replicates). 
Statistical significance determined by Student’s T-test; **=p <0.01, ***=p< 0.001 
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3. LIPOPOLYSACCHARIDES  
Previous challenge of RT4 cells with LPS, a ligand for TLR-4, failed to induce a NF-κB 
response. This suggested that TLR-4, generally considered one of the most important 
TLRs in pathogen recognition
149
, had a reduced function in the defence of the UT
137
. 
Nonetheless, activation of NF-κB in the uroepithelium in response to LPS has been 
described previously
150
. Thus the effects of LPS were re-examined, but using 10µg/ml 
(a two fold increase compared to previous experiments) and three different types of LPS 
(O26:B6, O55:B5 and O111:B4), all isolated from E. coli. RT4 NF-κB reporter cells 
were challenged for up to 24 hours, and luciferase activity was measured. The results 
are presented as fold increase over the negative control (PBS challenge) and shown in 
Figure 3.8.A.  
RT4 cells showed no significant change in NF-κB reporter activity in response to LPS 
in the first two hours post challenge. However, at four hours, the NF-κB activity was 
significantly upregulated and with all three LPS preparations (p<0.001). Following a dip 
in reporter activity at eight hours, the NF-κB activity peaked at 16 hours (9.3±1.3 for 
LPS O26:B6, 10.7±0.8 for LPS O55:B5 and 9.0±1.3) with all three types of LPS 
causing a significant response (p<0.001).  
Media bathing the cells were collected at 4, 8, 16 and 24 hours. At each time point, the 
media was pooled and the IL-8 concentrations measured. The data is shown in Figure 
3.8.B. 
A significantly increased concentration of IL-8 was measured at 8 hours post challenge, 
but only in response to LPS O26:B6 (898.2±93.2 pg/ml, p<0.001). However, at 16 and 
24 hours, and consistent with the NF-κB data all LPS types caused a significant increase 
in IL-8 (p<0.001 for LPS O26:B6, LPS O111:B4 and p<0.01 LPS O55:B5).  
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NF-κB reporter activation associated with LPS was much lower than observed with 
flagellin. Indeed while flagellin was associated with a mean peak response of 44.9±1.7 
fold, LPS induced only a peak response of 10.7±0.8 fold (LPS O55:B5). IL-8 secretion 
was also reduced when RT4 cells were challenged with LPS compared to flagellin 
(maximal secretion 2473.6±50.0 for LPS and 23879.0±631.1 pg/ml for flagellin).  
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Figure 3.8 Innate immune response of RT4 cells to three different types of E. coli’s LPS. 
(A) NF-κB response to 10 μg/ml of LPS. (N=9, 3 experiments with 3 replicates).  
(B) Measurement of RT4’s IL-8 secretion when challenged with 10 μg/ml LPS (N=3, using 
medium pooled of three replicates) *=p<0.05; **=p<0.01; ***p<0.001.  
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4. PEPTIDOGLYCAN 
Peptidoglycan is also part of the E. coli cell wall. It is known to induce NF-κB activity 
through two receptor families, TLR 2/6 and Nod-Like receptors
151
. TLR 2/6 recognise 
the intact peptidoglycan while Nod-Like receptors recognise breakdown products of 
peptidoglycan
63,66,151,152
.  
Previous research demonstrated the expression of TLR-2 in RT4 cells
137
. TLR-2 
functions as a dimer with TLR-6 and amplifying RT4 cDNA using primers specific for 
the TLR-6 gene resulted in a band with a size comparable to the expected 777 bp 
(Figure 3.9), which was confirmed as TLR-6 by DNA sequencing.  
 
Figure 3.9 Expression of TLR6 in RT4. The first lane shows Hyperladder IV. Second lane 
shows the amplification of RT4 cDNA using TLR6 specific primers resulting in a band of 
expected size (777 bp). 
Once the expression of TLR-2 and 6 were confirmed the effects of peptidoglycan  
(10 μg/ml, maximal concentration recommended by the supplier, Invivogen, USA) on 
RT4 NF-κB reporter activity were investigated153. As previous, the medium bathing the 
challenged cells was collected at four, eight, 16 and 24 hours and IL-8 secretion was 
measured. Results are shown in Figure 3.9. 
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Peptidoglycan caused a significant increase in NF-κB reporter activity but only after 
eight hours of challenge (5.4 ± 1.4, p<0.001; Fig. 3.10.A). This response stayed stable 
for up to 16 hours (6.3±0.6, p<0.001; Fig. 3.10.A). However, the maximal activation of 
NF-κB by peptidoglycan was <7 fold. This response was comparable to that of LPS but 
much lower than the observed with flagellin. The IL-8 concentrations measured in the 
media suggested an increase in IL-8 in response to PG, particularly at 16 and 24 hours, 
but these data were not statistically significant compared to control (Fig. 3.10.B).  
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Figure 3.10 Innate immune response of RT4 cells to 10 μg/ml of E. coli’s peptidoglycan. 
(A) NF-κB response of RT4 cells (N=9, 3 experiments with 3 replicates. ***=P<0.001). (B) 
Concentration of IL-8 secreted into the medium bathing the challenged cells of A). N=3 using 
medium pooled from 3 replicates 
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3.7. NF-ΚB AND IL-8 RESPONSE TO CLINICAL ISOLATES. 
From these data flagellin appeared to be the major activator of innate immunity in RT-4 
cells, thus linking bacterial motility to activation of the host innate response. With this 
in mind it could be predicted that clinical strains associated with UTI are able to avoid 
the host defences by their reduced motility. This was investigated further utilising 
clinical isolates of patients suffering infections of the urinary tract. 
1. DETERMINING THE MOTILITY OF CLINICAL ISOLATES OF 
UPEC STRAINS 
A collection of 24 clinical isolates related to patients with UTI was kindly provided by 
Dr Kathy Walton (Freeman Hospital, Newcastle upon Tyne, UK). Of these, eight 
clinical isolates were associated with asymptomatic bacteriuria, nine isolates with acute 
cystitis, four isolates with pyelonephritis and three with bacteraemia. All bacteria were 
clinically identified as E. coli following microbiological analyses at the Microbiology 
Laboratories, Freeman Hospital, Newcastle upon Tyne. Bacterial motility was 
determined by Dr Christopher Birchall and Dr Philip Aldridge (Newcastle University). 
The results are shown in Figure 3.11 and summarised in Table 3.2. 
Of the clinical isolates with a defined patient history 50 %, i.e. 12/24 were motile. 
Interestingly, the majority of motile isolates were related to symptomatic urinary tract 
infections, i.e. cystitis (six out of nine) and pyelonephritis (three out of four). In the 
asymptomatic bacteriuria group only two isolates out of eight were motile. The isolates 
collected from the bacteraemia patients contained two motile and one non-motile 
strains. In brief, those strains with the highest motility were associated with large halos, 
although halo sizes were variable. The most motile strains (biggest halo) were observed 
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in the cystitis group, followed by the pyelonephritis strains and asymptomatic 
bacteriuria group. The motile bacteraemia strain formed a small halo.  
 
Figure 3.11 Motility of the clinical UPEC Strains. Motility was determined using a soft 
agar using 0.3 % Bactoagar. The bacteria were seeded in the centre of each puncture and 
allowed to grow for eight hours at 37 ºC. Motile bacteria are seen by their halo like shape. 
The abbreviations are C= Acute Cystitis, ABU=asymptomatic bacteriurea, P=Pyelonephritis 
and B=bacteraemia, ND=strains of E. coli without defined clinical pathology. Experiment 
performed by Dr Christopher Birchall and Dr Phillip Aldridge. 
Table 3.2 Motility of clinical UPEC strains. 
Clinical picture Total Motile Non-motile 
Asymptomatic Bacteriuria 8 2 6 
Cystitis 9 6 3 
Pyelonephritis 4 3 1 
Bacteraemia 3 2 1 
2. INNATE IMMUNE RESPONSE OF THE URO-EPITHELIUM TO 
CLINICAL ISOLATES OF UPEC  
The clinical isolates were also investigated for their ability to trigger a NF-κB response. 
The clinical strains were grown to an OD600nm of 0.6, heat killed (100 ºC for 20 minutes) 
and used to challenge RT4 - NF-κB reporter cells grown on 96 wells plates. The cells 
were challenged for four, eight and 24 hours using 5x10
4
 CFU/ml of each clinical strain 
ND ND 
ND 
ND 
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or PBS. Media from each 24 hour challenge was collected and the IL-8 concentrations 
measured. The results of the NF-κB activation of each clinical isolate are shown in 
Figure 3.12. 
The strains were sub grouped into motile or non-motile and the mean NF-κB activation 
of the motile strains was found to be significantly higher than that of non-motile strains 
at all three time points (p<0.05 for four and eight hours; p<0.01 for 24 hours). 
Surprisingly, the IL-8 concentrations failed to show a significant difference between 
motile and non-motile clinical isolates (p=0.054).  
At four hours, only four motile strains caused a statistically significant difference in NF-
κB reporter activation (P<0.001). Three of the four, were isolated from patients 
suffering symptomatic cystitis and they were also the strains with the largest halos in 
the motility assay (Fig. 3.11). The other motile strain that caused a significant response 
was from a patient suffering from asymptomatic bacteriuria. None of the non-motile 
strains activated NF-κB significantly. 
At eight hours, one motile strain of the asymptomatic group was also found to cause 
significant NF-κB reporter activity (p<0.01, Fig. 3.12.B). At the final time point, 24 
hours, all but two motile strains showed significant activation of NF-κB (p<0.001 or 
p<0.01). The strains that did not activate NF-κB were both from the pyelonephritis 
group. 
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Figure 3.12 Innate Immune Response of RT4 to clinical UPEC isolates. 5x10
4
 CFU/ml of the clinical isolates were added to RT4 NF-κB reporter cells. The 
bars represent fold increase of luciferase activity of challenged cells over PBS challenged ones (N=6, 2 experiments with 3 repeats each). (A) Luminescence 
was measured after four hours.  (B) Luminescence was measured after eight hours.  (C) Luminescence was measured after 24 hours. (D) The IL-8 
concentration was measured on the pooled media of RT4 cells challenged for 24 hours (N=2, medium pooled from 3 replicates). Statistical significance 
between negative control (white bar) and clinical isolates was determined by two-way ANOVA with a Bonferroni post hoc test; *=p<0.05, **=p <0.01, 
***=p< 0.001. Statistical significance between motile and non-motile was determined by analysing the means using a Student’s T-test; †=p<0.05 and 
††=p<0.01. 
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3. INNATE IMMUNE RESPONSE TO FLAGELLIN ISOLATED FROM 
CLINICAL STRAINS 
Twelve clinical bacterial isolates associated with UTIs were motile and activated a NF-
κB signalling response, but it was noted that the intensities of the responses differed 
between isolates. To investigate this further, flagellin from 11 of the clinical strains was 
isolated (Dr Christopher Birchall and Dr Philip Aldridge) and used to challenge RT4-
NF-κB reporter cells. Typical results relating to the flagellin isolations are shown in 
Figure 3.13.A, where five motile strains were used as a flagellin source. A non-motile 
strain was used as control, hence the absence of a flagellin protein band. Flagellin 
protein bands shown in lanes 2, 5 and 6 migrate as a single band, while the flagellin 
isolations shown in lanes 4 and 7 migrate as multiple bands, with flagellin probably 
being the largest of the protein bands at 50 kDa and 60 kDa, respectively. The isolated 
flagellins ranged in size from 45 kDa to 75 kDa. 
The purified flagellins were used to challenge the RT4-NF-κB-luciferase cells and the 
resulting fold increases in NF-κB signalling ranged between 30.4±1.8 and 46.1±2.5 
(Figure 3.13.B). However, there were no statistical differences identified between the 
responses induced by the different flagellins. These data indicated that flagellin itself 
could not explain the differences in NF-κB signalling induced by the different clinical 
isolates.  
  
 90 
 
A 
A
B
U
C
ys
tit
is
P
ye
lo
ne
ph
ri
tis
B
ac
te
ra
em
ea
0
20
40
60
F
o
ld
 i
n
c
re
a
s
e
B 
Figure 3.13 Isolation of flagellin from clinical isolates and NF-κB response of RT4 cells 
to purified flagellin. (A) Example of purified flagellin electrophoresed on a 10 % Tricine 
SDS-PAGE. (B) NF-κB response of RT4 reporter cells when challenged with 250 ng/ml of 
flagellin. The challenge was performed for four hours (N=6, 2 experiments with 3 replicates).
  
3.8. INNATE IMMUNE RESPONSE TO CLINICAL STRAINS 
ISOLATED OF PATIENTS CARRYING TLR-5(C1174T) SNP 
The previous data showed that many clinical isolates associated with UTI are motile, 
have flagella and induce a NF-κB response in bladder epithelial cells, presumably via 
TLR-5. Thus for infection to occur either the bacteria are able to inhibit signalling 
pathways downstream of NF-κB or the host is unable to recognise the motile bacteria. 
To explore the latter and in collaboration with Mr Ased Ali, Newcastle University, a 
group of patients suffering from recurrent UTI and carrying a C1174T SNP in their 
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TLR-5 gene was identified
89
. The mutation results in an early stop codon, resulting in 
the synthesis of a truncated TLR-5 receptor and the reduced ability of the host 
epithelium to recognise flagellin
154
. Such patients were recruited to investigate the role 
of the mutation in the innate defences of the urinary tract. Urine was collected from 
three SNP patients during an UTI, the bacteria isolated and used to challenge the RT4 
NF-κB reporter cells. Gram staining of the bacteria isolate identified only gram negative 
species and analysis of colony growth did not suggested difference between the 
colonies. Urine IL-8 concentrations were measured using a sandwich ELISA.  
1. INNATE IMMUNE RESPONSE OF RT4-NF-ΚB TO BACTERIA 
ISOLATED FROM URINE OF TLR-5(C1174T) CARRIERS 
The bacterial strains were grown in LB-broth to an OD600 of 0.6, the CFU/ml was 
determined and the bacteria heat killed (100 ºC for 20 minutes). RT4 NF-κB reporter 
cells were infected with 5x10
4
 CFU/ml and the NF-κB activity was measured, as a fold 
increase over PBS challenged cells. The results are shown in Figure 3.14:  
The bacteria significantly activated NF-κB signalling as early as two hours following 
challenge, with fold increases ranging from 28.1±1.4 to 34.2±5.8 (p<0.001), and a peak 
response observed at four hours. At eight hours the signalling response was reduced but 
was still above control values and, moreover, this response was maintained up to the 
final time-point of 24 hours. These data indicated that the bacteria collected from the 
TLR-5 SNP patients elicited a ‘normal’ NF-κB signalling response in RT4 cells and that 
infection was probably due to the defect in the host TLR-5 receptor resulting in reduced 
NF-κB signalling and reduced innate defences.  
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Figure 3.14 NF-κB response of RT4 cells to bacteria isolated from patients carrying 
TLR-C1174T. RT4 reporter cells were incubated with 5x10
4
 CFU/ml of heat killed bacteria 
isolated from urine. Error bars represent standard error of the mean and statistical significance 
was determined by ANOVA; *=p<0.05, **=p <0.01, ***=p< 0.001. (N=6, 2 experiments 
with 3 replicates each) 
2. INHIBITION OF INNATE IMMUNE RESPONSE BY TLR-5 
BLOCKING 
To mimic the effects of the SNP, RT4 cells were treated with antibody to TLR-5 and the 
cells were challenged for 24 hours with the bacterial clinical isolates. The medium 
bathing the cells was collected and analysed for IL-8, which allowed downstream 
signalling effects of the SNP to be reported. The results are shown in Figure 3.15.  
 Challenging RT4 cells with 250 ng/ml of flagellin resulted in IL-8 mean concentration 
of 12429.5±130.4 pg/ml. Blocking TLR-5 resulted in a significant reduction in IL-8 
synthesis to 3130.7±372.7 pg/ml (4 fold, p<0.001). The three bacterial clinical isolates 
induced a mean IL-8 concentration of 20349.4±1080.8 pg/ml for strain 1(strain of 
patient 1) 19771.7±465.9 pg/ml for strain 2 (strain of patient 2) and 23181.9±745.4 
pg/ml for strain 3 (strain of patient 3). Treating the cells with the TLR-5 antibody 
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significantly reduced (p<0.001) the IL-8 concentrations for all challenges- 10.7 fold 
reduction for strain 1, 12.8 fold reduction for strain 2and 15.9 fold reduction for strain 3. 
These data confirmed the importance of the host innate defences in the recognition and 
clearance of bacteria associated with UTI. To further verify these findings, the urine IL-
8 concentrations of patients carrying the SNP and with active UTI were compared to 
those of normal controls also having an infection. 
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Figure 3.15 Inhibition of innate immune response to SNP-Bacteria by blocking TLR-5. RT4 
cells were challenged with 5x10
4
 CFU/ml of TLR-5 SNP bacteria in the presence or absence 
of 5 μg/ml of blocking TLR-5 specific antibody. Flagellin was used a positive control. RT4 
cells were additionally incubated with the blocking antibody only. Media bathing the cells 
was used to measure the IL-8 secretion (N=2, using pooled media from 3 replicates each). 
Statistical significance was investigated using a Student’s T-test;**=p <0.01, ***=p< 0.001 
 
3. IL-8 RESPONSE IN URINE OF PATIENTS WITH A URINARY 
TRACT INFECTION 
Figure 3.16 shows the group of TLR-5 SNP patients suffering from a UTI had a mean 
IL-8 urine concentration of 117.8±64.2 pg/ml, which was significantly reduced (p<0.05) 
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compared to the mean urine concentration of patients carrying wild-type TLR-5 
(705.1±302.3 pg/ml) although these data were not normalised to creatinine.  
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Figure 3.16 Measurement of IL-8 concentration in Urine from patients suffering a UTI. 
Measurement performed using a sandwich ELISA. Urine samples of UTI patients were grouped 
according to the presence of the C1174T SNP in the TLR-5 gene (N=3 for SNP Carriers and 
N=7 for normal TLR-5 gene carriers). Statistical significance was measured using a Student’s 
T-test. *=p<0.05. 
These data suggest that the TLR-5 SNP patients failed to recognise motile flagellated 
pathogens and this has predisposed them to recurrent UTI. It is worth noting that a 
number of the non-TLR-5 SNP patients also failed to induce IL-8. This may have been 
due to other genetic factors such as SNPs in the promoter regions of the IL-8 gene 
reducing gene expression and protein synthesis
155
.  
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3.9. DISCUSSION 
This Chapter focussed on the significance of bacterial PAMPs and cell surface TLRs in 
the innate defence of the uroepithelium from microbial assault.  
To analyse the early innate immune response in detail a qPCR gene array comprising 
genes associated with TLR signalling was utilised. RNA was isolated from RT4 cells 
modelling the uroepithelium challenged with three different E. coli strains, including 
NU14 associated with infection of the UT
24
. The results were generally disappointing 
with the majority of genes not showing differential expression. In reality the majority of 
genes on the array plate were more linked to the functioning of professional APC and 
adaptive immune cells than epithelia, which may explain their lack of activation in the 
experimental system used, i.e. RT4 cells. Another explanation for the limited data from 
the plates could be that the time point of four hours was too early to capture significant 
differential gene expression. Nonetheless, this time point was selected based on pilot 
data that indicated significant NF-κB signalling in RT4 cells challenged with E. coli137 
and was further supported by the NCTC 10418 array data (Table 3.1).  
The genes that were upregulated, however, showed a unique response of RT4 cells to 
each of the E. coli strains used K12, NCTC10418 and NU14. The strains were chosen 
according to their motile characteristics (K-12 and NCTC 10418 are motile strains
137
) 
and their pathological background (NU14 is a UPEC isolated from a cystitis event). 
While only two genes were upregulated in all three challenges - CD14, encoding a 
protein involved in LPS recognition and IL-8, regulated by NF-κB and encoding a 
chemoattractant for neutrophils, the latter result indicated the importance of NF-κB 
signalling in the innate defences of the uroepithelium.  
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To further investigate the signalling responses RT4 NF-κB reporter cells were used and 
all bacteria used in the challenge of the cells were heat killed to prevent cell cytotoxicity 
caused by the bacterial overgrowth
137
. An initial concern with this approach was that 
bacterial cell lysis released antigens, which epithelial cells in vivo would not normally 
be exposed to. However, bacterial cell lysis does occur in the bladder as a result of 
natural bacterial death and the action of antimicrobial agents including AMPs and 
lysozyme. Moreover, by killing the bacteria the number of challenge time-points was 
increased (up to 24 hours), experimental variation was reduced as all the bacterial cells 
were grown to OD600 of 0.6 and the challenges were all performed using the same 
numbers of bacterial cells.  
The NCTC 10418 strain, which was the most motile, induced the highest NF-κB 
response in the RT4 reporter cells (43 fold). In fact the signalling response was twice 
that of CFT 073 (20 fold), a laboratory strain originating from a patient with 
pyelonephritis
147
. The maximal NF-κB response to the non-motile UPEC strain NU14 
was also very weak (7 fold), supporting the pathogenic capabilities of the latter two 
strains to overcome the host defences. In addition these data indicate the significance of 
bacterial motility in the ability of the host to recognise potential pathogens. In fact, it 
could be argued that the lack of motility of the UPEC strain NU14 allows it to ‘hide’ 
from the host innate defences. Yet, the motility theory is not straightforward as CFT 
073 is motile and induces an innate response via NF-κB signalling, but is associated 
with UTI. CFT 073, however, has developed a method by which it can manipulate the 
host response. In 2008, Cirl and colleagues showed that CFT 073 secreted a protein that 
mimics the TIR domain of TLR
37
. The authors named this protein TcpC (TIR-domain 
containing protein of E. coli), and demonstrated its ability to prevent the attachment of 
the adaptor protein MyD88 by sequestering it
37
. This adaptation may explain the 
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reduced NF-κB signalling response observed in the RT4 cells but further challenge 
experiments using CFT 073 strains in which the TcpC protein is either mutated or 
deleted are required.  
Bacterial motility is linked to flagellin which is the ligand for TLR-5
94,146
. Flagellin 
(250 pg/ml) purified from E. coli induced a significant NF-κB response in RT4 cells as 
early as four hours and the response was, 34 times greater than that observed with LPS 
(10 μg/ml) or peptidoglycan (10 μg/ml). Flagellin was also associated with effector IL-8 
concentrations ten times greater than those detected following LPS challenge and 200 
times those associated with peptidoglycan. These data indicated that TLR-5 is a pivotal 
receptor in the defence of the uroepithelium and this was confirmed by experiments 
using a TLR-5 blocking monoclonal antibody. Analogous results were also reported 
using primary cells by Smith et al, in 2011
156
, where flagellin induced strong IL-6 and 
IL-8 responses, but only in proliferating uroepithelium
156
. 
The response to LPS was investigated to control for LPS contamination of the flagellin 
preparation. Initial experiments to purify the E. coli flagellin used a size exclusion 
column but this resulted in a catastrophic loss of sample (Fig. 3.4B). Thus flagellin was 
prepared and used without the size exclusion step, i.e. fine purification, so 
contamination of the flagellin stocks with LPS could not be excluded. Potential LPS 
contamination of flagellin was not considered a problem as during previous research, 
the TLR-4 ligands LPS and Lipid A failed to evoke an NF-κB response137. However, 
other investigators have reported LPS to induce an innate response in bladder cells
150
. 
Thus LPS challenges of RT4 cells were performed up to 24 hours, and compared to 
previous experiments, using an increased concentration, i.e. 10 µg/ml. The results 
revealed that LPS induced a NF-κB signalling response but the maximum response was 
<10 fold and at 16 hours post challenge. This compared to the flagellin response which 
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was 7 fold at one hour and maximum, i.e. 45 fold at 4 hours. These data indicated that 
LPS is less important in the induction of an innate response in the bladder although 
interestingly NU14 is known to have a mechanism, using the waaL gene, by which it 
manipulates its outer LPS to evade a host response
36
. It is worth noting that Smith et al. 
(2011), using 1 μg/ml did not detect any innate immune response of the uroepithelia to 
LPS. The findings reported here therefore indicate that higher concentrations of LPS are 
needed to evoke an uroepithelial innate immune response and supported previous 
findings that in the defence of the human uroepithelium TLR4 is less important than 
TLR-5. When RT4 cells were challenged with peptidoglycan, a TLR-2 ligand, NF-κB 
signalling was again detected but the response was weak and comparable to that of LPS. 
These data again suggested that TLR-2, like TLR4, is of reduced importance in the 
defence of the UT.  
The PAMPs used, i.e. flagellin, LPS and Peptidoglycan did not induce microscopically 
visible cytotoxic effects in RT4 cells. Nonetheless, an assessment of the cytotoxicity of 
the challenges must be performed in future research using a cell viability assay, e.g. 
MTT assay. 
As TLR-5 appeared to be a key UT defence factor it was predicted that clinical strains 
associated with UTI may avoid the host defences by adopting reduced motility. To 
explore this further the motility and NF-κB activating ability of 24 clinical isolates, 
defined as E. coli by standard clinical methodology, were investigated. However, 12/24 
strains were motile and ten of those induced NF-κB signalling, although the NF-κB 
signalling responses of the motile strains were quite variable. Induction of NF-κB 
signalling was surprising but as statistical analysis of the effector IL-8 concentrations 
failed to show significance, the data could be interpreted to support bacterial 
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mechanisms functioning to inhibit signalling pathways downstream of NF-κB. This 
requires further investigation.  
Conversely UTIs may result from motile, NF-κB activating bacteria infecting subjects 
characterised by defects in their host innate defences, including non-functioning TLR 
receptors. It is known that people suffering from a TLR-5 C1174T SNP are more prone 
to recurrent urinary tract infections
89
. In fact, bacteria isolates collected from the urine 
of such patients during an infection and used to challenge RT4 cells resulted in NF-κB 
activation and IL-8 synthesis. These observations support the premise that a functional 
TLR-5 is key in protecting the uroepithelium from infection.  
This chapter highlights the importance of bacterial motility, flagellin and TLR-5 in the 
recognition of potential pathogens by the uroepithelium. Activation of TLR-5 is known 
to result in IL-8 synthesis and the recruitment of APCs, and neutrophils, but for rapid 
bacterial clearance host agents able to kill the microbes are essential. One such agent is 
human β-Defensin 2 (hβD-2), and this was shown by a colleague, Mr Ased Ali 
(Newcastle University), to protect the uroepithelium from bacterial infection
157
. The 
following chapter focuses on the development of an hβD-2 specific reporter to 
investigate hβD-2 gene regulation.  
 
  
C H A P T E R  F O U R   
  
Human β-Defensin 2 Reporter 
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4.1. INTRODUCTION 
In the previous chapter, the interactions between pathogen and host were investigated in 
cells modelling the urinary tract. These data determined a pivotal role for TLR-5 in the 
recognition of motile bacteria and the resulting activation of the transcription factor NF-
κB. Impaired recognition, as a consequence of a SNP in the TLR-5 gene or by pathogen 
inhibition of cell signalling, resulted in a deficient NF-κB and thus innate immune 
response as evidenced by reduced IL-8 concentrations and hβD-2 secretion157. It is 
proposed that this impaired response increases the risk of recurrent (r)UTI in susceptible 
women. Restoring a normal hβD-2 response in such subjects could therefore help 
prevent or help treat rUTIs.  
Based on this premise, the investigations in this Chapter focussed on exploring the 
mechanisms, in addition to NF-κB, involved in regulating hβD-2 expression. To achieve 
this a bioinformatics approach was used to identify putative transcription factor binding 
sites in the 5’- non-translated promoter region and a hβD-2 reporter system was 
engineered to examine whether such sites could be exploited to activate hβD-2 
expression.   
Based on the bioinformatics data the roles of hormones and nutritional factors, 
specifically, oestrogen, resveratrol and vitamin D in the induction of hβD-2 were 
investigated using RT4 bladder and VK-2E6/E7 vaginal cells. In addition, hβD-2 
induction was investigated using Zymosan, a fungal cell wall preparation alone and in 
combination with oestrogen, resveratrol and Vitamin D.  
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4.2. TRANSCRIPTION FACTOR BINDING SITES IN THE 5’ 
UTR OF hβD-2  
Previous work has shown that hβD-2 is synthesised in response to infection of the uro-
genital tract and that a reduction in hβD-2 increases the chance of infection with 
flagellated E. coli strains
158,159. Hence, an understanding of hβD-2 expression is 
necessary for the design of future therapies directed at its enhancement. Thus the 5’ 
non-translated region of the hβD-2 or DEFB4 gene was investigated for potential 
transcription factor (TF) binding sites using bioinformatics. For this, the sequence of 
2030 bp preceding the 5’ start codon of the DEFB4 gene was obtained from the genome 
database GRCh37.p10 and analysed using the PROMO software
160
. The resulting TF 
binding sites found during this investigation are shown in Figure 4.1:  
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Figure 4.1 Transcription factor binding site search in the 5-UTR of the hβD-2 gene using 
the Bioinformatics software PROMO. Transcription factors included in the investigation were 
NF-kB, Activator Protein 1 (AP-1), Vitamin D receptor (VDR), Retanoic Acid Receptor (RAR-
beta) and Oestrogen Receptor (ER-alpha). The transcription factors in the legend are sorted by 
their proximity to the start codon (0). For details see materials & methods section 2.19.I 
Data mining of TF binding sites of the hβD-2 5’ untranslated region (Fig. 4.1) identified 
two NF-κB binding sites , 345 and 546 bp respectively from the start codon of the h-βD-
2 gene. Four AP-1 binding sites were also detected at positions 79, 634, 1644 and 1655 
bp respectively. Adjacent to the start codon with a distance of 19 bp was the Vitamin D 
Receptor (VDR) transcription factor binding site (Fig. 4.1). A further VDR binding site 
was detected at 656 bp from the start codon. A total of six binding sites were found for 
Retinoic Acid Receptor-beta (RAR-beta) at 146, 212, 434, 954, 1215 and 1421 bp from 
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the start codon; Oestrogen Receptor- alpha (ER-α) also had a total of six binding sites 
1172, 1181, 1383, 1405, 1592 and 1891 bp from the start codon.  
These data show that in addition to NF-kB, a number of other transcription factors are 
present in the 5’ non-translated region of the DEFB4 gene. Moreover, the presence of 
the ER-α and VDR elements raised the potential of exploiting vitamin D or oestrogen 
therapy to enhance hβD-2 expression and help prevent or treat UTIs. The roles and 
importance of such TF binding sites in the functioning of the urogenital epithelium in 
relation to hβD-2 expression were therefore investigated using a reporter gene assay. 
For this assay, 2030 bp of the 5’ non-translated region of hβD-2 were fused to a reporter 
gene, transfected into either RT4 bladder cells or VK-2 E6/E7 vaginal cells and 
challenged with E. coli, bacterial PAMPs and reagents including oestrogen and  
vitamin D. The aim was to identify potential agents that activated and /or enhanced 
hβD-2 expression in the urogenital tract.  
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4.3. CONSTRUCTION OF REPORTER PLASMID USING GFP 
REPORTER 
In order to engineer the reporter plasmid, 2030 bp of DNA 5’ to the start of the DEFB4 
gene was amplified as described in section 2.5.V. 
     
Figure 4.2 Amplification of a 2030 bp region 5’UTR of the DEFB4 gene. Lane 1, the marker 
Hyperladder I. Lane 2 shows the amplification of the 2030 bp region using KOD-polymerase. 
DNA was separated on a 0.8 % agarose gel. 
The amplification resulted in a band of the expected size, i.e. 2000 bp (Fig. 4.2, lane 2). 
This was cloned into the pGlow TOPO vector as described in section 2.12.II. The 
presence and orientation of the insert in the plasmid was confirmed by using unique 
EcoRI and KpnI restriction sites, determined using SerialCloning 2.5 Software, in the 
insert (Fig. 4.3).  
2000 
1500 
 
3000 
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A           B 
Figure 4.3 Engineering phβD-2-GFP Reporter. (A) Schematic view of plasmid after ligation 
with the restriction sites for Plasmid containing the first 2030 bp of the 5’ region of the DEFB4 
gene. (B) Cloning of the 5’ UTR into pGlow TOPO. The first lane is the undigested plasmid. 
The second lane shows the plasmids after ligation linearised with Eco RI, the third with Eco RI 
and Kpn I. The orange arrows show the products of expected size. The fourth lane shows Kpn I 
digestion of the plasmid after the ligation. The ladder is 1 kBp (lane 5, Promega).  DNA was 
separated on a 0.8 % agarose gel. 
The predicted plasmid, following cloning of the promoter region and highlighting the 
unique EcoR1 and Kpn1 restriction sites, is shown in Fig.4.3.A. Linearisation of the 
plasmid was achieved using either EcoRI or KpnI, and the linearised plasmid DNA 
migrated at approximately 7500 bp, which related to the expected size of 7363 bp 
(Lanes 2 and 4, Fig.4.3.B). The enzymatic restriction with EcoRI and KpnI 
simultaneously resulted in the expected two bands of approximately 5500 and 2000 bp, 
which agreed with the expected sizes of 5395 bp and 1968 bp respectively (lane3). 
These data indicated that the cDNA insert was the hβD-2 5’ region and was cloned in 
the correct orientation. DNA sequencing (GENEVISION, Newcastle, UK) confirmed 
the presence and orientation of the insert (Fig. 4.4). 
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Figure 4.4 Confirmation of engineered phβD-2-GFP Reporter by sequencing and alignment. (A and C) Sequencing using the forward primer at 
position 1: (A) Plasmid was sequenced by Genevision UK. (B) Sequence was aligned with predicted sequence using BLAST alignment tool. (B and D) 
Sequencing using a forward primer from position 1000. (C) Plasmid was sequenced by Genevision UK. (D) Sequence was aligned with predicted 
sequence using BLAST alignment tool (http://blast.ncbi.nlm.nih.gov/BlastAlign.cgi). 
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In fact, aligning the cloned sequences to the predicted sequence found in the RefSeq 
Genome database (http://www.ncbi.nlm.nih.gov/refseq/) showed 97 % identity. The 
plasmid was considered optimal and therefore the next step was the optimisation of its 
transfection into RT4 and VK-2 E6/E7 cells modelling the urogenital tract.  
1. TRANSFECTION OPTIMISATION OF RT4 AND VK-2 E6/E7 
CELLS 
The transfection conditions of the RT4 and VK-2 E6/E7 cells were optimised to achieve 
maximum transfection efficiency. For this, transfections a reporter plasmid with a 
strong promoter (CMV) and a luciferase reporter was used (pGL4.51, Promega, UK). 
For RT4 cell transfections the transfection reagent TurboFect was utilised while for 
VK-2 E6/E7 cells Attractene transfection agent was used. Attractene was used because 
no transfection was achieved when TurboFect was used to transfect the VK-2 E6/E7 
cells (data not shown). The concentrations of DNA-transfection reagent are shown in 
Table 4.1:  
Table 4.1: Concentration of DNA-Transfection Reagent Mixture 
 
 TurboFect Attractene 
Volume of trans-
fection reagent/μl 
Amount of DNA/ng Amount of DNA/ng 
0 0 0 
0.1 50 27 
0.2 100 54 
0.3 150 81 
0.4 200 108 
0.5 250 135 
0.6 300 162 
0.75 375 202.5 
The results of the transfection optimisation are shown in Figure 4.5: 
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Figure 4.5 Optimisation of transfection using CMV-Luciferase reporter plasmid. (A) 
Optimising transfection in RT4 cells using TurboFect transfection reagent (Thermo Scientific). 
(B) Optimisation of transfection in VK-2 E6/E7 cells using Attractene (QIAGEN). Values 
shown on the x-axis represent the volume of transfection reagent used. Reporter plasmid was 
CMV-Luc. N=6, 2 experiments with 3 replicates 
As shown in Figure 4.5.A, the concentration of TurboFect achieving the highest 
transfection efficiency in RT4 was 0.3 μl. Indeed, at volumes higher than 0.5 ml, cell 
cytotoxicity was observed and reporter activity, i.e. luminescence was reduced. In 
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accordance with this, the optimal volume for transfecting RT4 was determined as 0.3 μl 
of TurboFect-DNA. 
VK-2 E6/E7 cells transfected with 0.4 μl to 0.75 μl of Attractene-DNA mix showed a 
similar response with luminescence of 119631±4409 A.U. for 0.4 μl vs. 99979±4127 
A.U. for 0.75 μl (Fig. 4.5.B). Moreover, no cell cytotoxicity was observed when the 
cells were observed under the microscope. Therefore, 0.4 μl Attractene-DNA was used 
as the optimal concentration for transfection of VK-2 E6/E7 cells.  
4.4. VALIDATION OF PHΒD2-GFP REPORTER GENE 
Next, a pilot experiment using the optimal concentration of the transfection reagent-
DNA mix and RT4 cells was performed. To control that the optimised concentration for 
the transfection is suitable for a GFP assay, the cells were transfected with a positive 
control reporter containing a GFP reporter (CMV-GFP, SABiosciences) and the  
phβD-2-GFP reporter, as described in section 2.11.II. The latter cells challenged with 
flagellin or the E. coli strain NCTC 10418 for up to 16 hours. NCTC 10418 and 
flagellin were chosen as they induced the highest NF-κB activity in RT4. Fluorescence 
was detected using a fluorescent microscope (EVOS FL) and the results of the images 
taken are shown in Figure 4.6: 
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 A  B 
 C      D 
Figure 4.6 Validation of phβD-2-GFP using fluorescent microscopy RT4 cells were 
transfected with control reporter (A, CMV-GFP, SABiosciences) or with phβD-2-GFP reporter 
(B-D). (B) RT4 cells challenged with PBS, (C) 250 ng/ml flagellin, (D) 5x10
4
 CFU/ml of 
NCTC 10418.  Images taken using an EVOS FL microscope and, 100 x magnification. Bars 
represent 200 μm 
Transfection of the positive control (Fig. 4.6.A) resulted in fluorescence indicating that 
the RT4 cells were successfully transfected with the optimised concentration. The 
phβD-2-GFP transfected RT4 cells incubated with PBS did not show fluorescence (Fig. 
4.6.B), but did fluoresce when either flagellin or bacteria (NCTC 10418) were added to 
the cells (Fig. 4.6.C and D).  
The transfections appeared to work but the observations were subjective; the aim was 
now to develop a quantitative reporter gene assay to investigate the activation of the 
hβD-2 gene. Quantitation of the fluorescence was achieved using a BMG Omega 
FluoStar fluorometer. RT4 cells were transfected as described previously and 
challenged with flagellin and NCTC 10418 for up to 16 hours. In addition, TNF-α, a 
known endogenous activator of hβD-2161, is functioning as a positive control and was 
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added to the challenges. The fluorescence was measured and the results of the 
transfected cells are shown Figure 4.7: 
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Figure 4.7 phβD-2-GFP Reporter Activity in Challenged RT4 Cells. RT4 cells were 
transfected with the phβD-2 reporter plasmid and challenged with the endogenous hβD-2 
inducer TNF-α [20 ng/ml], bacterial flagellin [250 ng/ml], NCTC 10418 [5x104 CFU/ml] or 
PBS for 16 hours. Fluorescence of transfected and challenged RT4 cells was measured in RT4 
medium. N=12, 4 experiments with 3 replicates each. 
 
These data indicated that challenging RT4 cells transfected with the phβD-2-GFP 
reporter plasmid did not result in any measurable increase in fluorescence with any of 
the reagents shown previously to induce hβD-2 gene expression. To address the 
possibility of auto-fluorescence of the media masking the reporter activity, the 
fluorescence of transfected RT4 cells was measured in PBS and the result is shown in 
Figure 4.8:  
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Figure 4.8 phβD-2-GFP reporter activities in challenged RT4 cells maintained in PBS. RT4 
cells were transfected with the phβD-2 reporter plasmid and challenged with the endogenous 
hβD-2 inducer TNF-α [20 ng/ml], bacterial flagellin [250 ng/ml], NCTC 10418 [5x104 CFU/ml] 
or PBS for 16 hours. The medium was washed off twice and replaced by PBS. Fluorescence of 
transfected and challenged RT4 cells was measured in PBS solution. N=12, 4 experiments with 
3 replicates. 
 
Changing the media to PBS did not cause an effect on the fluorescence measurement, 
suggesting that the phβD-2-GFP reporter as a tool to investigate the hβD-2  
5’ region for TF activity was too insensitive due to the cellular autofluorescence. 
Therefore an alternative reporter system was investigated.  
4.5. CONSTRUCTION OF REPORTER PLASMID USING 
LUCIFERASE REPORTER VECTOR 
Luciferase has the advantage, when compared to GFP, that it circumvents any problems 
due to cell, eukaryote and prokaryote, auto-fluorescence. The luciferase vector chosen 
was pGL 4.10 luciferase and the 2032 bp 5’ non-translated region preceding the hβD-2 
gene was ligated into pGL 4.10 as described in section 2.12.II using KpnI and HindIII 
restriction sites. Cloning results are shown in Figure 4.9: 
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A        B 
Fig. 4.9 Engineering of the phβD-2-Luc Reporter. (A) Schematic view of phβD-2-Luc using 
Serial cloner v2.5. 2032 bp insert of the 5’non-translated region of the hβD-2 gene is depicted in 
blue. The luciferase gene is shown in green. The plasmid has a size of 6227 bp after ligation. 
Plasmid engineering was simulated using Serial Cloner 2.5. (B) Engineering of the reporter 
gene using the pGL4.10 vector. The gel shows: 1 kbp marker (Promega UK, lane 1), pGL4.10 
after purification (lane 2), pGL4.10 after double digestion using KpnI and HindIII (lane 3), the 
insert after double digestion using KpnI and HindIII (lane 4), ligation of the insert and pGL4.10 
creating phβD-2-Luc (lane5), phβD-2-Luc (insert + pGL 4.10) after transformation and 
purification (lane 6), plasmid linearised after Kpn I digestion (lane 7), insert verification of 
insert presence using Kpn I and Hind III (lane 8), linearisation of the phβD-2-Luc plasmid with 
HindIII (lane 9) and PCR product using phβD-2 primers and the plasmid as template (lane 10). 
DNA separated on 1 % Agarose gel. 
Lane 3 shows the linear pGL4.10 vector following restriction with KpnI and HindIII 
(4191 bp). Lane 4, shows the hβD-2 insert migrating at approximately 2 kbp consistent 
with expected size of 2032 bp. Lane 7 shows the KpnI linearised phβD-2-Luc plasmid 
migrating at approximately 6 kbp consistent with an expected size of 6227 bp (4191 bp 
for the pGL4.10 plus 2032 bp insert). A KpnI and HindIII double digestion of the phβD-
2-Luc plasmid resulted in the expected two bands with 2032 bp and 4187 bp (lane 8). 
Using the phβD-2-Luc plasmid as a template for a PCR and using the insert primers 
(Table 2.1) also resulted in a band of the expected size (2032 bp, lane 10). Plasmid 
authenticity was confirmed by DNA sequencing (Fig. 4.10): 
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Figure 4.10 Confirmation of engineered phβD-2-Luc Reporter by sequencing and alignment. Purified phβD-2-Luc plasmid was 
sequenced by Genevision. (A) Sequencing of the phβD-2-Luc plasmid using the forward primer and (B) reverse primer (B) BLAST 
alignment of (A) with predicted sequence. (C) BLAST alignment of sequence obtained from (A) with predicted sequence. (D) BLAST 
alignment of sequence obtained from (B) with predicted sequence. 
1
1
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Indeed sequencing using forward and reverse primers confirmed a high identity between 
the plasmid sequence and the predicted sequence (96 %, Fig. 4.10.B and Fig. 4.10.D). 
The plasmid was therefore used to transfect RT4 cells.  
4.6. CHALLENGING RT4 CELLS TRANSFECTED WITH 
PHΒD-2-LUC  
RT4 cells were, using new phβD-2-Luc reporter construct, transiently transfected and 
challenged with the known hβD-2 inducers flagellin, NCTC 10418 and TNF-α. The 
results are presented in Fig. 4.11 with data presented as fold increase in hβD-2 
expression compared to PBS challenge: 
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Figure 4.11 Validating phβD-2-Luc reporter activity in RT4. After 16 hours of 
transfection, the cells were challenged with PBS, flagellin [250 ng/ml], NCTC 10418 [5x10
4
 
CFU/ml] or TNF-α [20 ng/ml]. The luminescence was measured at 0,8,16 and 24 hours. 
Results are shown as fold-increase over PBS challenged RT4 cells N=6, 2 experiments with 3 
replicates **p<0.01; ***p<0.001. 
When compared to the PBS challenge, the highest response was observed when the RT4 
cells were challenged with flagellin, and at all three time points examined, i.e. 8, 16 and 
24 hours. The response to flagellin peaked at 16 hours (25.7±4.5, p<0.001), which was 
consistent with hβD-2 gene expression data (Mr A. Ali, personal communication and 
presented data
158
). Furthermore, the responses to NCTC 10418 and TNF-α were 
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significant at 16 and 24 hours when compared to the PBS challenge. These data 
indicated the phβD-2-Luc reporter system was functionally active and from these data 
16 hours was chosen as the optimal time point to measure luciferase activity. 
4.7. INVESTIGATING THE PHΒD-2-LUC REPORTER 
RESPONSE OF RT4 CELLS USING THE MOTILE NCTC 
10418 AND BACTERIAL COMPONENTS 
To further investigate hβD-2 gene regulation the RT4 cells were transiently transfected 
with the reporter and challenged up to 16 hours with a selection of PAMPS including 
LPS and peptidoglycan. The results are shown in Figure 4.12.  
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Figure 4.12 phβD-2-Luc response to E. coli strain NCTC 10418 or bacterial PAMPs. RT4 
cells were transfected with phβD-2-Luc. After 16 hours, the transfected RT4 cells were 
challenged for 16 hours with PBS, E. coli NCTC 10418 [5x10
4
 CFU/ml], Flagellin [250 ng/ml], 
LPS [10 μg/ml], or Peptidoglycan [10 μg/ml] N=6, 2 experiments with 3 replicates. **p<0.01; 
***p<0.001.  
As observed previously, the transfected RT4 cells showed a significant response 
(p<0.001) to flagellin (60.5±6.6 fold) and NCTC 10418 (16.4±4.4 fold) when compared 
to PBS. LPS did not induce a response from the phβD-2-Luc reporter (1.4±0.1,), 
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although upregulation was identified following peptidoglycan treatment (8.8±1.8 fold 
increase). However, the response to peptidoglycan was reduced by two and seven fold 
respectively compared to NCTC 10418 and flagellin.  
These data confirmed gene expression observations and showed that flagellin, activated 
hβD-2 presumably functioning through TLR-5 and NF-kB signalling. The phβD-2-Luc 
reporter was therefore used to investigate the effects of further treatments on hβD-2 
expression in conjunction with or independent of flagellin. 
4.8. ENHANCING PHΒD-2-LUC REPORTER RESPONSE 
USING IMMUNOMODULATORY TREATMENT IN RT4 
CELLS  
1. ZYMOSAN ENHANCES PHΒD-2-LUC REPORTER ACTIVITY  
Zymosan is a β-1,3 glucan, found in fungal cell walls, and known to activate NF-κB162. 
Using the reporter construct the effects of Zymosan on the flagellin response was 
investigated. To achieve this RT4 cells were transfected with the phβD-2-Luc reporter 
and challenged with either flagellin, or Zymosan or a combination of both. The results 
of the challenges are shown in Figure 4.13: 
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Figure 4.13. Enhancing hβD-2 response to flagellin using Zymosan in RT4. RT4 cells 
transfected with phβD-2-Luc were challenged for 16 hours with flagellin [250 ng/ml], 
Zymosan [50 μg/ml] or a combination of both N=6, 2 experiments with 3 replicates. 
***p<0.001.  
The flagellin challenge resulted in a fold increase of 60.5±6.6. When compared to 
flagellin, the response of the RT4 cells to Zymosan was reduced by approximately two-
fold (34.8±5.0). However, the hβD-2 response to flagellin plus Zymosan challenge was 
significantly higher (p<0.001) when compared to that of flagellin or Zymosan alone 
(152.8±3.4 fold increase). These data suggest that Zymosan is also an activator of hβD-
2 expression and moreover, significantly enhances the hβD-2 response to flagellin.  
2. FURTHER ENHANCEMENT OF HΒD-2 REPORTER ACTIVITY 
USING CALCITRIOL 
Bioinformatics analyses identified a number of different TF binding sites in 5’ region of 
hβD-2 gene including two VDR at 19 bp and 656 bp respectively. To explore the 
functioning of such sites RT4 cells were incubated for 16 hours with 10 nM 1,25 
dihydroxycholecalciferol, also named calcitriol, the active form of Vitamin D, before 
transfection with the phβD-2-Luc reporter and challenge with LPS, PG, flagellin, 
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Zymosan as well as flagellin in combination with Zymosan. The results of the challenge 
are presented in Figure 4.14: 
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Figure 4.14 phβD-2-Luc Response enhancement in RT4 cells by the presence of calcitriol. 
RT4 cells were grown in medium supplemented with calcitriol [10 nM] or in normal medium 
(untreated). The RT4 cells were transfected and challenged with NCTC 10418 or PAMPs for 16 
hours N=6, 2 experiments with 3 replicates. *<0.05, **p<0.01; ***p<0.001. 
Treatment with vitamin D induced a significant increase in hβD-2 in the unchallenged 
cells (6.0±0.8 calcitriol treated vs. 1.0±0.1 without calcitriol). Vitamin D had no effects 
on hβD-2 regulation when the cells were challenged with either LPS, peptidoglycan or 
NCTC 10418. In contrast, when calcitriol supplemented RT4 cells were challenged with 
flagellin there was the suggestion of a reduced hβD-2 response (44.6±6.0 calcitriol 
treated vs. 60.5±6.1 untreated). Moreover, when the calcitriol supplemented cells were 
challenged with either Zymosan or Zymosan and flagellin the responses were reduced 
significantly (21.2±0.8 calcitriol + Zymosan treated vs. 34.8±5.0 untreated, p<0.05) and 
(103.8±14.1 calcitriol +flagellin+ Zymosan treated vs. 151.8±3.4 untreated, p<0.01).  
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These data suggested that calcitriol is a hβD-2 inducer in the absence of bacterial 
challenge. However, in the presence of bacteria or PAMPs it appeared to suppress the 
hβD-2 response. 
3.  CYTOTOXIC EFFECT OF OESTROGEN OR RESVERATROL 
TREATMENT ON RT4 CELLS 
Bioinformatics analyses also identified six ER-α in the 5’ region of hβD-2 gene. 
Oestrogen is a known regulator of immunity (reviewed by Nadkarni et al., 2013
163
). To 
explore the functioning of the ER-α sites in hβD-2 gene regulation, RT4 cells were 
grown in 17β-oestradiol [4 nM] before being transfected with phβD-2-Luc and 
challenged as described in section 4.8.II. The results of the challenges are shown in 
Figure 4.15: 
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Figure 4.15 Cytotoxic effect of 17β-oestradiol. RT4 cells were grown in medium 
supplemented with 17β-oestradiol [4 nM] or in normal medium (untreated). The RT4 cells were 
transfected and challenged with NCTC 10418 or PAMPs for 16 hours. No statistical analysis 
was performed due to the observed cytotoxicity. N=6, 2 experiments with 3 replicates 
In the absence of 17β-oestradiol the responses were as previously reported. However, 
the hβD-2 responses in the presence of 17β-oestradiol were much reduced. When the 
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transfected cells were observed under the microscope cell death was evident thus 
explaining the data. Therefore it appeared that the transfection agent was killing the 
oestrogen treated cells suggesting that the data observed was due to cytotoxic rather 
than physiological effects.  
Resveratrol is a polyphenol produced by plants, e.g. grapes. It is found at high 
concentrations in red wine ranging from >1-12.3mg/l
164
 and known to act through the 
receptors ER-α and ER-β165. Hence, it was considered as an alternative to oestrogen 
treatment. Cells were grown in resveratrol at concentrations ranging from 1 to 50 μM. 
However, microscopic observations showed that resveratrol was highly cytotoxic to 
RT4 cells, and hence, transfection of resveratrol treated cells was not possible.  
4.9. INVESTIGATING PHΒD-2-LUC REPORTER RESPONSE 
IN VK-2 E6/E7 VAGINAL EPITHELIUM 
As mentioned in the introduction to this thesis, the route of a urinary tract infection in 
women is via the vagina. Since UPEC is present in the vagina before it infects the 
urinary tract
18
 enhancing the innate immunity of the vagina through increasing hβD-2 
expression could be a mechanism of preventing or treating urinary tract infections. 
Therefore, the reporter gene was used to investigate the expression of hβD-2 in VK-2 
E6/E7 cells used as a model of the vaginal epithelium. 
VK-2 E6/E7 cells were transfected with phβD-2-Luc using the optimised concentration 
of attractene described in Fig. 4.5, and challenged with E. coli NCTC 10418 or bacterial 
PAMPs. The results of the phβD-2-Luc response are shown in Figure 4.16: 
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Figure 4.16 phβD-2-Luc response in VK-2 E6/E7 transfected with reporter construct and 
challenged with E. coli NCTC 10418 or bacterial PAMPs. VK-2 E6/E7 were transfected with 
phβD-2-Luc and challenged for 16 hours with 5x104 CFU/ml of E. coli NCTC 10418, LPS [10 
μg/ml], peptidoglycan [10 μg/ml], flagellin [250 ng/ml] N=6, 2 experiments with 3 replicates, 
**p<0.01; ***p<0.001.  
NCTC 10418 induced a significant 19.9±3.8 fold increase (p<0.001) in hβD-2 reporter 
activity compared to cells challenged with PBS alone. The response to LPS or 
peptidoglycan was also significantly increased (p<0.01), with a 4.9±0.9 fold increase for 
LPS and 7.4±1.2 fold increase for peptidoglycan. As with the RT4 cells, the maximal 
response to a bacterial compound was measured, when VK-2 E6/E7 cells were 
challenged with flagellin (68.1±8.5 fold increase, p<0.001). 
1. ZYMOSAN ENHANCES OF PHΒD-2-LUC REPORTER RESPONSE 
IN VK-2 E6/E7  
Whether the hβD-2 response to flagellin could be enhanced by Zymosan was also 
investigated in VK-2 E6/E7 cells. For this, phβD-2-Luc transfected VK-2 E6/E7 cells 
were challenged with Zymosan in either the absence or presence of flagellin and the 
results are shown in Figure 4.17: 
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Figure 4.17 Enhancing the hβD-2 response in VK-2 E6/E7 to flagellin with Zymosan. VK-2 
E6/E7 cells were transfected with phβD-2-Luc and challenged with flagellin [250 ng/ml], 
Zymosan [50 μg/ml] or the combination of flagellin and Zymosan for 16 hours N=6, 2 
experiments with 3 replicates. *p<0.05, ***p<0.001.  
As observed with RT4 cells Zymosan induced a significant increase (p<0.001) in the 
hβD-2 response in VK-2 E6/E7 cells (27.2±2.9). Again, similar to that observed in RT4 
cells, the response to flagellin was higher (68.1± 8.5 fold for flagellin vs. 27.2±2.9 fold 
for Zymosan,). Moreover, the combination of flagellin and Zymosan induced a 
significantly higher hβD-2 response when compared to flagellin alone (189.7±39.8 for 
the combined challenge, p<0.05).  
2. FURTHER ENHANCEMENT OF PHΒD-2-LUC RESPONSE UPON 
CALCITRIOL TREATMENT 
The effects of calcitriol treatment on the hβD-2 response in VK-2 E6/E7 were 
investigated. Like the RT4 cells, the VK-2 E6/E7 cells were grown in 10 nM calcitriol 
and challenged as described before. The results are shown in Figure 4.18: 
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Figure 4.18 hβD-2 response enhancement in VK-2 E6/E7 to E. coli NCTC 10418 and 
PAMPs after calcitriol treatment. VK-2 E6/E7 were grown in 10 nM calcitriol and transfected 
with phβD-2-Luc, before being challenged for 16 hours with 5x104 CFU/ml of E. coli NCTC 
10418, LPS [10 μg/ml], peptidoglycan [10 μg/ml], flagellin [250 ng/ml], Zymosan [50 μg/ml] or 
the combination of flagellin and Zymosan. † Two outliners were removed from the calcitriol 
treated and flagellin challenged VK-2 E6/E7 cells N=6, 2 experiments with 3 replicates 
**p<0.01, ***p<0.001. 
Calcitriol treatment alone induced a significant reporter response in the VK-2 E6/E7 
cells (4.4±0.5 fold compared to 1.0±0.1 fold). The reporter response to NCTC 10418 
was also significantly increased when VK-2 E6/E7 cells were treated with calcitriol 
(40.1±4.3 vs. 19.9±3.8, p<0.01). In addition, there was the suggestion of an enhanced 
response to flagellin in the calcitriol treated cells but this was not statistically 
significant. However, when two low outlying data points (34.10 from the first 
experiment and 41.14 from the second experiment) were excluded from the data set the 
data was statistically significant (196.3±28.3 fold compared to 68.1±8.5). The responses 
to LPS and Peptidoglycan were not altered by the calcitriol treatment. 
This section demonstrated the ability of calcitriol to activate the hβD-2 response and 
enhance the response of the vaginal epithelium to motile bacteria and flagellin.  
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3. ENHANCEMENT OF PHΒD-2-LUC REPORTER RESPONSE 
THROUGH OESTROGEN TREATMENT 
Oestrogen dependent immunomodulation of the hβD-2 reporter was also investigated in 
VK-2 E6/E7 cells. VK-2 E6/E7 cells were grown in 17β-oestradiol and challenged with 
the compounds described previously as well as with E. coli NCTC 10418. The results 
are shown in Figure 4.19: 
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Figure 4.19 Enhancing the response to flagellin using 17β-oestradiol. VK-2 E6/E7 were 
grown in the presence of 17β-oestradiol and transfected with phβD-2-Luc and challenged for 16 
hours with 5x10
4
 CFU/ml of E. coli NCTC 10418, LPS [10 μg/ml], peptidoglycan [10 μg/ml], 
flagellin [250 ng/ml], Zymosan [50 μg/ml] or the combination of flagellin and Zymosan N=6, 2 
experiments with 3 replicates. *p<0.05, **p<0.01; ***p<0.001. 
The cytotoxic effects of 17β-oestradiol seen in the RT4 cells were not observed in the 
VK-2 E6/E7 after 16 hours of transfection. Moreover, 17β-oestradiol treatment induced 
a 5.7±1.7 fold increase (p<0.05) in reporter activity compared to the untreated cells 
(1.0±0.1). Furthermore, flagellin challenged VK-2 E6/E7 cells pre-treated with 
oestrogen induced a significantly higher reporter response (68.1±8.4 vs. 199.5±37.7, 
p<0.01). Similarly, the response to NCTC 10418 was also doubled when VK-2 E6/E7 
were pre-treated with oestrogen (19.9 ±3.8 fold vs. 40.2±6.6 for oestrogen treated, 
 127 
 
p<0.05). The hβD-2 response to a Zymosan challenge was also significantly higher 
when cells were treated with oestrogen (93.3±5.0 vs. 27.2±2.9, p<0.001). Interestingly, 
no statistically significant difference was observed when a combination of flagellin and 
Zymosan was used (186.7±39.8 vs. 210.9±40.2 for oestrogen treated). Also, no 
difference was observed in relation to either the LPS or peptidoglycan challenges. These 
data supported oestrogen potentiating the hβD-2 response to motile bacteria, flagellin 
and Zymosan but not to LPS or peptidoglycan. 
4. RESVERATROL HAS AN AMBIVALENT EFFECT ON THE PHΒD-
2-LUC ACTIVITY 
Resveratrol, an oestrogen mimic, has been described as having immunomodulatory 
effects
165
. To explore the effects of resveratrol, VK-2 E6/E7 cells were cultured in 
100µM resveratrol (concentration chosen after personal communication with Dr Claire 
Townes Newcastle University) and challenged as described previously. The results are 
shown in Figure 4.20: 
VK-2 E6/E7 treated with resveratrol
U
nc
ha
lle
ng
ed
N
C
TC
 1
04
18
LP
S
P
ep
tid
og
ly
ca
n
Fl
ag
el
lin
Zy
m
os
an
Fl
ag
el
lin
+Z
ym
os
an
0
50
100
150
200
250
Untreated
Resveratrol
***
**
*
F
o
ld
 i
n
c
re
a
s
e
 
Figure 4.20 hβD-2 response in VK-2 E6/E7 to E. coli NCTC 10418 and PAMPs after 
resveratrol treatment. VK-2 E6/E7 were grown in 100 μM resveratrol and transfected with 
phβD-2-Luc, before being challenged for 16 hours with 5x104 CFU/ml of E. coli NCTC 10418, 
LPS [10 μg/ml], peptidoglycan [10 μg/ml], flagellin [250 ng/ml], Zymosan [50 μg/ml] or the 
combination of flagellin and Zymosan. N=6, 2 experiments with 3 replicates.*p<0.05, 
**p<0.01; ***p<0.001.  
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As observed with 17β-estradiol, resveratrol induced an hβD-2 response in the 
unchallenged VK-2 E6/E7 cells (5.7±0.7 fold vs 1.0±0.1 fold, p<0.001). Again and 
similar to the 17β-oestradiol data, resveratrol did not significantly affect the responses 
to peptidoglycan or LPS. Additionally, no effects were observed when VK-2 E6/E7 
cells treated with resveratrol were challenged with Zymosan or with NCTC 10418. 
However, in contrast to the 17β-oestradiol data, reduced reporter activity was observed 
in the VK-2 E6/E7 cells treated with resveratrol and challenged with flagellin (68.1±8.5 
for untreated cells vs. 40.7±8.9 for resveratrol treated cells, p<0.05) or flagellin in 
combination with Zymosan (186.7±39.8 for untreated cells vs. 62.7±14.4 for resveratrol 
treated cells, p<0.01).  
4.10. COMPARISON OF THE PHΒD-2-LUC REPORTER 
ACTIVITY WITH THE HΒD-2 PROTEIN SECRETION USING 
AN ELISA 
The findings using the hβD-2 reporter showed that it was possible to enhance the hβD-2 
response by treating VK-2 E6/E7 cells with calcitriol and oestrogen. In contrast, the 
data suggested that the oestrogen mimic resveratrol reduced the induction of the hβD-2 
reporter. Hence, these findings needed confirmation via hβD-2 peptide measurements. 
Such analyses were performed by Dr Claire Townes, ICaMB, Newcastle University; the 
concentrations of hβD-2 in the media of the VK-2 E6/E7 cells treated with calcitriol, 
17β-oestradiol and resveratrol plus/minus challenge with flagellin and Zymosan were 
measured by ELISA (Leinco #B428). The results of the hβD-2 peptide concentrations 
are shown in Figure 4.21: 
  
  A  B 
 C  D 
Figure 4.21 Enhancement of hβD-2 peptide secretion in VK-2 E6/E7. VK-2 E6/E7 cells were treated with flagellin [250 ng/ml]. Additionally, VK-2 E6/E7 
cells were treated with Zymosan [50 μg/ml], calcitriol [10nM], oestrogen (17β-oestradiol) [4 nM] or resveratrol [100 μM]. The protein was collected at each 
time point and measured using a hβD-2 specific sandwich ELISA (Leinco #B428). The experiments were performed by Dr Claire Townes. N=6, 2 
experiments with 3 replicates 
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As expected challenging VK-2 E6/E7 cells with flagellin was linked with increased 
concentrations of the hβD-2 peptide. Moreover, challenging with flagellin and Zymosan 
enhanced the hβD-2 peptide concentration further. However, in contrast to the findings 
of phβD-2-Luc reporter were the hβD-2 peptide concentrations observed when the VK-
2 E6/E7 cells were challenged with Zymosan. Essentially, the hβD-2 reporter activity 
following Zymosan treatment was reduced when compared to that of flagellin treatment 
(Section 4.9.I), but the peptide measurements did not reflect this (Fig. 4.21.A).  
Calcitriol and 17β-oestradiol treatments also showed a difference in hβD-2 peptide 
concentrations in comparison to the phβD-2-Luc reporter activities. The phβD-2-Luc 
reporter was activated by calcitriol, 17β-oestradiol and resveratrol treatments (Fig. 4.18, 
4.19 and 4.20). This induction, however, was not observed in the hβD-2 concentrations 
measured. However, the induction of the phβD-2-Luc reporter was low (4.4, 5.7 and 5.7 
fold), hence, it was feasible that hβD-2 synthesis was increased but the levels were 
below the sensitivity of the ELISA and thus not detectable. In support, increased peptide 
levels were detected when flagellin was added to the calcitriol, 17β-oestradiol treated 
VK-2 E6/E7 cells (Fig. 4.21.B and C), and reduced when challenged with flagellin in 
the presence of resveratrol (Fig. 4.21.D) reflecting the data obtained using the phβD-2-
Luc reporter.  
In conclusion, the phβD-2-Luc reporter findings were in general supported by the hβD-2 
peptide measurements.  
4.11. DISCUSSION 
The data presented in Chapter 3 showed NF-kB activation in RT cells in response to 
bacterial and flagellin challenges. NF-kB activation is linked to IL-8 and hβD-2 
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synthesis, the latter of which is a potent bacterial killing agent. The data also showed 
that when the NF-kB response was reduced, through TLR-5 blocking, the host innate 
response was diminished. In parallel colleagues have shown that this truncated host 
response involves reduced synthesis of anti-bacterial factors including hβD-2. Human 
βD-2 has been shown to kill gram negative bacteria including E. coli166 thus the 
regulation of the hβD-2 gene in the urogenital tract is of immunological and therapeutic 
interest. This Chapter through the construction and use of a hβD-2 reporter and in vitro 
systems modelling the urogenital tissues focussed therefore on exploring the regulation 
of the hβD-2 (DEFB4) gene.  
Two kbp of UTR sequence 5’ to the start of the hβD-2 gene was cloned and analysed. 
This fragment size was chosen following bioinformatic analyses using PROMO 
software, which revealed a number of TF binding sites including those for NF-κB, AP-
1, VDR, RAR and ER alpha (Fig. 4.1). Two NF-κB binding sites were identified at 
positions 345 and 546. NF-κB binding sites have been identified by other groups but in 
contrast to our findings, were located at positions 199-208
167,168
 and at positions 564, 
175, 165
169
.  
Nonetheless, the positions found by the groups Vora et al. (2004) and Wada et al. 
(2001) have to be viewed critically, since the database used to map the positions was 
AF071216 (last release 2000)
168,170
, while the current database (used in this 
investigation) was GRCh37.p10 ( last version 31.08.2012). Interestingly, performing a 
BLAST analysis of the primers used in the construction of their reporter (Fw- 5’-
GGCTCGAGGGCTCGGACATCAGCACCAAA-3’ and Rv- 5’-
AAAAGCTTAGGAGCTGAGTCTGGGGAGGA-3’)168, using the current genome 
reference data base (GRCh37.p10), showed a product of 2088 bp rather than 2111 bp 
and located 24 bp away from the start codon, indicating the differences in the genome 
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databases. Wang et al. (2003) did not state the database, or the primers used to engineer 
their wild type hβD-2 promoter reporter169. Hence, an assessment of their NF-κB 
binding sites was not possible. 
A further discrepancy related to the VDR binding sites. Two were identified in this 
bioinformatics analyses, one adjacent to the DEFB 4 gene (19 bp 5’ to the start codon) 
and one at position 656 bp, which conflicted with the one VDR binding site reported by 
Wang et al., (2004) at position 1231 bp
171
. Wang et al., do not state which database was 
used. Using BLAST alignment of the primers used to construct the promoter reporter 
with the current database (GRCh37.p10) showed a product of 1287 bp, located at 14 bp 
before the DEFB4 gene. Wang et al. (2004), however, state that their promoter reporter 
construct starts 23 bp before the start codon and is 1266 or 1225 bp long
171
, indicating 
differences between the current database version and the one used in their investigation. 
Therefore, a direct comparison of the binding position is not possible. 
The initial hβD-2 reporter construct was engineered using pGlow TOPO, which 
contains a GFP reporter. The advantage of the GFP system was that it allowed reporter, 
i.e. GFP measurements to be done without killing the cells, thus increasing the number 
of time-points analysed. This was in comparison to the luciferase system that required 
cell death to measure reporter activity, and restricted the number of time-points. 
However, while the GFP system worked reasonably successfully as visualised via 
microscopy, quantitation of the data was not possible due to a combination of cell 
autofluorescence and the limited sensitivity of plate reader. Thus for the hβD-2 reporter 
experiments the pGL4.10 luciferase system was adopted.  
Previous work had shown that RT4 cells challenged with flagellin resulted in the 
upregulation of hβD-2 expression158. Experiments in which RT4 cells were transfected 
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with the phβD-2-Luc reporter and similarly challenged mirrored these findings (Fig. 
4.11) and the reporter system was therefore adopted as a valid tool to investigate hβD-2 
induction. With this knowledge it was clear that the reporter data also supported another 
finding, namely that LPS did not cause a hβD-2 response in RT4 cells, again 
highlighting the importance of flagella in initiating the host uroepithelial innate 
response.  
Bioinformatics indicated VDR and ER binding sites located in the hβD-2 5’UTR, which 
suggested potential roles for the steroids Vitamin D, namely 1,25 (OH)2 
dihydroxycholecalciferol, also called calcitriol, and oestrogen in hβD-2 gene regulation. 
Surprisingly, investigation of a hβD-2 induction in RT4 using oestrogen (17β-
oestradiol) and resveratrol an oestrogen mimic was not possible. In fact, transfection of 
the 17β-oestradiol treated cells with TurboFect resulted consistently in cell death 
suggesting the transfection reagent, under the conditions studied, was cytotoxic. As no 
product information was available to confirm this observation or help address the 
problem, no further experiments were attempted. In hindsight a potential solution to this 
issue was to remove the 17β-oestradiol during the actual transfection procedure but to 
supplement the transfection media with 17β-oestradiol during the challenges. In contrast 
to RT4, challenging VK-2 E6/E7 cells with oestrogen was possible and resulted in a 
higher hβD-2 response to flagellin and to Zymosan but not to the combination of 
flagellin and Zymosan. It appears that the response to a combination of flagellin and 
Zymosan is the maximal response, unable of any further increase.  
Resveratrol also caused problems in that it actually killed RT4 cell growth. RT4 cells 
died within hours after addition of resveratrol (1 to 50 µM) and even lowering the 
concentration to 1 μM still caused cell death. These observations were in contrast to 
reports in the literature, particularly one study, which reported that incubating bladder 
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cells in low doses of resveratrol (0.1 to 20 µM) protected against oxidative stress, 
although the cells used in cited study were ECV 304 and not RT4
172
. An explanation for 
the observed cell death of RT4 cells may relate to the anti-carcinogenic activity of 
resveratrol. In fact numerous cell lines, such as breast (MCF-7) and ovarian (A2780) 
cancer cell lines, as well as the bladder tumour cell line T24, interestingly from which 
ECV 304 cells were derived, have been shown to be killed by resveratrol
173-175
. 
Cytotoxic effects in T24 cells were reported at 50 μM and higher concentrations as early 
as 24 hours post treatment
173
. A future possibility is to repeat the experiments but using 
polydatin, a natural precursor of resveratrol, as it has been described as a hβD-2 inducer 
in keratinocytes
176
. 
On the other hand, in VK-2 E6/E7 cells resveratrol induced a trend towards lowering 
the hβD-2 response, which can be explained by its ability to inhibit NF-kB 
activation
173,177. Interestingly, although lowering the hβD-2 response, resveratrol by 
itself induced hβD-2. It could hence, be used as a preventive agent. However, Zymosan 
and oestrogen induced a higher response when challenged with flagellin, which was the 
aim of this investigation.  
The induction of hβD-2 by Zymosan reported in this thesis was novel and to the best of 
knowledge has not been shown before in the uroepithelium or indeed in epithelia. To 
date, the only literature suggesting Zymosan as a NF-kB activator in vaginal epithelium 
was that of Pivarcsi et al. (2005)
178
. The authors, using PK2 E6/E7 vaginal cells derived 
from a post-menopausal subject and a Zymosan concentration of 10 μg/ml, reported 
Zymosan to induce IL-8 but interestingly not hβD-2. In view of the data reported in this 
thesis the lack of hβD-2 detection was surprising but may relate to the concentration of 
Zymosan used by Pivarcsi et al. (2005), which was five times less than that used in this 
study, i.e. 50 μg/ml.  
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Importantly, however, in this study the hβD-2 response to flagellin was significantly 
enhanced in bladder and vaginal cells (2.5 and 2.8 fold) in the presence of Zymosan, 
and the in vitro reporter data demonstrate a potential therapeutic role for Zymosan in 
controlling UTIs. In fact these data suggest that Zymosan can function as a potential 
protective agent in the urogenital tract and the therapeutic potential of Zymosan will be 
investigated further in Chapter 6. 
Vitamin D (25-vitamin D3 and calcitriol) treatment has been shown in vitro to induce 
the expression of the cathelicidin gene hCAP-18 in the UT
179
. Identification of putative 
VDR elements in 5’UTR of hβD-2 gene endorsed the experiments investigating the 
effects of the active metabolite of Vitamin D, i.e. calcitriol (1,25 
dihydroxycholecalciferol) on hβD-2 gene regulation. The RT4 data was surprising. 
Vitamin D treatment enhanced hβD-2 expression in unchallenged cells but the presence 
of either flagellin, Zymosan, or flagellin plus Zymosan appeared to inhibit gene 
expression. The absence of peptide data however, makes it difficult to comment further 
and these experiments need to be repeated with ELISAs performed concurrently. In 
contrast, the hβD-2 gene expression data relating to the VK-2 E6/E7 cells treated with 
vitamin D was supported by peptide data and indicated a role for vitamin D in 
enhancing the hβD-2 response. The literature also supports this, with hβD-2 expression 
upregulated in keratinocytes treated with calcitriol
171
. They showed that the induction of 
hβD-2 by IL-1 was significantly upregulated when primary keratinocytes and cell lines 
were treated with calcitriol
171
. Vitamin D is therefore a good therapeutic candidate as it 
can be administered topically or supplemented nutritionally. 
The data mining revealed multiple binding sites for all transcription factors. The 
contribution of each TF binding site could be analysed by introducing mutation in those 
positions by site directed mutagenesis. The mutation would also clarify if the 
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differences noticed between the here reported binding sites and the ones published in 
the literature are indeed due to the changes in the sequenced Genome data bases. 
Overall these data suggest that Zymosan, Vitamin D as well as Oestrogen can enhance 
hβD-2 gene expression and synthesis in VK-2 E6/E7 cells and therefore can be 
considered as potential targets in future therapeutic strategies.  
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Investigating Human β-Defensin 3 
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5.1. INTRODUCTION 
The Defensin hβD-2 is induced in the urogenital tract of the host in response to and to 
help fight infection. Human βD-2 is however, a salt sensitive antimicrobial peptide, 
which has a reduced antimicrobial activity in physiological salt concentrations, hence its 
killing activities are probably limited to the epithelial layer
5
. Another member of the 
Defensin family, hβD-3, which is known to possess potent microbial killing properties, 
including against E. coli, is not salt sensitive, thus enabling bacterial killing in elevated 
salt environments such as that of urine
180. The antimicrobial activity of hβD-3 could 
also be complementary to the hβD-2 activity, as hβD-3 has also a potent antimicrobial 
activity against gram positive bacteria
180
. Hence, this chapter aimed to investigate hβD-
3 expression in the urogenital tract in vitro by using the cell lines RT4 and VK-2 E6/E7.  
5.2. DETECTION OF HΒD-3 EXPRESSION IN THE 
UROGENITAL TRACT 
First, the expression of hβD-3 was analysed in VK-2 E6/E7 and RT4 cells, as well as in 
three bladder biopsies, using endpoint RT-PCR. The expected size of the hβD-3 PCR 
product was 224 bp and the results are shown in Figure 5.1: 
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1        2               3 
A 
 
    B C 
Figure 5.1 Detection of hβD-3 expression in VK-2 E6/E7 vagina and RT4 bladder 
epithelium. (A) Binding sites of the end-point and quantitative primers in the DEFB103 gene. 
(B-C) Product of the PCR amplification using the end-point primers. The cDNA of VK-2 
E6/E7, RT4 and bladder biopsies were amplified using 30 cycles. The expected size of the PCR 
product is 224 bp. (B) Left hand side (LHS) Lane 1 shows Hyperladder IV, lane 2 the 
amplification product using VK-2 E6/E7 cDNA and right hand side (RHS) using cDNA of RT4. 
(C) Lane 1 shows Hyperladder IV. Lane 2-4 show bands indicative for the amplification of 
hβD-3 in bladder biopsies. DNA was separated on a 2 % Agarose TBE gel. 
A cDNA band of approximately 220 bp (expected size was 224 bp) and shown in Fig. 
5.1.B (LHS panel), suggested that hβD-3 was constitutively expressed in VK-2 E6/E7 
cells. In contrast, no cDNA band was detected when RNA isolated from the RT4 cells 
was analysed suggesting that hβD-3 was not expressed constitutively in RT4 bladder 
cells (Fig. 5.1.B: RHS panel), although interestingly, hβD-3 was detected in the bladder 
biopsies of three different donors (Fig. 5.1.C). It is known that hβD-3 is upregulated in 
many tissues upon bacterial challenge
181,182. The expression of hβD-3 was therefore 
investigated after challenging the VK-2 E6/E7 and RT4 cell lines with bacteria and 
bacterial components. To facilitate this, a qPCR assay was developed to quantitate hβD-
3 expression.  
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5.3. DEVELOPMENT OF HΒD-3 ASSAYS 
1. QUANTITATIVE GENE EXPRESSION MEASUREMENTS USING A 
PCR ASSAY 
I. ENGINEERING A hβD-3 CALIBRATOR PLASMID  
A quantitative hβD-3 PCR assay, using SYBR green was developed. The efficiency and 
limit of detection of the reaction must be determined using a positive control
144
. To 
achieve this, the 220 bp DNA band encoding hβD-3, shown in Fig. 5.1.B, lane 2 was 
excised and inserted into a pGem-T easy vector, as described in Section 2.3. Successful 
cloning was confirmed by restriction digest, PCR and DNA sequencing. The results are 
shown in Figure 5.2: 
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 A    B  
 C  
 D  
Figure 5.2 Engineering a pGem-T-easy plasmid containing part of the hβD-3 gene. (A) 
pGem-T-easy after ligation with hβD-3 product from Fig. 5.1. Lane 1 shows isolated plasmid. 
Lane 2 shows the result of digesting the plasmid with Eco RV, a cutting site found only in the 
hβD-3 gene. Lane 3 is the marker (Hyperladder IV). (B) Lane 1 shows the marker 
(Hyperladder I). Lane 2 Amplification using hβD-3 endpoint primer and the isolated plasmid 
to confirm the presence of the insert. (C) Sequencing result was used to perform a BLAST 
search. (D) Result of the blast search. 
The engineered hβD-3 plasmid was successfully isolated and verified by linearisation 
with Eco RV (Fig. 5.2A lane 2), which provided a unique cutting site in the sequence of 
the hβD-3 insert and resulted in a band of approximately 3.2 kbp (predicted 3239 bp). 
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The plasmid was used as a template for PCR using the hβD-3 endpoint primers and 
resulted in a band of approximately 220 bp (expected size 224 bp, Fig. 5.2.B, lane 2, 
orange arrow). The hβD-3 plasmid insert was sequenced by GeneVision (Newcastle, 
UK) with the results of the BLAST search (Fig. 5.2.C) confirming its authenticity (Fig. 
5.2.D.). This plasmid was utilised in the development of the hβD-3 qPCR assay. 
II. ESTABLISHING A WORKING STANDARD CURVE 
The optimal efficiency of a PCR reaction is 2, meaning that the amount of the amplicon 
is doubled at each reaction cycle. Since many factors can impact on the efficiency, 
including primer binding, ion concentration and the actual PCR instrument itself, the 
efficiency of the reaction had to be established. Reaction efficiency was calculated 
using the threshold value (Cq) obtained from a dilution series of the hβD-3-pGemT easy 
plasmid. A standard was therefore created by diluting the calibrator plasmid 10
-3
 to 10
-12 
times. The qPCR amplification was carried out using a Lightcycler 480 (see section 
2.5.VII), and the standard curve data is shown in Figure 5.3: 
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 A 
 B 
 C 
Figure 5.3 First trial for a standard curve determination. (A) Standard curve formation 
using the Cq-value and concentration of hβD-3 template. The slope of -3.67 and the Y-intercept 
of 31.15 were used to determine the efficiency. (B) Amplification curves of hβD-3-pGemT-
easy. (C) Analysis of the disassociation curve of the qPCR assay with two peaks (at 81.5 °C and 
85.5 °C).  
 
The resulting Cq values, calculated by the LightCycler 480 software (Roche Applied 
Science, UK) and the concentration of the hβD-3 template were plotted in a XY-
diagram (Fig. 5.3.A). The Cq values could only be defined over a magnitude of 10
4
. The 
y-intercept and slope, and the correlation coefficient R
2
 of the standard curve were 
calculated using Excel (Microsoft Office 2010, Fig. 3.5.A, red rectangle). The PCR 
efficiency was calculated using the formula proposed by the MIQE-committee
144
: 
y = -3.6656x + 31.154 
R² = 0.9945 
0
5
10
15
20
25
30
35
0 0.5 1 1.5 2 2.5 3 3.5 4
C
q
- 
V
al
u
es
 
Concentration/ Log10 
 144 
 
                
 
 
             
The standard curve shows a slope of -3.6656, hence the efficiency is: 
               
 
                      
 
The calculated efficiency was 87.4 %. For the assay to be valid the PCR efficiency must 
lie between 95 and 105 %, and have a correlation coefficient between 0.9 and 1.0
183
. In 
view of these requirements the data generated was a concern; the results meant that, 
with each amplification cycle, a 12.6 % error chance was introduced into the 
quantitation of the gene expression.  
Furthermore, the analysis of the amplification curve showed a positive result even for 
the negative control (Figure 5.3.B) at Cq of 28 cycles, indicating contamination with the 
plasmid. Finally, the disassociation curve showed more than one peak suggesting the 
presence of two amplification products. To verify if the plasmid was contaminated with 
foreign DNA, the engineering of the hβD-3-reporter plasmid was repeated (data not 
shown). The results were reproducible, strongly suggesting that the primers themselves 
were inadequate since they were creating two products.  
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Primer sequences used in the second qPCR assay were obtained from the literature
184
. 
Their binding sites are shown in Fig. 5.1.A (qPCR primer Kalus et al.) and are located 
within the sequence of the amplification product used to engineer the hβD-3 reporter 
plasmid. Hence, the previous hβD-3 template was serially diluted five-fold, amplified 
using the new qPCR primers and the results are shown in Figure 5.4:  
 A 
 B 
 C 
Figure 5.4 Second trial for a standard curve determination. (A) Standard curve using Cq 
value and arbitrary concentration of hβD-3-template. (B) Analysis of amplification curve. Red 
lines are the hβD-3 templates at different concentration. Green line represents the negative 
control. (C) Disassociation curve of PCR products. Arrow indicates the peak. Light blue line 
represents the negative control. 
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The standard curve was plotted in a XY diagram using the Cq-values, calculated by the 
LightCycler 480 software, on the y-axis and the arbitrary concentration of the hβD-3 
template on the x-axis (Fig. 5.4.A). The PCR efficiency was again calculated using the 
formula proposed by the MIQE-committee: 
                
 
 
             
The trendline shows a slope of -3.3734, therefore the efficiency is: 
               
 
                      
 
For this hβD-3 assay, the calculated efficiency of 97.9 % and the correlation coefficient 
of 0.996 were acceptable. The theoretical detection limit of the qPCR assay was 
extrapolated to 36.9 cycles. Nonetheless, Cq-values beyond 35 cycles were considered 
to be replication of random products (personal communication Dr Alison Howard, 
Newcastle University) and considered as such in subsequent analyses.   
Amplification and disassociation curve analysis were performed. The amplification 
curve showed no increase in fluorescence for the negative control (Fig. 5.4.B, green 
line) and the disassociation curve identified only one amplified product (Fig.5.4.C). All 
amplicons showed the same peak, Tm at ~81 °C (red arrow on dark blue curve, Figure 
5.4.C). The negative control did not show a peak (light blue line, Figure 5.4.C). The 
assay was considered successful and adopted for use. 
To support the molecular analyses and data an ELISA to measure hβD-3 peptide 
concentration was also developed.  
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2. DEVELOPMENT OF A HΒD-3 ELISA 
Two ELISA methods were explored: the first was a simple indirect ELISA and the 
second was a sandwich ELISA.  
I. INDIRECT ELISA SPECIFIC FOR HΒD-3  
To measure the concentration of hβD-3 peptide an indirect ELISA, the simplest form of 
ELISA, was developed. Three different concentrations of hβD-3 specific antibody, 
ranging from 0.5 to 2 μg/ml, were used and a standard curve was constructed using 
synthetic hβD-3 ranging from 10 to 500 ng/ml. The results are shown in Figure 5.5 and 
Table 5.1: 
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Fig. 5.5 Determination of a hβD-3 peptide standard curve using indirect ELISA. Synthetic 
hβD-3 was incubated over night at 4ºC and the concentration measured using monoclonal hβD-
3 antibody (N=2). 
Table 5.1 Linear regression analysis of the standard curve determined by indirect ELISA 
Concentration 
of antibody 
Slope Y-Intercept R² 
0.5 mg/ml 0.0001470 ± 0.00003190 0.1240 ± 0.006192 0.6026 
1 mg/ml 0.0004006 ± 0.00004076 0.1449 ± 0.007910 0.8734 
2 mg/ml 0.001241 ± 0.0001019 0.2739 ± 0.01978 0.9136 
The linear regression analysis showed that a standard curve with a R
2
>0.9 only occurred 
when a concentration of 2 μg/ml primary antibody was used. However, at this 
concentration they intercept the Y-axis at an absorbance of 0.27±0.01 indicated a high 
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background (Tab. 5.1, Y-Intercept). Therefore, the indirect ELISA was considered 
inadequate to measure the concentration of hβD-3 peptide and development switched to 
a more complex sandwich ELISA. 
II. DEVELOPMENT OF A SANDWICH ELISA SPECIFIC FOR HΒD-3 
Through the use of two antibodies rather than one a sandwich ELISA has superior 
sensitivity and a higher specificity. The first antibody, used in the previous assay as 
detection antibody, was immobilised in a 96 wells plate and captures the hβD-3 from 
solution while a new second antibody is used for detection of the captured hβD-3.  
The antibodies used in the sandwich assay were first optimised using synthetic hβD-3. 
The sensitivity of the hβD-3 sandwich ELISA was much higher than that of the indirect 
ELISA. In fact, trying to determine a standard curve using the same concentration of 
synthetic hβD-3 as in the indirect ELISA (500 ng/ml- 31.25 ng/ml) caused an 
absorbance value at 450 nm beyond 4.0 (data not shown), making a concentration 
depending absorbance reading impossible. Therefore, the concentration of the synthetic 
hβD-3 was reduced to 1000 pg/ml and serially diluted to 31.25 pg/ml. The results of the 
hβD-3 sandwich ELISA optimisation using the lower concentration of hβD-3 are shown 
in Figure 5.6 and Table 5.2: 
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Figure 5.6 Determination of a hβD-3 specific standard curve using a sandwich 
ELISA. The capture antibody was used at 0.25 μg/ml (A and B) or at 0.5 μg/ml (C and 
D). The secondary detection antibody was used at a concentration of 1 μg/ml (A and C) 
or at 2 μg/ml (B and D). The concentration of synthetic hβD-3 varied between 31.25 
and 1000 pg/ml. Absorbance was measured at 450 nm and corrected at 570 nm. 
 
Table 5.2 Linear regression analysis of the standard curve resulted by a sandwich ELISA 
 
Concentration of the antibodies Slope Y-intercept R² 
0.25 μg/ml pAb & 1 μg/ml sAb 0.002389 ± 0.00005008 0.06479 ± 0.02487 0.9904 
0.25 μg/ml pAb & 2 μg/ml sAb 0.003855 ± 0.0001523 0.01980 ± 0.07561 0.9668 
0.5 μg/ml pAb & 1 μg/ml sAb 0.002422 ± 0.0001584 0.03015 ± 0.07864 0.914 
0.5 μg/ml pAb & 1 μg/ml sAb 0.003802 ± 0.0001373 0.07545 ± 0.06821 0.9721 
 
Linear regression analyses showed that all combinations of primary and secondary 
antibodies resulted in a coefficient of determination R
2
>0.9 (Table 5.2), indicating a 
linear correlation between the absorbance measured and the concentration of hβD-3. 
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The highest coefficient of determination R
2
, was measured for the lowest concentration 
of primary and secondary antibody (0.25 μg/ml and 1 μg/ml, respectively; Table 5.2, 
R
2
=0.9904). Additionally, the Y-intercept, which determines the unspecific binding of 
the antibodies was 0.07± 0.03, indicating very low levels of unspecific bindings. Hence, 
these antibody concentrations were adopted as the working concentrations. The 
sandwich ELISA assay was considered optimised to measure the secretion of hβD-3. 
With the qPCR and ELISA assays established the hβD-3 responses of the epithelial cells 
modelling the urogenital tract, to bacterial challenge, were investigated.  
5.4. RT4 HΒD-3 RESPONSE TO E. COLI  CHALLENGE  
The E. coli strains NCTC 10418 (motile) and NU14 (non-motile) were used to 
challenge RT4 cells. Both strains were heat killed and RT4 cells were challenged up to 
24 hours with 10
5
 CFU/ml bacteria. The results are shown in Figure 5.7: 
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Figure 5.7 Expression of hβD-3 in RT4 challenged with E. coli strains. (A) The expression of 
hβD-3 was quantified in RNA isolated from RT4 cells challenged with 105 CFU/ml for up to 24 
hours. The Y-axis represents the Cq-value calculated by the Lightcycler 480 Software. (B) Cq-
value of the reference gene GAPDH. Bars represent the mean with their standard error as error 
bars. N=6, 2 experiments with 3 replicates  
Results of the quantitative PCR (the limit of detection is marked by the red line) 
indicated that very low or no expression was detected in RT4 cells at 0 hours (Cq 34±0.2 
for PBS, Cq 35±0.5 for NCTC 10418, Cq 35±0.2 for NU14, Fig. 5.7.A), and these data 
concurred with end-point PCR results shown in Fig. 5.1.B. Following challenge with E. 
coli strains NCTC 10418 and NU14 no upregulation of hβD-3 expression at either 8 (Cq 
35±0.2 for PBS, Cq 35±0.4 for NCTC 10418, Cq 35±0.5 for NU14, Fig. 5.7.A), 16 (Cq 
34±0.5 for PBS, Cq 35±0.2 for NCTC 10418, Cq 35±0.3 for NU14, Fig. 5.7.A) or 24 
hours (Cq 36±0.7 for PBS, Cq 35±0.5for NCTC 10418, Cq 35±0.3 for NU14, Fig. 5.7.A) 
was detected. The presence of RNA was verified using GAPDH as the reference gene 
and GAPDH was expressed at the expected levels (personal communication Dr Alison 
Howard, Newcastle University), with a Cq-value of ≤ 18 cycles (Fig. 5.7.B), confirming 
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that the mRNA was successfully reverse transcribed. Overall these data indicated that 
the hβD-3 gene was not expressed in RT4 cells either constitutively or following 
bacterial challenge.  
Next, the PAMP associated with the highest immune response, i.e. flagellin, was used to 
investigate if hβD-3 gene expression was induced when a high concentration of a 
purified bacterial compound was used. RT4 cells were challenged with 250 ng/ml of 
flagellin for up to 24 hours and the results of hβD-3 expression are shown in Figure 5.8: 
  
 153 
 
RT4 challenged with Flagellin- hD-3
0 8 16 24
0
5
10
15
20
25
30
35
40
Negative control (PBS)
Flagellin [250 ng/ml]
Hours
C
q
A  
RT4 challenged with Flagellin- GAPDH
0 8 16 24
0
5
10
15
20
25
Flagellin [250 ng/ml]
Negative Control (PBS)
Hours
C
q
  B 
Figure 5.8. Expression of hβD-3 in RT4 cells challenged with flagellin. RT4 cells were 
challenged with 250 ng/ml of flagellin isolated from E. coli. The RNA was reverse 
transcribed and the gene expression for (A) hβD-3 and (B) GAPDH was measured using 
qPCR. N=6, 2 experiments with 3 replicates. Red line shows the limit of detection according 
to MIQE. 
  
The results (Fig. 5.8.A & B) were comparable to previous. Essentially, no expression of 
hβD-3 was detected in the RT4 cells as all Cq-values were ≥ 35 cycles (Fig. 5.8.A). The 
mRNA reverse transcription was successful as demonstrated by Cq-values of the 
GAPDH reference gene (Cq ≥18 cycles, except 24 hours with Cq-value of 19±0.4 for 
PBS and 20±1.1 for flagellin, Fig. 5.8.B).  Therefore, it was concluded that RT4 does 
not express hβD-3 constitutively or following challenge with either E. coli or the 
bacterial component flagellin. 
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5.5. VK-2 E6/E7 HΒD-3 RESPONSE TO E. COLI  
CHALLENGE  
As mentioned in the introduction and in section 4.9, the vaginal epithelium plays a 
major role in regulating the colonisation of UPEC by inducing hβD-2 activation and 
secretion. The expression of hβD-3 was therefore analysed in VK-2 E6/E7 cells to 
explore potential roles for hβD-3 in the vaginal innate defences. VK-2 E6/E7 cells were 
challenged for up to 24 hours using 5x10
4
 CFU/ml of bacteria. Human βD-3 gene 
expression and peptide synthesis were quantitated as previously described (sections 
5.3.1 and 5.3.2.II). The results of the hβD-3 expression were normalised using GAPDH 
expression and are shown in Figure 5.9:  
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Figure 5.9: Quantification of hβD-3 expression in VK-2 E6/E7 challenged with E. coli 
strains using qPCR. VK-2 E6/E7 challenged with PBS and 5*10
4 
CFU/ml of (A) Motile 
NCTC 10418 (N=9, 3 experiments with 3 replicates), limit of the Y-axis is set to 6000. (B) 
Motile K-12 (N=6, 2 experiments with 3 replicates), limit of the Y-axis is set to 100. (C) Motile 
CFT 073 (N= 6, 2 experiments with 3 replicates), limit of the Y-axis is set to 2000. (D) Non-
motile NU14, limit of the Y-axis is set to 150. (N=6, 2 experiments with 3 replicates). Y-Axis 
represent the fold increase of hβD-3 expression normalised using GAPDH shown in arbitrary 
units (A.U.) and using the Pfaffl method
185
. Statistical significance was investigated using 
ANOVA and a Bonferroni post hoc test. **=p <0.01, ***=p< 0.001. 
In these experiments the E. coli strains, K-12 and CFT 073, in addition to NCTC 10418 
and NU-14 were used. They were added because K-12 is a standard laboratory E. coli 
strain with moderate motility and CFT 073 is a motile UPEC. The results are shown as 
fold increase compared to the 0 hour time point using the Pfaffl method
185
. As shown in 
Figure 5.9.A, the NCTC 10418 challenge of VK-2 E6/E7 resulted in a significantly 
higher expression of hβD-3 when compared to the negative control (PBS), and the 
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increase was detected from the first time-point, i.e. eight hours post challenge 
(518.5±139.2 for NCTC 10418 challenged cells vs. 70.5±13.4, p<0.001). 
The expression of hβD-3 increased with time and the highest value was measured at the 
final time point, i.e. 24 hours (4275.6±969.3 for NCTC 10418 and 26.8±6.2 for PBS). 
In contrast, K-12 showed significant upregulation of hβD-3 only at 16 hours of 
challenge (Fig. 5.9.B; p<0.01). Furthermore, hβD-3 induction in VK-2 E6/E7 cells by 
K-12 was reduced by 32 fold when compared to NCTC 10418 (73.5±19.7, Fig. 5.9.B vs 
2379.3±606.1, Fig. 5.9.A). Note that the scale of the Y-axis in Fig. 5.9.A is 2000 while 
in Fig. 5.9.B is only 100 for presentation purposes. 
The motile UPEC CFT 073 did not affect hβD-3 expression for the first 16 hours of 
challenge (Fig. 5.9.C), but at 24 hours, the expression of hβD-3 was significantly 
increased (1496.0±196.5 for CFT 073 vs. 28.7±6.2 for PBS; p<0.001). Nonetheless, the 
hβD-3 response induced by CFT 073 (Fig. 5.9.C) at 24 hours was 2.7 fold lower than 
the response seen for NCTC 10418 (Fig. 5.9.A).  
The non-motile UPEC NU14 did not induce hβD-3 expression at any time point 
measured (Fig. 5.9.D).  
From these results it can be concluded that the two strains with a higher motility, NCTC 
10418 and CFT 073, induced the strongest hβD-3 expression at 24 hours. The strain 
with the lowest motility, K-12, also induced the lowest expression of hβD-3 and the 
non-motile strain failed to induce a hβD-3 response.  
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In order to validate these findings, hβD-3 peptide concentrations were measured in the 
media bathing the VK-2 E6/E7 cells challenged with the four E. coli strains, using the 
sandwich ELISA. The results are shown in Figure 5.10: 
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Figure 5.10 hβD-3 secretion of VK-2 E6/E7 upon challenge with E. coli strains. VK-2 
E6/E7 was challenged with 5*10
4
 CFU/ml with (A) NCTC 10418, (B) K-12, (C) CFT 073 and 
(D) NU14. N=2, using media pooled of 3 replicates. Human βD-3 concentration was measured 
using the developed sandwich ELISA. Statistical significance was investigated using ANOVA 
with a Bonferroni post hoc test. *=p<0.05, **=p <0.01, ***=p< 0.001. 
Supporting the molecular data, the NCTC 10418 challenge was associated with a 
significantly higher hβD-3 concentration in the media bathing the VK-2 E6/E7 cells 
after 24 hours of challenge than that of the PBS challenged cells (Fig. 5.10.A, 
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1456.9±209.7 pg/ml for NCTC 10418, 657.9±49.7 pg/ml for PBS). The challenge with 
K-12 also suggested induction of hβD-3 synthesis, however, statistical significance 
could only be determined at 8 hours due to the large variations within the individual 
measurements (Fig. 5.10.B, 1141.0±227.8 pg/ml at 16 hours and 1000.6±248.1 pg/ml at 
24 hours, p<0.05). The ELISA data suggested that challenge with the motile UPEC CFT 
073 inhibited hβD-3 secretion up to 8 hours (Fig. 5.10.C, p<0.05), but as with the 
mRNA expression, the hβD-3 concentrations were significantly increased at 24 hours 
(Fig. 5.10.C, 1119.2±77.8 pg/ml for CFT 073 vs. 657.9±50.0 pg/ml for PBS, p<0.001). 
NU14 challenged VK-2 E6/E7 cells showed no significant difference in hβD-3 
concentrations at 8 hours (559.0±15.4 pg/ml for NU14 vs. 717.5±106.6 pg/ml for PBS). 
This was comparable to the 8 hour CFT 073 effects (Fig. 5.10.C, 474.8±31.3 pg/ml for 
CFT 073 at 8 hours). However, contradicting the mRNA data, the NU14 challenge was 
associated with significantly elevated hβD-3 concentrations at 16 hours (Fig. 5.10.D, 
1150.8±187.7 pg/ml for NU14 vs. 661.68±79.5 pg/ml for PBS, p<0.01).  
Apart from one time point of the NU14 challenge, all peptide findings mirrored the gene 
expression data. Interestingly, the highest hβD-3 expression and peptide concentrations 
were associated with the two highly motile strains NCTC 10418 and CFT 073 at 24 
hours post challenge. Moreover, both UPEC strains, CFT 073 and NU14, showed a 
tendency to reduce hβD-3 expression and synthesis for up to 8 hours of challenge. The 
measurements of hβD-3 secreted by VK-2 E6/E7 when challenged with K-12 did not 
result in consistent data and therefore, need to be evaluated with caution.  
Concluding, challenges with the motile strains caused a higher hβD-3 response and 
therefore, the role of flagellin was further investigated. Additionally, components of the 
bacterial cell wall including LPS and peptidoglycan, which may have contaminated the 
flagellin preparation were also tested.  
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5.6. HΒD-3 REGULATION IN VK-2 E6/E7 CHALLENGED 
WITH COMPOUNDS OF THE BACTERIAL CELL WALL 
1. FLAGELLIN 
Flagellin isolated from E. coli (see section 3.5) was used to challenge the VK-2 E6/E7 
cells. The hβD-3 expression was measured using qPCR and the concentration of the 
peptide in the media bathing the cells was determined by ELISA. The results are shown 
in Figure 5.11: 
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Figure 5.11 hβD-3 response of VK-2 E6/E7 cells to flagellin. VK-2 E6/E7 cells were 
challenged with 250 ng/ml for up to 24 hours. (A) Quantitation of hβD-3 mRNA expression 
using qPCR. The expression was normalised against GAPDH. (N=9, 3 experiments with 3 
replicates). (B) Media of PBS or flagellin challenged VK-2 E6/E7 cells was collected and hβD-
3 secretion was measured using sandwich ELISA (N=6, 2 experiments with 3 replicates). 
Statistical significance was investigated using ANOVA and a Bonferroni post hoc test. **=p 
<0.01, ***=p< 0.001. 
Flagellin induced a hβD-3 response at the mRNA level as early as 8 hours after 
challenge (Fig. 5.11.A, 518.5±139.2 for flagellin vs. 70.5±13.4 for PBS, p<0.01). The 
response increased with time and the highest response was measured at the final time 
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point, i.e. 24 hours after challenge (4032.2±915.4 compared to PBS control of 28.8±6.2; 
p<0.001). This response was similar to that observed for NCTC 10418 (Fig. 5.9.A, 
4275.6±969.3). 
Human βD-3 peptide concentrations were also significantly increased at 24 hours after 
flagellin challenge (Fig. 5.11.B, 1712.9±112.6 pg/ml for flagellin vs. 657.9±49.73 pg/ml 
for PBS, p<0.001). Again, this value was comparable to the concentrations measured 
when VK-2 E6/E7 cells were challenged with the highly motile NCTC 10418 strain 
(Fig. 5.9.B. 1456.9±209.7 pg/ml).  
In conclusion, the highest induction of hβD-3 expression and secretion in the VK-2 
E6/E7 cells following bacterial challenge was observed using the motile E. coli strain 
NCTC 10418. Flagellin (250 ng/ml), the component responsible for bacterial motility, 
also induced comparable levels of hβD-3 expression and synthesis. 
2. LIPOPOLYSACCHARIDES (LPS) 
LPS was the first of the two bacterial cell wall components that were used to investigate 
hβD-3 gene regulation. To allow comparisons to previous experiments the VK-2 E6/E7 
cells were challenged with 10 μg/ml of LPS for up to 24 hours. RNA was collected for 
gene expression analyses and the cell bathing media was analysed for hβD-3 peptide 
concentrations. The results are shown in Figure 5.12: 
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Figure 5.12 hβD-3 response of VK-2 E6/E7 cells challenged with LPS. VK-2 E6/E7 cells 
were challenged using 10 μg/ml of LPS isolated from E. coli. (A) mRNA expression of hβD-3 
was measured using RT-qPCR. The expression was normalised against GAPDH. (B) media of 
PBS or LPS challenged VK-2 E6/E7 cells was collected and hβD-3 concentration was 
determined using sandwich ELISA (N=2). Statistical significance was investigated using 
ANOVA and a Bonferroni post hoc test. **=p <0.01, ***=p< 0.001. 
LPS in contrast to flagellin, did not induce hβD-3 significant mRNA up-regulation at 8 
hours after challenge (Fig. 5.12.A, 241.4±126.8 for LPS vs. 70.5±13.4 for PBS), 
although arguably there was a suggestion of upregulation masked by the large error bars 
associated with this time point. Significant upregulation was measured at 16 hours after 
challenge, which also represented the peak of hβD-3 expression (Fig.5.12.A, 
612.2±260.8 for LPS vs. 27.0±8.1 for PBS, p<0.001). The final 24 hour time point, 
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values showed a reduction in hβD-3 expression, although the mean value determined 
was still statistically significantly higher than that measured for the PBS challenged 
cells (Fig.5.12.A 245.3±22.8 for LPS vs. 28.8±6.2 for PBS, p<0.01).  
The hβD-3 peptide concentrations following LPS challenge were significant at 24 hours 
(Fig. 5.12.B, 1177.5±168.8 pg/ml for LPS compared to 657.9±49.7 pg/ml for PBS, 
p<0.001. These data indicate that the hβD-3 response to LPS was reduced when 
compared to those observed for the motile bacteria NCTC 10418 and for flagellin.  
3. PEPTIDOGLYCAN 
VK-2 E6/E7 cells were challenged with the same concentration of PG as LPS. Human 
βD-3 gene expression and peptide responses were measured and the results are shown in 
Figure 5.13: 
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Figure 5.13: hβD-3 response to Peptidoglycan in VK-2 E6/E7. VK-2 E6/E7 cells were 
challenged using 10 μg/ml of peptidoglycan isolated from E. coli. (A) Messenger RNA 
expression of hβD-3 was measured using RT-qPCR. The expression was normalised against 
GAPDH. (B) Media of PBS or peptidoglycan challenged VK-2 E6/E7 cells was collected and 
hβD-3 concentration was determined using sandwich ELISA (N=2). Statistical significance was 
investigated using ANOVA and a Bonferroni post hoc test. *=p<0.05, **=p <0.01, ***=p< 
0.001. 
Peptidoglycan did not induce any significant changes in hβD-3 expression or peptide 
concentrations (Fig. 5.13.A and B). Although the data suggested increased hβD-3 
peptide levels at 16 hours post challenge, the statistical analysis did not show any 
significant differences when the data were compared to the negative control (Figure 
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5.13.B, 969.375±242.5 pg/ml for peptidoglycan and 661.7±79.5 pg/ml for PBS). 
Summarising, these data suggested peptidoglycan did not activate either hβD-3 
expression or synthesis. 
In conclusion, hβD-3 expression and synthesis was induced in vaginal cells following a 
bacterial challenge that modelled infection. Flagellin was linked with a marked hβD-3 
response suggesting that microbial motility plays a key role in the hβD-3 induction in 
vaginal epithelia. Human βD-3 activation by LPS was also observed but using a similar 
concentration, peptidoglycan failed to induce a hβD-3 response altogether.  
5.7. ALTERNATIVE ACTIVATION OF HΒD-3 USING 
FUNGAL CELL WALL COMPONENT ZYMOSAN 
As reported in Chapter 4, Zymosan activated hβD-2 reporter activity in the bladder 
(section 4.8.I) as well as vaginal epithelia (section 4.9.I), high-lighting a potential role 
for Zymosan in protecting against bacterial infection and recurrent UTI. Therefore, it 
was also investigated whether Zymosan could induce a hβD-3 response in VK-2 E6/E7 
cells, by challenging the cells with 50 μg/ml of Zymosan. Human βD-3 gene expression 
and peptide were measured using qPCR and ELISA. The results are shown in Figure 
5.14: 
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Figure 5.14 hβD-3 response in VK-2 E6/E7 challenged with Zymosan.VK-2 E6/E7 cells 
were challenged up to 24 hours using 50 μg/ml of Zymosan. (A) mRNA expression of hβD-3 
was measured using RT-qPCR. The expression was normalised against GAPDH. (B) media of 
PBS or Zymosan challenged VK-2 E6/E7 cells was collected and hβD-3 concentration was 
determined using sandwich ELISA (n=3). Statistical significance was investigated using 
ANOVA and a Bonferroni post hoc test. **=p <0.01, ***=p< 0.001. 
 
Zymosan induced a significant hβD-3 mRNA response in VK-2 E6/E7 as early as 8 
hours (Fig. 5.14.A, 280.8±65.7 for Zymosan vs. 70.5±13.4 for PBS, p<0.01). The 
response was significant (p<0.001) at the following time points up to 24 hours. 
Zymosan also induced a significant increase in hβD-3 peptide concentrations but only at 
24 hours after challenge (Fig. 5.14.B, 1342.9±99.1 for Zymosan vs. 657.9±49.7 for 
PBS, p<0.001). Although the hβD-3 mRNA response was four fold lower when 
compared to either the motile strain NCTC 10418 or flagellin, the peptide 
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concentrations were comparable (1342.4±99.1 pg/ml vs 1456.9±209.7 pg/ml and 
1712.9±112.6, respectively).  
5.8. DISCUSSION 
Work presented in the previous chapter indicated that hβD-2 was induced in the uro-
genital tract in response to infection and as such was an important factor in the innate 
defences of such tissues. This Chapter explored whether another member of the 
Defensin family, namely hβD-3, also played a role in such defences. Such investigations 
were motivated by studies published in the literature that supported hβD-3 gene 
induction and synthesis in infected tissues
186
. Moreover, physiologically hβD-3 is 
probably important in urogenital defences as unlike hβD-2, it is salt insensitive180,187, 
which means that its bacterial killing activities can continue in urine regardless of 
fluctuating sodium concentrations associated with fluid intake.  
The studies first necessitated the development of new qPCR and ELISA assays. Using 
primer sequences reported previously
184
, the qPCR assay established in the laboratory 
fulfilled the required MIQE standards. In addition, the development of a sandwich 
ELISA allowed quantification of hβD-3 in the picogram range as its sensitivity was 
1000 fold increased compared to that of the indirect ELISA, due to a reduction in the 
background absorbance (Figs 5.5 & 5.6).  
To perform the experiments in vitro cell models were required. Despite the development 
and use of sensitive molecular and peptide assays neither hβD-3 expression nor peptide 
synthesis was detected in RT4 cells either constitutively or after challenging with E. coli 
strains mimicking an UTI. This result was in direct contrast to the findings in the 
bladder biopsies. Interestingly, Lüthje et al. (2013), also showed that although hβD-3 
was present in exfoliated cells in urine, the cell lines 5637 and the telomerase-
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immortalized normal human urothelial cell line (TERT-NHUC) did not express hβD-
3
188
. Additionally, the investigation showed that postmenopausal women had 
significantly less hβD-3 expression in the exfoliated cells when compared to 
premenopausal ones
188
, suggesting an direct or indirect effect of oestrogen on the 
induction of hβD-3 in the urinary tract. Sørensen et al. (2005), also showed that in skin, 
hβD-3 induction is TGF-α and EGFR dependent189. TGF-α is known to be induced in 
MDA-MB-231 breast cancer cells in an ER-α dependent fashion190. Hence, the absence 
of hβD-3 in the uroepithelium cell lines was probably a consequence of required 
cofactors not being present in the in vitro environment. Experiments stimulating RT4 
cells with TGF-α and EGF in addition to challenges should be performed to validate this 
hypothesis.  
In contrast to the RT4 observations, hβD-3 expression and peptide was detected in VK-
2 E6/E7 cells. Furthermore, expression was constitutive, which if translated to the in 
vivo situation suggests that hβD-3 functions as a constant innate defence mechanism 
functioning to control microbial numbers in the vaginal tissues. In theVK-2 E6/E7 cell 
model the presence of hβD-3 can be explained by the presence of EGF in the culture 
medium. Challenging the vaginal cells with E. coli, including two UPEC strains, also 
resulted in an increased hβD-3 response. These data thus supported a significant role for 
hβD-3 in vaginal epithelial defences. A publication by Mitchel et al., (2013) also 
supports the importance of hβD-3 in the vaginal environment, as lower levels of hβD-3 
were associated with increased levels of bacterial vaginosis in pregnant women
191
.  
Human βD-3 induction is via an AP-1 dependent pathway, and is thus independent of 
NF-κB186,192. However, the hβD-3 induction profiles in response to bacteria and 
flagellin challenges were comparable to the observations described in chapter three. The 
hβD-3 gene response to the NCTC 10418 challenge was ‘early’ and occurred within 8 
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hours, while the response to CFT 073, a motile strain associated with UTIs, was delayed 
until 24 hours. Similar to previous findings NU14 failed to induce a hβD-3 response 
completely. Taken together these data suggest that the UPEC strains have adapted to 
inhibit Defensin gene expression, i.e. host innate defences, thus allowing them to 
colonise the vaginal tissues. The observations relating to CFT 073 can be explained, 
since the protein that inhibits NF-κB activation, TcpC, might also be involved in the 
inhibition of hβD-3. Indeed the signalling cascades initiated by MyD88, which is 
inhibited by TcpC, also result in the MAP kinase dependent activation of AP-1
96
, thus 
increasing the virulence potential of TcpC
+
 UPEC. The ability of flagellin to cause 
induction of hβD-3 was also observed by Scharf et al. (2010), but in lung epithelia186, 
further supporting hβD-3 induction by motile bacteria, in this case Legionella 
pneumophila.  
The data in this Chapter indicated that similar to hβD-2 induction, motility rather than 
bacterial cell wall components such as LPS and peptidoglycan, plays a key role in the 
activation of hβD-3 (Figure 5.11). Challenging VK-2 E6/E7 with LPS did result in the 
upregulation of hβD-3 gene expression and synthesis, but expression was reduced by 
2.8 fold, when compared to that measured for flagellin and peptide concentrations by 31 
%. These data therefore suggest that the recognition of bacterial motility by the host is 
essential in the defence of the vaginal tissues.  
Peptidoglycan (PG) treatment did not induce expression of hβD-3. The PG findings, 
however, contradict the work of Dusio et al. (2011)
193
. These investigators were able to 
detect an increase in hβD-3 when VK-2 E6/E7 cells were challenged with 
peptidoglycan for 18 hours
193
. A potential explanation for the conflicting results may be 
simple, for example, contamination of the peptidoglycan used by Dusio et al (2011) 
with LPS. 
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As described in chapter three, TLR-5 is an important host factor in the recognition of 
potential uropathogens. Research in Newcastle has shown that TLR-5 activation results 
in NF-κB signalling, hβD-2 synthesis and microbial killing157. The flagellin challenge 
data presented in this Chapter also support the importance of TLR-5 in the induction of 
hβD-3 expression and synthesis in vaginal epithelia although it cannot be excluded that 
LPS, functioning presumably via TLR4, may also play a significant role
194
.  
The data presented in Chapter 4 indicated that the fungal β-1,3 glucan Zymosan could 
also activate hβD-2 gene expression and synthesis, presumably by a TLR-5 independent 
mechanism. Zymosan also activated the expression and synthesis of hβD-3 and this, to 
our knowledge, is the first description of this observation. Zymosan is known to act 
through a TLR-2 pathway, which classically, is the receptor through which PG 
signals
195,196
. This was interesting as challenging the VK-2 E6/E7 cells with PG did not 
induce a hβD-3 response (Fig. 5.12). These data did nonetheless suggest that Zymosan 
is an inducer of the innate response through Defensin synthesis and understanding its 
mechanism of induction may provide a potential therapeutic avenue that can be 
exploited in the treatment of UTIs.  
The next Chapter focuses on investigating the receptor associated with the Zymosan 
recognition. 
 
  
C H A P T E R  S I X  
 
 
  
The Dectin-1 Receptor in 
the Urogenital Tract 
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6.1. INTRODUCTION 
Chapter three highlighted the importance of bacterial motility in urinary tract infections. 
From the host’s perspective, TLR-5 was identified as a key defence factor in protecting 
the urogenital epithelium from potential infections with activation associated with the 
synthesis of effectors including IL-8 (Section 3.6.1) and hβD-2158. However, data 
presented in Chapter four indicated that when either RT4 or VK-2 E6/E7 cells 
transfected with the hβD-2 reporter were challenged with Zymosan, not known as a 
TLR-5 ligand, reporter activity was induced, which translated to hβD-2 synthesis. In 
addition the Chapter five results also showed that Zymosan also induced hβD-3 
expression and secretion in VK-2 E6/E7 cells. These data indicated that Zymosan is 
recognised by cells of the urogenital tract resulting, presumably, in an innate response 
involving Defensin expression, synthesis and microbial killing.   
Zymosan is a β-1,3 glucan found in the fungal cell wall197. It is known to activate the 
host’s innate immune response in macrophages and dendritic cells through TLR-2/TLR-
6 and Dectin-1, a calcium independent C-type lectin
196,197
, signalling. There are reports 
of Dectin-1 being expressed in lung and in skin epithelia, however, there is no current 
evidence for the receptor being expressed in the urogenital tract
75,198
. This is perhaps 
surprising, as the vagina is a common area for fungal infections
199
.  
This chapter explores the expression, localisation and activation of the Dectin-1 receptor 
in the urogenital epithelia with aim of identifying alternative host signalling pathways 
that could be exploited to help protect against UTI.  
 
 
 173 
 
6.2. THE NF-ΚB RESPONSE TO FUNGAL ZYMOSAN 
Previous data showed that Zymosan was able to induce hβD-2 reporter activation and 
secretion (Figures 4.13, 4.17 and 4.20) and that hβD-2 is NF-kB dependent; to verify 
that Zymosan can activate NF-κB, RT4 NF-kB cells (used in chapter three), and VK-2 
E6/E7 cells, transiently transfected with a NF-kB-GFP reporter (section 2.11; Figure 
6.1), were challenged with 50 μg/ml Zymosan.  
 
Figure 6.1 Reporter construct used to measure NF-κB activity in VK-2 E6/E7. The reporter 
contains diverse NF-kB binding sites, which when activated induce the expression of a modified 
version of GFP (MonsterGFP). The fluorescence of transfected cells was measured using the 
filers 480nm for excitation and 530nm for emission.  
1. ZYMOSAN INDUCES NF-ΚB ACTIVATION IN RT4 AND VK-2 
E6/E7  
RT4 and VK-2 E6/E7 cell lines were challenged for up to 24 hours using 50 μg/ml of 
Zymosan. NF-kB activation, via luciferase and GFP activities, was measured every 
eight hours and the results represent the findings of two independent experiments. NF-
kB activity of cells challenged with Zymosan was determined as a fold increase over the 
NF-kB activity of PBS challenged cells. The results are shown in in Figure 6.2: 
  
NF-κB-Luciferase 
Reporter construct 
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Figure 6.2 NF-κB activity of RT4 or VK-2 E6/E7 challenged with Zymosan. The cell lines 
were challenged with 50 μg/ml of Zymosan for eight, 16 and 24 hours. (A) NF-κB activity of 
RT4 cells was measured using a NF-κB-Luciferase reporter. (B) NF-κB activity of VK-2 E6/E7 
cells measured using a NF-κB-GFP reporter. N=6, 2 experiments with 3 replicates,  
*** p<0.001 
The NF-κB response of the RT4 cells challenged with 50ug/ml of Zymosan peaked at 
eight hours with a significant increase of 20.2±2.1 fold over the PBS negative 
(unchallenged) control (p<0.001, Fig. 6.2.A.). After 16 hours of challenge the response 
was reduced, 9.1±0.8 fold, but still significantly increased compared to the negative 
control (p<0.001, Fig. 6.2.A). The NF-κB response remained elevated, 9.6±0.4 fold, at 
24 hours (p<0.001). These data indicated that Zymosan was able to induce a NF-κB 
response in RT4 cells modelling the bladder epithelium.  
In VK-2 E6/E7 cells, the first significant response to Zymosan was identified at a later 
time-point, i.e. after 16 hours of challenge, when the NF-κB activity was increased by 
3.9±0.4 fold (p<0.001) compared to the negative control (PBS challenge). This response 
continued for up to 24 hours, with the fold increase measured as 3.2±0.3 (p<0.001, Fig. 
6.2.B).  
The fold increases detected in RT4 and VK-2 E6/E7 were not directly comparable due 
to the different reporter systems. However, it can be concluded from the data that 
Zymosan induced NF-kB reporter activity in both cell lines. A downstream effect of this 
NF-kB activation was analysed by investigating the secretion of IL-8. 
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2. ZYMOSAN INDUCES IL-8 SECRETION IN RT4 AND VK-2 E6/E7 
To achieve this the media bathing the RT4 and VK-2 E6/E7 cells challenged with either 
PBS or Zymosan were collected, pooled where appropriate and analysed for IL-8 using 
a sandwich ELISA. The results are shown in Figure 6.3:  
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Figure 6.3 IL-8 secretion of urogenital epithelial cell lines when challenged with  
Zymosan. The secretion was measured using Sandwich ELISA. IL-8 secretion into the pooled 
medium bathing challenged (A) RT4 uroepithelium and (B) VK-2 E6/E7 vaginal epithelium. 
N=2, using pooled medium of three replicates. *** p<0.001. 
The background concentration of IL-8 in RT4 cells was 503.0 ± 22.5 pg/ml (Fig. 6.3.A), 
but when the cells were challenged with Zymosan, a significant 37 fold increase 
(p<0.001), to 18740.7 ±697.8 pg/ml (Fig. 6.3.A) was observed. In VK-2 E6/E7 cells, 
the background IL-8 concentration was lower and recorded as 403.9±39.0 pg/ml. 
Following challenge with Zymosan, a significant (p<0.001), 13.5 fold increase to 
5462.5 ± 411.7 pg/ml of IL-8 (Fig. 6.3.B) was observed. Interestingly, the increase in 
IL-8 concentration in RT4 cells following challenge was three times that of the VK-2 
E6/E7 cells.  
Summarising, Zymosan challenge of RT4 and VK-2 E6/E7 cells induced NF-κB 
activation and increased IL-8 synthesis. As mentioned in Chapter 1, in macrophages and 
dendritic cells, Zymosan functions through TLR-2/6 and Dectin-1 signalling 
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mechanisms. TLR-2 expression had been shown previously in RT4 cells, thus the role 
of TLR-2 in the recognition of Zymosan was investigated
137
.  
6.3. INVESTIGATING THE ROLE OF TLR-2 IN THE 
RECOG-NITION OF ZYMOSAN 
To achieve this investigations were performed using monoclonal antibodies that 
blocked TLR-2 signalling. Thus the RT4 containing the NF-kB luciferase reporter cells 
were preincubated with a TLR-2 specific monoclonal antibody (10 μg/ml, Invivogen, 
USA) before being challenged with Zymosan (50 μg/ml) for eight hours. The results are 
shown in Figure 6.4:  
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Figure 6.4 NF-κB activation in RT4 cells challenged with Zymosan after blocking TLR-2. 
TLR-2 was blocked by preincubating RT4 reporter cells with 10 μg/ml of monoclonal anti-
TLR-2 antibody, before challenging with 50 μg/ml of Zymosan for eight hours. N=6, 2 
experiments with 3 replicates. 
Zymosan induced a NF-κB response of 22.8±0.6 fold. Furthermore, challenging RT4 
cells with Zymosan in the presence of TLR-2 blocking antibody induced an equivalent 
response (Fig. 6.4, 22.8±1.5 fold activation). However, the antibody itself did not 
induce a NF-κB response, as the response was comparable to that of PBS control 
(1.3±0.3 and 1.1±0.1 fold, respectively).  
 177 
 
Thus blocking TLR-2 in RT4 cells did not affect NF-κB activation by Zymosan, 
suggesting that in bladder cells TLR-2 is not involved in Zymosan recognition.  
6.4. DETECTION OF MULTIPLE ISOFORMS OF DECTIN-1 
IN RT4 AND VK-2 E6/E7  
In macrophages and dendritic cells Dectin-1 also functions as a β-1,3 Glucan receptor. 
Eight isoforms of Dectin-1 have been identified and these as well as the CLEC7A gene, 
encoding the Dectin-1 receptor, are shown in Figure 6.5: 
 
Figure 6.5 The Dectin-1 gene with its different known and predicted isoforms. The primers 
used for the PCR are in the first line, coloured in orange and marked with white arrows. The 
CLEC7A gene is shown in the second lane and coloured in purple. The known isoforms are 
coloured in green and shown in lanes 3 to 10. Isoforms with a functional recognition domain are 
in the red rectangles. The predicted sequence XR_242899.1 is shown in pink. The diagram was 
constructed using UGENE software and locus NC_000012. 
The expression of CLEC7 was investigated in the urogenital RT4 and VK-2 E6/E7 cell 
models. To achieve this, mRNA from the cell lines was reverse transcribed and 
analysed by RT-PCR using specific primers to the Dectin-1 receptor (Table 2.2).The 
primer pair covered all functional isoforms of Dectin-1 (Figure 6.5, white arrows). The 
expected product size was 330 bp for the isoforms 1, 2 and 5, and 211 for the isoforms 3 
and 4. The results of the RT-PCR are shown in Figure 6.6:  
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  A             B 
6.6 Expression of Dectin-1 in urogenital epithelial cell lines. First lane shows the 
amplification using Dectin-1 specific primers. Lane 2 shows the DNA ladder Hyperladder IV. 
The expression of Dectin-1 was investigated using RT-PCR in (A) RT4 bladder cells and in (B) 
VK-2 E6/E7 vaginal cells.  
A similar cDNA banding pattern for Dectin-1 expression was observed for each of the 
two cell lines. Multiple bands were detected and included the expected band of 330 bp 
(Figure 6.6. bold arrow). Additionally, bands relating to the 211 bp, 417 bp and 580 bp 
isoforms were observed, supporting the expression of different isoforms. The bands 
were isolated using a PCR purification kit (section 2.7), identified by DNA sequencing 
(Genevision, UK) (Figure 6.7 & Appendix) and BLAST analyses was used to identify 
different isoforms.  
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Figure 6.7 Sequencing and BLAST results for the bands from the Dectin-1 PCR, 
performed using RT4 mRNA. (A) Sequencing result of the 210 bp band of RT4. (B) 
Sequencing result of the 330 bp product of RT4. (C) Sequencing of the 400 bp band. (D) 
Sequencing result of the 580 bp band. (E) BLAST alignment of the sequence of the 210 bp 
band with isoform 3. (F) BLAST alignment of the sequence of the 330 bp band with isoform 
1. White arrow highlights exon 5. (G) BLAST alignment of the sequence of the 410 bp band 
with predicted Dectin-1 isoform XR_242899. 
The 211 bp cDNA band related to isoforms 3 or 4 of the CLEC7A gene, which lack 
exon 5 (Fig. 6.7.E). The 330 bp band related to the isoforms 1, 2 or 5 as it contained a 
sequence encoding the fifth exon (Fig. 6.7.F). Additionally, the band at 417 bp was 
XR_242899 
Aligned 417 bp band  
Aligned 330 bp band  
Aligned 211 bp band  
Dectin-1(Isoform 3) 
Dectin-1(Isoform 1) 
Dectin-1 (XR_242899) 
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identified as a predicted sequence with the assertion number XR_242899.1 (Fig. 6.7.G). 
The BLAST search using the sequence of the 580 bp fragment, which, admittedly, was 
very poor quality (Fig. 6.7D), did not result in any matches to the CLEC7A gene. All 
findings were confirmed in both cell lines RT4 and VK-2 E6/E7.  
These molecular data therefore indicated the expression and synthesis of at least three 
different isoforms of the Dectin-1 (CLEC7A) gene in RT4 and VK-2 E6/E7 cells.  
6.5. DECTIN-1 DETECTION USING FLOW CYTOMETRY 
To confirm the synthesis of Dectin-1 protein the cells, and in this study the focus was 
VK-2 E6/E7 cells, were stained with a monoclonal antibody specific for Dectin-1 
(MAB 1859, R & D Biosystem) and analysed by flow cytometry. In addition, to observe 
any effects of a microbial challenge on Dectin-1 expression the VK-2 E6/E7 cells were 
challenged with Zymosan, flagellin, motile E. coli NCTC 10418 and LPS for 18 hours 
before Dectin-1 analyses. Fluorescent cell sorting was performed using a FACSCalibur 
flowcytometer as described in section 2.17. The results of the flow cytometry analyses 
are shown in Figure 6.8: 
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Figure 6.8 Determining the cell surface presence and concentration of Dectin-1 using flow 
cytometry. VK-2 E6/E7 cells were challenged for 16 hours with PBS, NCTC 10418 [5x10
4
 
CFU/ml], Flagellin [250ng/ml], Zymosan [50 μg/ml] or LPS [10μg/ml], before being stained for 
Dectin-1 using a monoclonal anti-Dectin-1 antibody [2.5 μg/106 cells] and a secondary antibody 
labelled with Alexa 488[1/500]. (A) VK-2 E6/E7 cells stained using IgG2b control antibody 
[2.5 μg/106 cells] (orange histogram), unstained (black histogram), only stained with primary 
antibody (red histogram) or stained with primary and secondary antibody (yellow histogram). 
(B) VK-2 E6/E7 cells unchallenged (PBS, yellow histogram) or challenged with Zymosan 
(green histogram). (C) VK-2 E6/E7 challenged with NCTC 10418 (orange histogram) or 
flagellin (red histogram) or LPS (blue histogram) and stained with primary and secondary 
antibody. N=1, 10000 events were measured. FACS analyses were performed on a FACSCanto 
II (BD Biosystems) 
The control staining (Fig. 6.8.A) showed that non-specific binding of the antibody was 
minimal with unstained and IgG stained cells shown as the grey and orange peaks 
respectively. Dectin-1 stained VK-2 E6/E7 cells are shown by the yellow peak and in 
fact staining for Dectin-1 with the primary and secondary antibody shifted the 
fluorescence by 100 fold. Challenging the VK-2 E6/E7 cells with Zymosan for 18 hours 
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(Fig. 6.8.B, green curve), shifted the Dectin-1 staining peak to the right suggesting a 
higher number of Dectin-1 receptors on the cell surface. In contrast, challenging VK-2 
E6/E7 cells with motile bacteria or flagellin shifted the peak to the left (Fig. 6.8.C, 
orange and red), suggesting a reduction in the surface concentration of Dectin-1 
receptors. LPS also caused a reduction in the cell surface concentration of Dectin-1 
receptors (Fig. 6.8.C blue curve), but the effects of LPS were reduced when compared 
to those observed with the motile bacteria and flagellin.  
These data relate to one experiment and indicated Dectin-1 receptors were synthesised 
by VK-2 E6/E7 cells. Additionally, Zymosan challenge increased the numbers of 
receptors but in contrast flagellin, motile bacteria and LPS challenge reduced the 
numbers of receptors. This experiment was repeated twice more and the results are 
shown in Figure 6.9: 
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Figure 6.9 Repetition of the cell surface concentration determination of Dectin-1 using 
flow cytometry. The challenges and stainings were repeated. (A) Second repetition of the 
FACS experiment, VK-2 E6/E7 were not stained (black curve), stained with primary and 
secondary antibody after challenging with PBS (yellow histogram), Zymosan (green histogram), 
flagellin (red histogram), LPS (blue histogram). (B) Third repetition of the FACS experiment. 
VK-2 E6/E7 were not stained (black curve), stained with primary and secondary antibody after 
challenging with PBS (yellow histogram). Zymosan (green histogram), flagellin (red 
histogram), LPS (blue histogram). 10000 events were measured. FACS analyses were 
performed on a FACSCanto II (BD Biosystems) 
Disappointingly, the distinct peaks supportive of Dectin-1 staining and peak shifts 
following Zymosan, flagellin and LPS challenge were not reproduced. In Figure 6.9.A, 
no Dectin-1 staining was observed and in Figure 6.9.B while there was a suggestion of 
Dectin-1 staining (yellow) and peak shifts (blue and green) the peaks were very broad 
and thus the data unreliable. Thus the original data shown in Fig. 6.8 could not be 
reproduced. One explanation for the different results was the loss or destruction of 
receptors due to the proteolytic activity of the trypsin used to harvest the cells. The flow 
cytometry results were therefore deemed untrustworthy and a new approach was 
adopted in which the harvesting of the cells was not necessary.  
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6.6. DETECTION OF DECTIN-1 IN UROGENITAL CELL 
LINES USING IMMUNOCYTOCHEMISTRY 
Immunocytochemistry was therefore employed to detect Dectin-1 receptors. To achieve 
this RT4 and VK-2 E6/E7 cells were cultured on cover slips, fixed and stained for 
Dectin-1 and cell nuclei as described in section 2.18. To ensure that only a limited 
permeabilisation and hence mainly cell surface epitopes were available, the fixation was 
performed using paraformaldehyde rather than methanol. The results of the cell staining 
are shown in Figure 6.10.A and B: 
 A   B 
Figure 6.10 Detection of Dectin-1 in the urogenital tract using fluorescent microscopy. 
RT4 cells were stained using a Dectin-1 specific antibody (A) or using a non-specific IgG 
control (inlet). VK-2 E6/E7 cells were stained using a Dectin-1 specific antibody (B) or 
using a non-specific IgG control (inlet). White arrows show non-specific staining. All 
counter stainings were done using nucleic acid specific PI. Images were taken using Nikon 
Eclipse Ti and 100 x magnification.  
The green staining shown in Figure 6.10.A and B, was indicative of Dectin-1 staining 
and was supported by the negative IgG control data (Fig. 6.10 inlets). To confirm 
specificity of the Dectin-1 antibody, the antibody was mixed with an excess of 
recombinant Dectin-1 for 1h and used to stain the VK-2 E6/E7 cells. Non-absorbed 
antibody was used as the positive control. Results are shown in Figure 6.11.: 
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 A  B 
Figure 6.11 Dectin-1 Antibody specificity control using recombinant Dectin-1. (A) The 
Dectin-1antibody was preincubated with recombinant Dectin-1 and used to stain VK-2 E6/E7. 
White arrows highlight fluorescent spots. (B) Positive control using untreated Dectin-1 
antibody. White arrows highlight unstained cells. All counterstainings were done using nucleic 
acid specific PI. Images were taken using Nikon Eclipse Ti and 600 x magnification. 
 
When pre-incubated with recombinant Dectin-1 the antibody did not bind to the cells 
(Fig. 6.11.A) and only red staining, associated with nuclear staining, was observed. 
Hence, these results confirmed that the antibody was specific for Dectin-1. The 
fluorescent spots marked by the white arrows in Fig. 6.11.A did not co-localise with 
cells and were probably antibody-recombinant Dectin-1 complexes, which were not 
removed during the wash steps. In contrast, the staining in Figure 6.11.B. which used 
unabsorbed antibody confirmed the earlier data, showing green fluorescence and 
indicative of Dectin-1 receptor staining. Interestingly, two cells in Figure 6.11.B marked 
with white arrows appear not to have stained for Dectin-1.  
6.7. LOCALISATION OF DECTIN-1 USING CONFOCAL 
MICROSCOPY 
The cellular localisation of Dectin-1 was further analysed using confocal microscopy. 
RT4 and VK-2 E6/E7 cells were cultured on cover slips, fixed using paraformaldehyde 
and stained as described in section 2.18. Confocal images were taken on a Nikon A1R 
microscope at the Bioimaging Unit (Newcastle University) and the results are shown in 
Figure 6.12: 
8.53 μm 
8.73 μm 
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 A 
 B 
Figure 6.12 Cellular Localisation of Dectin-1 using confocal microscopy. (A) RT4 cells 
were stained for Dectin-1 (green staining) and for DNA (red) using PI. White arrow indicates 
the fluorescent staining. X-axis and Y-axis are 120.94 μm long, Z-axis is 19.48 μm long. (B) 
Dectin-1 stained VK-2 E6/E7 cells. Red staining is the nucleus using PI. X-axis and Y-axis are 
120.94 μm long, while Z-axis is 7.08 μm long. All images were taken using Nikon A1R 
microscope and 400 x magnification 
Confocal imaging suggested that in RT4 cells, the Dectin-1 staining was stronger on the 
apical membrane (White arrow, Figure 6.12.A). The staining of the lower basal regions 
was much fainter (compare area highlighted by white arrow to that of blue arrow, Fig. 
6.12.A). These data were suggestive of the receptor in RT4 cells being located apically. 
In VK-2 E6/E7 cells, a similar pattern was observed with strong outer membrane 
staining supportive of Dectin-1 receptors although faint intracellular staining (Fig. 
6.12.B) was also identified suggestive of intracellular located receptors or background 
fluorescence.  
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Overall the ICC data confirmed the presence of Dectin-1 receptors in RT4 and VK-2 
E6/E7 cells supportive of their presence in the urogenital tissues. 
6.8. ACTIVATION OF THE DECTIN-1 RECEPTOR IN 
VAGINAL EPITHELIA 
Further in vitro investigations relating to Dectin-1 focussed on the VK-2 E6/E7 vaginal 
cells. The rationale for this decision was that uropathogenic bacteria, in order to 
colonise the bladder, need to first evade the defences of the vaginal epithelium and thus 
understanding the vaginal innate defences, and their triggers, may underpin the 
development of future antimicrobial therapies. 
Firstly, Dectin-1 receptor localisation in untreated cells was compared to that in cells 
challenged with 50 μg/ml of Zymosan for 24 hours. The results are shown in Figure 
6.13: 
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A 
 
B 
Figure 6.13 Clustering of Dectin-1 in VK-2 E6/E7 when challenged with Zymosan. Cells 
were challenged with (A) PBS or (B) 50 μg/ml of Zymosan for 24 hours, before being fixed 
using 4 % paraformaldehyde and stained for Dectin-1. DNA in the nucleus was stained red 
using Propidium iodine. Images were taken with Leica TCS SP2 microscope and 630x 
magnification with oil immersion. Squares represent 5 μm. 
Confirming previous observations (Figure 6.12.B) the Dectin-1 receptor was localised, 
randomly, to the outer membrane of the VK-2 E6/E7 cells (Fig. 6.13.A). However, 
receptor localisation changed dramatically when the cells were challenged with 
Zymosan with Dectin-1 immuno-staining concentrated in clusters (Fig. 6.13.B and 
clusters marked with white arrows). Following ligand binding, Dectin-1 receptors form 
homodimers and homopolymers, which may explain the observed clusters. Homodimer 
formation is necessary to activate and phosphorylate the adaptor protein SYK 
76
, thus 
the clustering response observed suggested activation of a Dectin-1 responsive 
signalling response. The presence and phosphorylation of SYK were investigated in the 
Zymosan challenged VK-2 E6/E7 cells. 
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6.9. PHOSPHORYLATION OF SYK ADAPTOR PROTEIN 
In macrophages, the phosphorylation of SYK occurs within 60 minutes of a Zymosan 
challenge
200
. Using this knowledge, VK-2 E6/E7 cells were challenged for 15, 30, 45 
minutes, 1.5 and 2.5 hours with Zymosan (50 μg/ml) and western analyses were used to 
investigate the phosphorylation of SYK (section 2.15). The results of the western blot 
are shown in Figure 6.14: 
 
 SYK (72 kDa)                                A 
 
 
 
 
p-SYK (72 kDa)           B 
 
  
β-actin (42 kDa)           C 
Figure 6.14 Detection of SYK and phosphorylated SYK by Western Blot. (A) Total SYK 
was measured in VK-2 E6/E7 cells challenged with 50 μg/ml of Zymosan from 15 minutes to 
2.5 hours, N.C.= not challenged. (B) Phosphorylated of SYK after challenging VK-2 E6/E7 
with Zymosan (C) Protein loading control using β-actin. Western blot performed using Li-
Cor Odyssey. 
The adaptor protein SYK, with a weight of 72 kDa was detected in all samples (Fig. 
6.14.A). The signalling cascade is initiated by the phosphorylation of SYK, therefore, a 
western blot was performed using an antibody which specifically recognises the 
phosphorylated form of SYK. As seen in Figure 6.14.B, SYK was not phosphorylated in 
unchallenged (NC) VK-2 E6/E7 cells. Following challenge with Zymosan, the adaptor 
molecule was phosphorylated within 15 minutes as shown by a 72 kDa band. The band 
appeared strongest between 30 to 45 minutes, but these data suggested that 
phosphorylated material was still present up to 2.5 hours. β-actin showed a band at the 
expected size of 42 kDa and showed no significant differences in protein loading 
between the lanes (Fig. 6.14.C).  
N.C.        15’      30’      45’     1.5h     2.5h 
N.C.   15’             30’                45’            1.5h             2.5h 
 191 
 
The presence of Dectin-1 receptor and phosphorylation of SYK in VK-2 E6/E7 cells in 
response to Zymosan provides strong evidence for a physiological role for this receptor 
in the defence of vaginal epithelium.  
6.10.  DECTIN-1 IN PRIMARY VAGINAL EPITHELIA  
VK-2 E6/E7 cells represent in vitro cell models of the vaginal epithelium; to confirm 
Dectin-1 expression in vivo, vaginal epithelial cells were expanded from vaginal 
biopsies and analysed by ICC for Dectin-1 immunoreactivity. Vaginal tissue biopsies 
were obtained under ethical consent from patients undergoing surgery at the Royal 
Victoria Infirmary, Newcastle upon Tyne (see section 2.2.IV). Epithelium-layers were 
isolated from the tissue using dispase and trypsin as described in section 2.2.III. Primary 
cultures were successfully expanded from six donor biopsies. Of these, four were 
passaged at least three times. Figure 6.15 shows microscopic images of one of the four 
cell lines: 
   A   B 
Figure 6.15 Primary vaginal epithelium. (A) Confluent grow of vaginal cells after seeding 
epithelial layer in a six well-plate. (B) Vaginal cells were grown on cover slips for 
immunocytochemistry. Images taken using AMG Evos XL Core Microscope and 100x 
magnification.  
Primary epithelial vaginal cells were cultured on 6 well plates, as well as methanol 
sterilised 10mm diameter glass cover slips (Figure 6.15). Cells attained confluence after 
two weeks on a six well plate (Figure 6.15.A) and after one week on 10mm diameter 
cover slips. Primary cells on the cover slips were used for immunocytochemistry. 
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To prove the epithelial characteristics of the cells they were stained with C11 antibody 
from Leico Biosystems (Section 2.18). This antibody recognises cytokeratins 4, 5, 6, 8, 
10, 13 and 18 and acts as a marker for epithelial cells
138,201-203
. The result of the 
cytokeratin staining for four different primary vaginal cell lines is shown in Figure 6.16: 
A B 
C D 
Figure 6.16 Control for epithelial cell marker cytokeratin using C11- antibody. (A-D) 
Four primary vagina cells were permebealised according to the manufacturer’s instruction 
and stained using NCL-C11 antibody. Nucleic acid was stained using PI. All images were 
taken using Nikon Eclipse Ti and 600 x magnification.  
All primary cell lines showed a positive staining for cytokeratin as seen by the intense 
green staining (Fig. 6.16). The staining pattern also supported  the presence of only one 
type of cells, i.e. epithelial cells. The negative control data are shown in Figure 6.17; 
only the nuclei were visible supporting the specificity of the NCL-11 antibody.  
  
8.26 μm 8.03 μm 
9.04 μm 
8.73 μm 
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 A  B 
 C  D 
Figure 6.17 Control for unspecific binding in the primary vaginal cultures. 
Immunostaining was performed using non-specific IgG. Nucleic acid was stained using 
PI.All images were taken using Nikon Eclipse Ti and 600 x magnification. 
Having confirmed the expanded vaginal primary cells as being epithelial, the presence 
of Dectin-1 was investigated using the Dectin-1 antibody. The results of the immune 
staining are shown in Figure 6.18:  
  
8.76 μm 8.48 μm 
7.83 μm 10.73 μm 
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 A  B 
 C  D 
Figure 6.18. Immunostaining of Dectin-1 in Primary Vaginal Epithelia. (A-D)The four 
primary cell lines were stained for Dectin-1 using immunocytochemistry. Nucleic acid was 
stained using PI. All images were taken using Nikon Eclipse Ti and 600 x magnification. 
Fluorescence confirmed Dectin-1 production in the cells expanded from four different 
biopsies (Fig. 6.18). Moreover, the Dectin-1 staining was dispersed over each cell and 
the pattern similar to that observed in the unchallenged VK-2 E6/E7 cells (Fig. 6.18.A-
D).  
These data confirmed the presence of the Dectin-1 receptor in the urogenital epithelia 
and in vitro experiments using VK-2 E6/E7 cells supported its activation by Zymosan.  
6.11. DECTIN-1 ACTIVITY IN THE ABSENCE OF TLR-5  
These data thus supported exploitation of the Dectin-1 receptor as a mechanism to boost 
the innate defences of patients carrying the C1174T TLR-5 SNP. However, interplay 
between Dectin-1 and TLRs, specifically 2 and 6, has been shown previously
162
. To 
explore any mechanistic links between Dectin-1 and TLR-5 Zymosan challenge 
experiments were performed in the absence of TLR-5. Essentially, RT4 and VK-2 
7.94 μm 
8.13 μm 
9.90μm 
9.23 μm 
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E6/E7 cells were treated with monoclonal antibody to block TLR-5, simulating the 
TLR-5 C1174T SNP, challenged with Zymosan and the activation of NF-kB 
investigated using NF-kB reporter assays. The results are shown in Figure 6.19: 
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Figure 6.19 Inhibition of Zymosan induced NF-kB activation by blocking TLR-5. (A) RT4 
NF-kB reporter cells or (B) VK-2 E6/E7 transiently transfected with NF-kB-GFP reporter were 
treated with TLR-5 blocking Ab and challenged with Zymosan [50 μg/ml] in the presence or not 
of a blocking TLR-5 Ab [10 μg/ml] (8 hours for RT4 and 16 hours for VK-2 E6/E7). N=6, 2 
experiments with 3 replicates each, **p<0.01. 
Zymosan induced a 24.2±1.7 fold increase in NF-kB activity in RT4 when compared to 
the NF-kB activity of PBS challenged RT4 (Fig. 6.19.A). The treatment with the TLR-5 
blocking antibody resulted in a significant decrease in NF-kB activation to 15.6±1.1 
(Fig. 6.19.A, p<0.01). Similar results were observed in VK-2 E6/E7 (Fig. 6.19B) with 
Zymosan inducing a 4.2±0.4 fold increase in NF-kB activity which, following treatment 
with a TLR-5 blocking antibody, was significantly reduced to 2.8±0.1 , p<0.01).These 
data suggested a mechanistic relationship between the Dectin-1 and TLR-5 receptors.  
6.12. COLOCALISATION OF TLR-5 AND DECTIN-1 USING 
IMMUNOCYTOCHEMISTRY 
To further explore the relationship between TLR-5 and Dectin-1, VK-2 E6/E7 cells 
were challenged with Zymosan and flagellin and stained for TLR-5 and Dectin-1. The 
aim was to investigate whether there was colocalisation of the TLR-5 and Dectin-1 
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receptors following ligand binding. The results of the immunostaining are shown in 
Figure 6.20: 
 A  B 
 C  D 
Figure 6.20 Dual immunostaining VK-2 E6/E7 for TLR-5 and Dectin-1. VK-2 E6/E7 cells 
were stained with anti-TLR-5 antibody [10 μg/ml] (recognised by reporter-antibody labelled 
with Alexa350, blue colour) and Anti-Dectin-1 antibody [10 μg/ml] (recognised by reporter-
antibody labelled with Alexa480, green colour). (A) Staining of unchallenged cells. (B) VK-2 
E6/E7 cells challenged for 16 hours with Zymosan [50 μg/ml]. (C) VK-2 E6/E7 cells 
challenged for 16 hours with flagellin [250 ng/ml]. (D) VK-2 E6/E7 cells challenged for 16 
hours with flagellin [250 ng/ml] and Zymosan [50 μg/ml]. Images taken using a Leica TCS SP2 
microscope and 400 x magnification 
Figure 6.20 shows the dual immunostaining data for TLR-5 and Dectin-1 proteins in 
VK-2 E6/E7 cells. TLR-5 antibody staining was recognised by a secondary detection 
antibody labelled with alexa350 that stained blue, while the primary Dectin-1 antibody 
was recognised by a secondary detection antibody linked to alexa480 and stained green. 
No blue colour was observed following staining of the cells with TLR-5 (6.20.A), 
indicating either no TLR-5 protein was present on the cells or that the staining had not 
worked. However, green staining was observed consistent with the presence of the 
Dectin-1 receptor. Panel B shows the immunostaining after the VK-2 E6/E7 cells were 
challenged with Zymosan. Again while no staining supporting the presence of TLR-5 
13.85 μm 12.78 μm 
11.45 μm 13.23 μm 
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receptors was detected, immunostaining supportive of Dectin-1 receptors was evident. 
The VK-2 E6/E7 cells were also challenged with flagellin and the results are shown in 
panel C. In this case blue staining as well as green was observed indicative of TLR-5 as 
well as Dectin-1. Moreover, there was the suggestion of receptor co-localisation (white 
arrows). Although TLR-5 and Dectin-1 immunostaining were observed in cells 
challenged with Zymosan and flagellin (Panel D), the staining was poor thus credible 
analyses of the data was not possible. 
6.13. DISCUSSION 
This chapter investigated the presence of the Dectin-1 receptor in vaginal and bladder 
epithelia and its activation by the fungal β-1,3 glucan, known commercially as 
Zymosan.  
Zymosan was shown to induce NF-kB activity in RT4 and VK-2 E6/E7 cells, which 
resulted in IL-8 secretion. These data indicated that Zymosan challenge (mimicking a 
fungal infection) of the urogenital epithelia, induced an innate response, which 
functioned via a NF-kB signalling pathway. In 1999 Steele et al., from research using 
naive mice recognised that in the genital tract, the vaginal epithelial cells were 
important in defending against fungal, specifically Candida albicans, infection
204
. Two 
years later, the group using vaginal epithelial cells harvested from women by vaginal 
lavage showed human cells to inhibit C. albicans growth and suggested the functioning 
of an innate host defence mechanism, although the authors were not able to define the 
actual mechanisms
199
. The data presented in this Chapter together with the findings of 
section 4.8.I and 4.9.I, in which Zymosan was shown to activate hβD-2 expression and 
synthesis in RT4 and VK-2 E6/E7 cells, and the results of section 5.7, in which 
Zymosan induced hβD-3 expression and synthesis, suggest that the mechanism involves 
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the production of Defensins, and that these antimicrobial molecules play significant 
roles in protecting the host epithelium against fungal infections.  
To further understand the signalling mechanisms, the receptor(s) involved in Zymosan 
recognition in the urogenital epithelium needed to be identified. Zymosan has been 
shown to activate the host innate immune response in macrophages and dendritic cells 
through TLR-2
196
, but experiments in RT4 cells in which TLR-2 signalling was blocked 
did not result in a lowering of the NF-kB response. Acknowledging that the experiments 
were not repeated in VK-2 E6/E7 cells these data did suggest that the TLR-2 receptor 
was either not involved or played a minimal role in Zymosan recognition by urogenital 
cells. Thus as TLR-2 did not respond to Zymosan an alternative receptor was 
investigated. 
It has been shown in oral epithelial cells that their anti-fungal activity is destroyed by 
periodic acid treatment, indicating that surface carbohydrates play a role in detecting 
potential fungal pathogens
205
. Furthermore it is well established that in macrophages the 
main receptor for fungal detection is the calcium independent C-type lectin named 
CLEC7A or Dectin-1
73
. In 2001, Wilment et al., showed that the Dectin-1 receptor has 
eight different isoforms of which only six contain the Carbohydrate Recognition 
Domain (CRD) and that only two of them are able to bind Zymosan and are therefore 
functional
72
. Molecular analyses of RT4 and VK-2 E6/E7 RNA using primers designed 
to detect isoforms containing the CRD of the Dectin-1 gene resulted in several bands, 
and sequencing revealed that at least two known isoforms of Dectin-1 were expressed.  
These isoforms related to functional receptors as when the DNA sequences were 
translated they encoded CRD. These data thus supported the synthesis of functional 
Dectin-1 receptors in RT4 and VK-2 E6/E7 cells. This was further supported by the NF-
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kB and IL-8 responses observed following Zymosan challenge, but additional challenge 
experiments using antibodies to block Dectin-1 receptor functioning would allow 
confirmation. The molecular analyses (Fig. 6.6) also identified a third cDNA band that 
showed significant identity to the predicted sequence XR-242899.1. This suggested the 
expression of a third isoform containing an additional exon extending the CRD peptide 
sequence. The actual roles of the different isoforms are not known and such 
understanding will require further experimental analyses initially using siRNA 
technology.  
The presence of the Dectin-1 receptor protein in RT4 and VK-2 E6/E7 cells was 
investigated using flow cytometry. Initial data was exciting, indicating the presence of 
the receptor, receptor induction in response to Zymosan and down-regulation in 
response to flagellin and motile bacteria (Fig. 6.8). However, the results were not 
reproducible and this was attributed to harvesting the cells before FACS analyses by 
trypsinisation. It has been shown previously that trypsin reduces cell surface 
receptors
206
, so the technique was considered inappropriate and the data unreliable. 
To address these problems the cells were cultured on cover slips and using 
immunocytochemistry, the presence of the Dectin-1 receptor on the cell surface was 
confirmed (Figures 6.10 and 6.11). Dectin-1 staining for RT4 showed cell membrane 
specific staining (Fig. 6.10) comparable to that seen in skin keratinocytes (de Koning et 
al., Fig. S1)
198
. De Koning and colleagues identified the presence of Dectin-1 in 
keratinocytes and showed the receptors to be upregulated in psoriasis indicating a role 
in the chronic inflamed skin
198
. However, in contrast to the data reported using vaginal 
and bladder cells, Zymosan failed to induce a cytokine or antimicrobial peptide 
response
198
. 
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Increasing the magnification supported membrane staining indicating the presence of 
Dectin-1 receptors on the VK-2 E6/E7 cell surface (Fig. 6.11.B). The localisation of 
Dectin-1 on the surface of the RT4 and VK-2 E6/E7 cells was further analysed using 
confocal microscopy. Localisation of the Dectin-1 staining on RT4 was apical, which 
suggests Dectin-1 expression on the lumen side of the epithelium. Analyses of VK-2 
E6/E7 images supported staining throughout the cell layer.  
In addition to the analyses of the immortalised cells, primary vaginal epithelia cultures 
were investigated for Dectin-1 immunostaining. Epithelial cells from four different 
vaginal biopsies were expanded successfully showing vaginal epithelial morphology 
comparable to that published previously
138
 and cytokeratin staining consistent with 
epithelia
202,207
. These cells also stained positively for Dectin-1, supporting the presence 
of the receptor in vivo. However, immunohistological investigations should also be 
performed on bladder and vaginal biopsies to confirm these findings.  
Immunocytochemical (ICC) analyses of vaginal VK-2 E6/E7 cells was attempted to 
explore the cellular localisation of Dectin-1 before and after challenging with Zymosan, 
and the images showed the formation of cluster structures (Fig. 6.13). It has been 
reported previously that Zymosan induces dimerisation of Dectin-1
208
. It was feasible 
therefore that the areas with higher Dectin-1 concentrations comprised Dectin-1 dimers. 
Receptor clustering and NF-κB activation provided strong evidence for functional 
Dectin-1 receptors and functionality was supported by experiments showing 
phosphorylation of the Dectin-1 adaptor molecule SYK in response to Zymosan. 
However, a pivotal experiment to confirm Dectin-1 requires the receptor to be blocked 
and the Zymosan challenges repeated.  
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Activation of the Zymosan-Dectin-1 signalling pathway resulted in NF-κB activity, IL-8 
and Defensin synthesis. Thus this pathway represents an alternative signaling system to 
induce Defensin activity that could be exploited therapeutically in women with rUTI 
and TLR-5 SNP C1174T (R392STOP). However, interaction of TLR-5 with Dectin-1 
has been described before, although mainly as a synergistic effect
198
. Interestingly my 
work showed that blocking the TLR-5 receptor reduced the NF-κB activating capacity 
of Zymosan in RT4 and in VK-2 E6/E7 cells. A similar observation was reported using 
murine macrophages, where the absence of MyD88 abolished TNF-α secretion76. 
Together these data indicate a functional relationship between the Dectin-1 and TLR-5 
receptors either at level of receptors themselves or via signalling molecules.  
To pursue this further co-localisation of the receptors was investigated by ICC 
following challenge of VK-2 E6/E7 cells with Zymosan. This experiment was 
performed only once, therefore the data has be interpreted with caution. However, from 
the immunostaining data there was a suggestion of co-localisation between the Dectin-
1and TLR-5 receptors (6.20.C). This was exciting as it supported the biochemical data 
where antibody blocking of TLR-5 and challenging with Zymosan resulted in reduced 
NF-kB signalling. However, the challenge experiments and ICC analyses need to be 
repeated before any conclusions can be made. If co-localistion is not confirmed then 
further experiments exploring the synergistic effects of Dectin-1 and TLR-5 will be 
focussed at the adaptor molecule level.  
In summary, these data showed the synthesis of Dectin-1 in urogenital epithelia and 
functioning of receptor in response to Zymosan. Although not proven these data also 
hint of functional interactions between Dectin-1 and TLR-5. 
 
  
C H A P T E R  7  
  
Final Discussion 
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7.1. LIMITATIONS OF THE INVESTIGATION 
In Chapter 4 limitations of a GFP reporter system were shown. The autofluorescence of 
the RT4 cells inhibited the detection of the fluorescence of the reporter construct. 
Swenson et al. (2007) and others, showed that many tissues have autofluorescence and 
that GFP should only be used as a reporter for highly expressed genes due to its diverse 
limitations
209,210
. The solution was to change the reporter to luciferase as RT4 cells do 
not contain auto-luminescence. Nonetheless, using the luciferase reporter system had its 
limitations: the transfection efficiency was normalised across the plates using the 
positive control and negative control. This however did not measure variances between 
single wells transfection efficiencies. A solution would be to use second reporter with a 
stable expression, perform a simultaneous transfection of both reporter constructs (gene 
of interest and normalisation plasmid), e.g. the Dual-Luciferase system (Promega, UK) 
and normalise the result from each well using the normaliser plasmid, or to stably 
transfect the RT4 cells with the reporter. The reporter construct used in chapter 3 was 
stably transfected into the urothelial cell line RT4. Therefore, there was no variance 
between the wells due to variable transfection efficiency. 
The gene expression could alternatively be measured using quantitative PCR and the 
protein secretion could be measured using ELISA or Western blot. Analyses of 
transcription factor binding sites could be done using electromobility shift assays.   
The TLR-array used in the third chapter of this thesis and the qPCR assay used in 
Chapter 5 are based on SYBR-green detection of gene expression using predesigned 
primers. These primers are not publicly available and must therefore verified further 
using qPCR primers for the specific genes. SYBR green intercalates with double 
stranded DNA, changing its fluorescent characteristics and can therefore be used for 
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quantification of DNA. However, the binding of SYBR green to double stranded DNA 
is nonspecific. The results when using this method have to be analysed carefully, as 
nonspecific primer dimers or nonspecific amplification of DNA would be reported as 
false positives. Additional information is necessary in order to validate findings with 
SYBR green. Analyses of the melting curves give information about the presence of 
multiple products with different melting temperatures. Additionally, the products of the 
qPCR could be send to sequencing and the obtained sequence could then be compared 
to predicted sequence. An alternative for the SYBR green detection method is the 
Taqman technology: The reporter is directly attached to the primer, ensuring a high 
specificity and reducing the risk of false positive quantitation of gene expression. 
The results in Chapter 3 revealed that flagellin is the main bacterial PAMP recognised 
by TLR-5. Nonetheless, it is known that TLR-tolerance can be achieved by continuous 
stimulation of the TLRs
211,212
. The tolerance of TLR-5 was not investigated and should 
be part of the future investigations.  
7.2. FUTURE WORK AND FINAL HYPOTHESIS 
The literature published to date has identified the importance of TLR-4 in the defence of 
the urinary tract against infection. Overall, however, such research has focussed on 
using the rodent as the in vivo model
82,213
. Using an in vitro cell line of human origin to 
model the uroepithelium, the research presented in Chapter 3 of this thesis supported 
TLR-5 rather than TLR-4 as the key host factor in the uroepithelial detection of 
microbes. TLR-5 functions following activation by flagellin, which is part of the 
flagella structure and involved in microbial motility. The cytotoxic effect of the PAMP 
challenges is not known. To address this, the viability of RT4 cells needs to be analysed 
using a MTT assay while challenging the cells with flagellin, LPS or peptidoglycan. 
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Additionally, the synergistic effect of the activation of multiple TLRs should be 
investigated by challenging with a combination of the PAMPs. As mentioned before , 
experiments using repetitive challenges could address the question of TLR tolerance in 
the urogenital epithelia.  
It was proposed that UPEC strains could avoid detection by the host defences through a 
reduction in flagellin and hence reduced motility. However, this was not the case, as 
12/24 clinical isolates examined were found to be motile and activated NF-κB 
signalling, as well as IL-8 synthesis in RT4 bladder cells. However, the signalling 
responses were reduced compared to those of the motile E. coli strain NCTC10418 
suggesting bacterial mechanisms functioning to inhibit signalling pathways downstream 
of NF-κB. This area is one of further research in the laboratory in collaboration with Dr 
Philip Aldridge, Newcastle University. Additional clinical isolates of UPEC are being 
collected, the motility as well as the presence and function of immune inhibitory 
proteins, e.g. TcpC will be investigated.  
Focussing on the host rather than the bacteria, it was evident that the impaired 
recognition of bacterial motility increased a person’s vulnerability to recurrent UTI 
(rUTI)
89
. Indeed, bacteria isolated from TLR-5 SNP C1174T carriers suffering from 
rUTIs were able to induce a NF-κB response in RT4 cells, which was comparable to 
that of NCTC 10418. These findings suggest that the truncated TLR-5 receptor resulting 
from the SNP was significant (if not the actual cause) in their susceptibility to UTI. The 
fact that the isolated bacteria were motile, induced NF-κB signalling and IL-8 synthesis 
meant that the use of agents boosting the innate defences of such patients could present 
an alternative treatment to that of antibiotics. Concerning the bacteria isolated from the 
urine of TRL-5 SNP patients: A Gram staining revealed only gram negative strains. 
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Future investigations should identify the bacterial species in the urine using 16S rRNA 
and fatty acid methyl ester analyses.  
With this in mind, research focussed on exploring host defence factors and their 
potential augmentation in vitro. A colleague, Mr Ased Ali, showed that hβD-2 
synthesised by the urogenital epithelia was able to kill E. coli and thus a key host factor 
in the UT
157. Hence, a reporter assay containing 2000 bp of hβD-2 5’UTR sequence was 
engineered to explore potential agents that could boost hβD-2 expression and synthesis. 
17β-oestradiol was found to be a potent inducer of reporter activity in VK-2 E6/E7 cells 
suggesting that oestrogen plays a role in the genital innate defences. In fact, oestrogen 
treatment has been used to prevent rUTI in postmenopausal women and analysing nine 
studies in which oestrogen was used, Perrotta et al. (2008), concluded that it is only 
effective if applied topically to the vagina
4
. The data presented in this thesis provides a 
mechanism by which oestrogen functions to help protect the UT, i.e. enhancing hβD-2 
concentrations. Based on these data and that of Mr Ali, a project investigating the roles 
of oestrogen in the urogenital defences of women including post-menopausal women 
has been funded and a significant focus of the study is to examine hβD-2 expression in 
vaginal tissues and peptide concentrations in urine.  
Interestingly, resveratrol, chemically related to oestrogen enhanced hβD-2 reporter 
activity in absence of infection but actually inhibited hβD-2 expression in the presence 
of flagellin. As discussed in Chapter 4, these data can only be explained if resveratrol 
induces hβD-2 gene regulation via a mechanism independent of NF-kB. Experiments in 
which the hβD-2 reporter is transfected into VK-2 E6/E7 cells, NF-kB signalling is 
inhibited, and the cells are treated with resveratrol will answer this conundrum. 
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To investigate if differences in the position of transcription factor binding sites of the 
DEFB4 gene is due to the different databases used, mutations abrogating the 
transcription factor binding site will be introduced by site directed mutagenesis. 
Additionally, the binding sites for the transcription factors AP-1 and retinoic acid 
receptor (RAR) were found and may be alternatives for the here investigated 
transcription factors. 
As Defensins are potent microbial killing agents, the role of another Defensin, hβD-3, in 
the defence of the urogenital tract was explored. Human βD-3 was targeted as its 
expression was detected in bladder biopsies from three different donors and reported in 
exfoliated uroepithelium
188
. The data presented in Chapter 5 shows that hβD-3 
expression in the bladder could not be modelled in vitro as the RT4 cells did not express 
the gene either constitutively or in response to infection. Whether this was due to the 
absence of required co-factors in the growth medium, as argued, requires further 
investigation. Such investigations will be performed by culturing the RT4 cells in the 
presence of the growth factors EGF and TGF-α and measuring hβD-3 expression.  
VK-2 E6/E7 cells were routinely cultured in the presence of EGF, and hβD-3 
expression was detected. Moreover, hβD-3 expression was upregulated in response to 
infection. Similar to the findings in Chapter 3, the motile strains NCTC 10418 and CFT 
073 induced the strongest hβD-3 response. Investigations using TLR ligands, again 
showed that flagellin induced the highest response, followed by LPS. Peptidoglycan 
failed to cause a response altogether, but another potential TLR-2 ligand, Zymosan, did 
induce hβD-3 gene upregulation and increased peptide secretion. 
Blocking the TLR-2 receptor and challenging RT4 cells with Zymosan, a β1,3-glucan 
found in the fungal cell wall, still activated NF-κB signalling, suggesting that TLR-2 
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was not involved in Zymosan recognition. Research in Chapter 6 led to the discovery of 
the Dectin-1 receptor, an alternative receptor for Zymosan found in macrophages
214
, in 
both RT4 and VK-2 E6/E7 epithelial cell lines. Moreover, receptor functionality was 
proven in VK-2 E6/E7 cells by challenging them with Zymosan and observing (i) the 
activation of NF-κB and IL-8 secretion, (ii) clustering of the Dectin-1 receptor on the 
cell surface and (iii) the phosphorylation of its adaptor molecule SYK. Additional 
experiments to confirm the importance of Dectin-1 in the recognition of Zymosan are  
(i) challenging VK-2 E6/E7 and RT4 cells, while blocking Dectin-1 with a specific 
antibody and (ii) inhibiting the expression of Dectin-1 using the siRNA method.  
These data were novel and furthermore as Zymosan was shown to enhance hβD-2 and 
hβD-3 expression in vitro it provided the source of a potential therapeutic agent that 
could be used to treat the TLR-5SNP patients. However, experiments blocking TLR-5 
in both RT4 and VK-2 E6/E7 cell lines reduced the NF-κB response to Zymosan and a 
pilot experiment using VK-2 E6/E7 cells hinted at co-localisation of the TLR-5 and 
Dectin-1 receptors challenged with flagellin. These data suggested potential TLR-
5/Dectin-1 receptor interactions and future experiments will determine the mechanisms 
with the focus being on ICC to determine structural relationships and signalling 
inhibitor experiments to explore shared adaptor molecules. If a structural relationship is 
proven this would suggest that TLR-5, to date known to function as a homodimer can 
also function as a heterodimer in the innate defences.  
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In conclusion, the original hypothesis was confirmed and magnified therefore being: 
Host recognition of bacterial motility is pivotal for an innate 
immune response in the urinary tract and this response can 
be enhanced by Zymosan, a ligand of the novel urogenital 
receptor Dectin-1. 
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